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Abstract 
Liver glycogen, a highly branched glucose polymer, has a critical role in the maintenance of 
blood glucose homeostasis. Liver glycogen consists of glucose units that are attached to form 
linear chains via -(1→4) linkages. These chains are connected via -(1→6)-linked branch 
points to form highly branched glycogen “” particles (~20 nm in diameter) that can further 
join to form much larger “” particles (~100-200 nm). Given the characteristically poor blood-
glucose control associated with type 2 diabetes, a link between the structure/function 
relationships of liver glycogen and type 2 diabetes is probable.  It is shown that diabetic (db/db) 
mice have an impaired ability to synthesize the large composite glycogen  particles present 
in normal, healthy mice and that  particles are held together via a bond more acid-labile than 
normal glycosidic linkages, with the most likely bond being proteinaceous. The structure of 
healthy mouse-liver glycogen over the diurnal cycle is characterized using size exclusion 
chromatography and transmission electron microscopy. Glycogen is observed to be initially 
formed as smaller  particles, only being assembled into the larger  particles significantly 
after the time when glycogen content reaches a maximum. This pathway, impaired in diabetic 
animals, is likely to give optimal blood-glucose control, as explained by the particles’ surface 
area to volume ratio. Lack of this control may result from, or contribute to, the poor glycaemic 
regulation associated with diabetes. This discovery suggests novel approaches to diabetes 
management that promote  particle formation. Significant improvements in the extraction and 
characterization of liver glycogen has also been achieved, paving the way for future 
experiments exploring glycogen’s role in diabetes. Glycogen can now be effectively and 
rapidly extracted from formalin-fixed tissues using a novel technique, allowing the analysis of 
human tissue samples from pathology laboratories that routinely employ this method of 
fixation. The use of aqueous size exclusion chromatography has been shown to dramatically 
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improve peak resolution when compared to the previously used dimethyl sulfoxide method, 
achieving separation of -particle and -particle peaks. This allows for a more detailed and 
quantitative analysis and comparison between liver glycogen samples. 
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1. Chapter 1: Literature Review 
Liver glycogen, a highly branched polymer of glucose, acts as a blood-glucose buffer. After a 
meal, blood glucose concentrations can be rapidly controlled by trapping glucose in glycogen. 
In animals, the cells with the largest stores of glycogen are in the liver and skeletal muscle. 
Glycogen is also contained in brain, heart, skin and adipose tissues1. Liver glycogen is 
synthesized when blood-glucose levels are high, removing excess glucose from the blood and 
storing it for future use. When blood-glucose levels are low, liver glycogen is degraded, 
releasing glucose into the blood2. 
1.1 Glycogen Structure 
1.1.1 The three levels of glycogen structure 
Liver glycogen has three levels of structure: 1) glucose units are attached to form linear chains 
via -(1→4) linkages with branch points joined together via -(1→6)-linkages; 2) these chains 
are able to form highly branched glycogen “” particles (~20 nm in diameter); and 3) these  
particles are joined together to form much larger “” particles (~100-200 nm).  
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These three levels of structure are illustrated in Figure 1. 
 
 
 
Figure  1: The three levels of glycogen structure. 
Glycogen’s average chain-length has been reported to be anywhere between 10-18 glucose 
residues, with the majority of studies finding the average length to be between 10-14 residues3. 
The  particles have diameters varying between 10 nm and 50 nm4, with average molecular 
weights of ~106-107, as measured by mulitple-angle laser light scattering (MALLS)5.  In liver 
cells these  particles are joined, forming large super-molecular complexes known as  
particles (or  rosettes), which can have diameters as large as 300 nm6 and molecular weights 
as high as 109.   
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A transmission electron microscope (TEM) image is given in Figure 27. 
 
Figure 27: TEM images of rat-liver glycogen samples7. 
The three main parameters associated with glycogen’s branching structure that are generally 
reported include the number-average degree of polymerization (X̅n), number-average exterior 
degree of polymerization (X̅n,e) and number-average interior degree of polymerization (X̅n,i). 
X̅n is simply the statistical average length of chains in a sample; X̅n,e is the average length of 
chain between the terminal glucose unit and the outermost branch point; and X̅n,i is defined as 
the average length of chain between two branch points. X̅n can be obtained experimentally 
using isoamylase, an enzyme that breaks -(1→6) bonds (branch points), and characterizing 
the molecular weight distribution of the resulting linear molecules by standard methods such 
as size-exclusion chromatography. Another parameter often tested is the -amylolysis limit (-
limit), referring to the degree of hydrolysis glycogen undergoes when treated with -amylase. 
-amylase degrades the exterior part of chains down to a few glucose residues from the 
outermost branch points. The -limit is then calculated by measuring the amount of maltose 
released. This parameter allows the calculation of X̅n,e, and if X̅n has been calculated then X̅n,i 
can be calculated from Equation 18:  
X̅n,i= X̅n - X̅n,e – 1    1   
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Typical values for glycogen include a -limit of 45-55%, X̅n of 10-14, X̅n,e of 6-9 and a X̅n,i of 
3-49. 
Glycogen chains can either be labelled as A-, B- or C-chains, a concept introduced by Peat et 
al.10, where A-chains are the chains with no substituents, B-chains have one or more branching 
points along the chain and C-chains carry the sole reducing group in the molecule and have 
multiple branching points. 
A number of models for glycogen’s branching structure were proposed in the 1940s. The 
Haworth “laminated” form11 is a proposed structure where each new branch would have 
another new branch connected via an -(1→6) linkage, practically making all chains B-chains 
(see Figure 3a). Staudinger and Husemann’s model involves a comb-like structure12, where 
chains are connected at C2, C3 and C6 of a central chain, consisting of ~100 -(1→4)-linked 
glucose units, practically making all chains A-chains (see Figure 3b). In 1941 Meyer and Fuld 
proposed a different tree-like structure13, where there are inner chains that have multiple 
branching points connected via -(1→6) linkages (see Figure 3c). This model has both A- and 
B-chains in approximately equal numbers. Meyer’s model was shown to be the most correct 
out of these early three models, with Larner et al.14 using stepwise enzyme degradation 
experiments to determine that glycogen consists of multiple branching. 
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Figure 315: The three early models proposed for the structure of glycogen. (a) represents 
Haworth’s “laminated” form; (b) the comb form proposed by Staudinger et al.; and (c) the 
Meyer “tree” form. 
While the Meyer model was shown to be the most accurate of these early models, this model 
suggested that every B-chain contains at least one A-chain, a feature that was shown to be 
inconsistent with debranching (isoamylase) experiments16. Enzymatic data from these 
experiments using isoamylase, phosphorylase and -amylase led to a new model being 
proposed, the Whelan model (see Figure 4). 
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 Figure 49,17: The structure of glycogen proposed by Whelan17.  
The structure of glycogen suggested by Whelan17 consists of an equal number of A (those 
carrying no substituents) and B (substituent-carrying) chains (see Figure 4). This model was 
supported by experiments which found that the A:B chain ratio is close to 1:114,17. Other 
evidence that supported this model was obtained using fractionation of isoamylase-debranched 
glycogen and by using radioactive labels on the reducing ends16. 
1.1.2 Glycogen-associating proteins 
Glycogen forms granules in cells that contain not only glycogen, but also a variety of bound 
proteins such as glycogen phosphorylase and glycogen synthase, all involved in glycogen 
metabolism (see section 1.2 for these enzymes’ roles)18. Many of the proteins involved can be 
seen in Figure 5 and have been confirmed using proteomics19. 
A = chains with no substituents 
B = chains with substituents 
C = chain with free reducing group 
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Figure 520: Proteins associated with glycogen: metabolic enzymes shown in mauve include 
glycogenin (GN), glycogen synthase (GS), phosphorylase (PH) and debranching enzyme 
(DBE); protein kinases shown in red include phosphorylase kinase (PH kinase) and AMP-
dependent protein kinase (AMPK); phosphatases are shown in green and include type 1 
catalystic subunit protein phosphatase 1c (PP1c) and laforin (LF); units that target PP1 are 
shown in blue and include the regulatory-targeting subunit RGL, GL and protein targeting to 
glycogen (PTG)20. Starch-binding domain-containing protein 1 (Stbd1) has recently been 
shown to bind to glycogen19 and is generally regarded as a membrane-anchoring protein. Malin, 
a protein catalysing the polyubiquitylation (and hence degradation) of laforin is shown in 
brown. 
1.1.3 Phosphorylation of glycogen 
Before the 1980s the presence of phosphate in glycogen was considered to be a contaminant, 
with the purity of samples often being correlated to the phosphate content20. After phosphate 
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was demonstrated to be an integral part of glycogen21, a number of studies focused on 
determining the chemical linkage between phosphate and glycogen, as well as the role of 
phosphate in glycogen structure/metabolism. The concentration of phosphate has been reported 
to be ~one per 1500 glucose units in mouse skeletal muscle22 and ~one per 650 units in rabbit 
muscle23, with levels of phosphorylation shown to be significantly less in the liver of rabbits24. 
It was initially postulated that phosphate was both: 1) connected to some of the C6 positions of 
glycogen, forming monoesters and blocking a potential branchpoint; and 2) forming C1-C6 
phosphodiesters, essentially being an alternative method for forming a branch point. It was also 
suggested that perhaps the level of phosphorylation of a glycogen molecule may be related to 
its age, acting as a molecular marker and potentially signalling the transport of glycogen to the 
lysosome21. A subsequent study using mass spectroscopy and NMR found phosphate to exist 
as C2- and C3-phosphomonoesters, with no evidence for the previously hypothesized C6-
phosphoesters25. A more recent study however developed an assay that was able to specifically 
measure phosphorylation at the C6 position, finding a significant amount in muscle glycogen 
(with less occurring in liver glycogen). This study also addressed whether glycogen 
phosphorylation has a specific role in glycogen structure/metabolism or simply resulted from  
a catalytic error from glycogen synthase. They found that phosphophorylation is not mediated 
by glycogen synthase or glycogen phosphorylase, providing evidence that there may be an 
important function in the phosphorylation of glycogen and raising the question of what enzyme 
is responsible. Interestingly, they found that the inner part of the molecule had higher levels of 
phosphorylation, leading them to suggest that perhaps this plays a role in preventing excessive 
branching (and thus crowding) in the early stages of glycogen synthesis26. 
While some phosphorylation may be physiologically important, overphosphorylation has been 
shown to be associated with Lafora disease, a form of epilepsy that ultimately leads to 
neurodegeneration and death23. This overphosphorylation results from an inability to remove 
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phosphate from the glycogen, with half of the cases of Lafora disease resulting from mutations 
in the gene encoding laforin, a phosphatase able to cleave the phosphate covalently attached to 
glycogen. This hyper-phosphorylated glycogen forms insoluble polyglucosan bodies (known 
as Lafora bodies), which accumulate in neurons, causing the pathology of the disease22. 
1.1.4 -Particle binding 
Although a number of studies have provided insight into the formation of  particles, there has 
been conflicting theories regarding not only how these particles form, but what bonds hold 
them together. 
One possibility that has almost been eliminated is that of non-covalent bonds, with a broad 
range of disaggregating agents such as urea, guanidine, LiBr and thiocynate having been 
reported to have no effect on the molecular weight spectrum of the glycogen27. These results 
have been confirmed in a number of subsequent experiments28. 
After the determination that a gluco-protein (glycogenin) is the precursor for glycogen 
synthesis and the suggestion that this protein may be involved in -particle binding29, it was 
reported30 that there was an elimination of large glycogen particles upon treatment with 2-
mercaptoethanol (which disrupts disulfide bonds) with the reduced sulfhydryl groups being 
subsequently blocked by adding iodoacetamide. This resulted in the conclusion that  particles 
are composed of  particles attached via disulfide linkages31,32. The properties of this 2-
mercapoethanol treated glycogen were further studied, showing that the number-average 
molecular weight (M̅n) decreased from 6.2 x 10
7 to 2.7 x 107, a decrease of ~ 56%33.  However 
it was suggested by Manners3 that a possible by-product in this experiment, hydroiodic acid, 
could hydrolyze  particles. Another factor noted by Manners was that it has now been 
determined that glycogenin only contains 2 cysteine residues34, reducing  the ability of this 
protein to form multiple disulfide bonds, an important factor in Geddes et al.’s model. Matsuda 
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et al.35 constructed size frequency histograms from electron micrographs of glycogen treated 
with 2-mercaptoethanol and iodoacetamide and reported no significant size decrease, 
suggesting that Nakumara’s  hypothesis36 that  particles are created on elongated exterior 
chains was correct, implying an -(1→4)-link between  particles35. It has been theorized37 
that in β particles, the local molecular density becomes so high after ~12 layers of glucose 
monomer units that further growth cannot occur (perhaps due to inaccessibility to glycogen 
synthase). One can combine these ideas into a “crowding/budding” mechanism, where 
occasional exterior chains in a β particle are less crowded and can form new “buds” of growing 
branches via glycogen synthase, which grow to become β particles bonded to the original 
particle. While some time ago we had suggested38 that this postulate was inconsistent with 
observed glycogen number distributions28,30, which does not show the maximum that might be 
expected at a size corresponding to the onset of crowding, we can now point out that because 
new β particles can start after molecules reach this size, a shoulder rather than a maximum is 
more likely, as is indeed observed28. Further evidence consistent with such a model, as opposed 
to one where  particles or  particle units come together to form  particles, is that there is 
approximately one glycogenin molecule for every  particle in the liver39. If  particles, each 
needing an initiating glycogenin molecule, were synthesized separately and then joined, there 
should be many more glycogenin molecules than  particles. However a more recent study 
found that there may actually be much more glycogenin in liver than the previous study 
reported19. 
1.2 Glycogen Metabolism 
1.2.1 Glucose homeostasis 
Glucose is an important cellular energy source that must be tightly regulated to maintain blood-
glucose homeostasis. A non-diabetic range of blood-glucose levels lies within the narrow range 
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of 3.9 to 5.6 mM40. If blood-glucose levels are too high or too low, the body’s functioning is 
impaired and conditions such as diabetes or hypoglycaemia may result. An equilibrium 
between endogenous glucose production (EGP) and glucose utilization maintains homeostasis. 
Insulin, epinephrine and glucagon are the main hormones regulating this process with 
metabolites (such as glucose) also playing a crucial role40. 
Insulin-producing cells(-cells) in the pancreas are able to sense glucose concentrations in the 
blood and adjust the amount of insulin released41. Insulin is secreted following food digestion, 
promoting the uptake of glucose into the liver, skeletal muscle, heart and adipocytes. In the 
liver this increased concentration of glucose results in the synthesis of glycogen and the 
inhibition of glycogenolysis and gluconeogenesis. After fasting, the level of glucose in the 
blood drops, causing the secretion of the hormone glucagon from pancreatic -cells. The 
glucagon peptide promotes a rapid increase in gluconeogenesis and glycogenolysis, resulting 
in the restoration of blood-glucose levels42. Epinephrine (adrenaline) stimulates glycogen 
breakdown in the muscle, and to some extent glycogen breakdown in the liver43. 
To ensure that the net flux is in the appropriate direction, key enzymes in opposing metabolic 
pathways, glycolysis and glycogenesis, must be regulated42. 
The concentration of human hepatic glycogen varies from approximately 200 to 450 mM, 
depending on whether the person is in the fed or fasting state. Diabetic sufferers (both type 1 
and type 2) synthesize only 25-45% of the hepatic glycogen synthesized by non-diabetic 
humans40. 
Insulin-independent uptake of glucose in the hepatocytes is achieved via the GLUT-2 glucose 
transporter. This transporter allows the entry of glucose even when there are high 
concentrations of glucose in the sinusoids (small blood vessels in the liver). This glucose is 
then phosphorylated to glucose-6-phosphate where it can either undergo glycolysis (to be used 
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for energy release) or undergo further reactions to become UDP-glucose, a precursor for 
glycogen synthesis (see Figure 6)40. 
 
Figure 640: A schematic diagram representing two different fates of glucose after entering 
hepatic cells. 
1.2.2 Glycogen synthesis 
Glycogen biosynthesis is initiated by the autocatalytic enzyme glycogenin, which is 
glycosylated on tyrosine-194 from an active form of glucose, uridine diphosphate glucose 
(UDP-glucose) (see Figure 7). Glycogenin forms an active dimer with a coordinated Mn2+, 
which is believed to interact with UDP-glucose (see Figure 7), acting as a Lewis acid to make 
the UDP leaving group more stable44. Approximately 8-12 more glucose residues are 
subsequently added to the glycosylated tyrosine-194 residue, catalysed by the other glycogenin 
subunit, allowing the biosynthesis of glycogen to  begin43,45,46. 
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Figure 7: Glycogenin catalyses the above two reactions. Firstly, Tyr194 is glycosylated from 
UDP-glucose (a), which is followed by the glycosylation of the C4-hydroxyl group of the 
terminal glucose (b), forming an -(1→4) glycosidic link47.  
After the initial stages of glycogen production, glycogen branching enzyme is able to cleave 
the distal end of the growing chain and attach it via an -(1→6) link to either another chain, or 
the same chain, creating a new branch48. During glycogen synthesis, glycogen branching 
enzyme continues to create new branching points, resulting in a hyperbranched molecule. 
Typically, the number of residues transferred is approximately 7 monomer units in length and 
comes from a chain with a minimum length of 11 units. Another specific requirement is that 
the new branch point is at least 4 monomer units away from another branch point. The high 
level of branching increases the solubility of the molecule, both by exposing more terminal 
hydroxyl groups, as well as preventing chains from undergoing retrogadation, as seen in starch. 
Also more terminal sites become available for glycogen synthase and glycogen phosphorylase 
to act, increasing the rate of synthesis and degradation of glycogen43. 
Glycogen synthesis is mainly regulated by the reversible phosphorylation of a number of sites 
on glycogen synthase. The phosphorylation state of these sites is controlled by several protein 
kinases such as glycogen synthase kinase (GSK) and protein kinase A. The phosphorylation of 
glycogen synthase converts it from the active a form to the inactive b form. 
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1.2.3 Glycogen degradation 
Glycogenolysis is the degradation of glycogen into glucose 6-phosphate, an important 
metabolite. Four enzymatic activities are required for efficient glycogen breakdown. The first 
key enzyme involved with this process is glycogen phosphorylase, which cleaves terminal 
glucose monomers from glycogen using orthophosphate (Pi). The product of this 
phosphorolysis reaction, glucose-1-phosphate, is converted to glucose-6-phosphate by 
phosphoglucomutase. Glucose-6-phosphate in the liver can either be converted into free 
glucose by glucose-6-phosphatase, an enzyme absent from the muscle, to be subsequently 
released into the bloodstream, or can undergo glycolysis in the liver. The other possible fate of 
the glucose-6-phosphate (besides simply being incorporated back into glycogen - see Figure 
640), is for it to enter the pentose phosphate pathway to create ribose derivatives and NADPH43. 
Glycogen phosphorylase can only remove glucose monomers down to a branch length of 4 
glucose units. Two more enzymes are needed to remove these units, making the molecule 
suitable for further phosphorylase degradation, a transferase and an -1,6-glucosidase. In 
mammals glycosyltransferase and glucosidase activity is performed by a single bifunctional 
enzyme (glycogen debranching enzyme). Once a branch is 4 glucose units long and cannot 
undergo further degradation by glycogen phosphorylase, the glucosyltransferase catalytic site 
on glycogen debranching enzyme moves three glucose units to another branch. The glucosidase 
site then cleaves the remaining α-(1⟶6) bond, allowing further phosphorolysis degradation43. 
The regulation of glycogen degradation depends largely on controlling the activity of glycogen 
phosphorylase. This regulation is sensitive to a number of allosteric effectors that reflect the 
energy requirements of the cell, as well as reversible phosphorylation, which is controlled by 
hormones such as insulin, epinephrine and glucagon. Unlike glycogen synthase, the 
phosphorylated form of glycogen phosphorylase, phosphorylase a, is the active form43. It has 
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been determined that the elevated glucose output from hepatocytes in type 2 diabetes is partly 
due to increased glycogenolysis49. 
1.2.4 Diurnal cycle of glycogen metabolism 
Liver-glycogen metabolism in mice, like many animal species50-53, follows a daily rhythm. This 
rhythm in rodents has been studied during a 12 hour light/12 hour dark cycle, with hepatic 
glycogen contents peaking during the dark period and decreasing during the light period, as 
seen in Figure 854-58.  
 
 
Figure 854: Hepatic glycogen content as a function of time of day. 
Previous results and conclusions for glycogen structural changes during synthesis and 
degradation have been conflicting. In 1967, Parodi reported59 that, while glycogen content 
increased significantly after administering glucose to overnight-fasted mice, the glycogen size 
distributions (using sucrose gradient centrifugation) remained almost unchanged. However, 
Geddes in 197132, found that sucrose-density-centrifugation size distributions varied 
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significantly with glycogen content in refed rabbits after 4 days of starvation. Further studies 
into the structural changes of glycogen during the diurnal cycle are needed in order to obtain a 
better understanding of the role glycogen structure plays in its metabolism. 
1.3 Characterizing Glycogen Structure 
1.3.1 Size-exclusion chromatography 
Glycogen molecules have a wide distribution of sizes, and due to differences in branching 
structure, for each size there is a range of molecular weights60.  The shape and breadth of these 
distributions will depend on the polymerization mechanism, as well as the kinetics and 
conditions of biosynthesis60.  
Size-exclusion chromatography (SEC), also known as gel permeation chromatography (GPC), 
is a method which separates polymer molecules, including glycogen, based on their 
hydrodynamic volume (Vh); it is a common misapprehension that SEC separates by molecular 
weight60. Vh is defined by the International Union of Pure and Applied Chemistry (IUPAC) as 
‘the volume of a hydrodynamically equivalent sphere’61, as applicable to the particular 
technique being used. In this thesis, results are usually reported in terms of the corresponding 
hydrodynamic radius Rh with Vh = 4/3 πRh3. Some examples of detectors that allow the 
conversion of hydrodynamic volume data into structurally relevant and meaningful information 
include differential refractive index (DRI), viscometry and multiple-angle laser light scattering 
(MALLS).  
One useful distribution that can be obtained is the SEC weight distribution, which gives the 
total weight of molecules that have a size between log10Vh and log10Vh + dlog10Vh. Obtaining 
this distribution requires a DRI detector, which measures the refractive index of the solution 
passing through the SEC column in reference to a cell that contains pure solvent. The 
instrument factor fDRI, the concentration of molecules at each elution volume c(Vel), and the 
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refractive index increment dn/dc (where n is the refractive index) all determine the DRI signal 
intensity (Equation 2). 
   SDRI(Vel) = fDRI dn/dc c(Vel)    2 
The SEC weight distribution is given by the DRI detector in conjunction with the universal 
calibration curve (Equation  3)31. 
   w(logVh) =  −SDRI(Vel)
d Ṽel(Vh)
d log Vh
    3 
 
1.3.2 Dynamic light scattering 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS), is a 
technique that relates a particle’s Brownian motion, that is the movement of particles due to 
random collision with solvent molecules, to its size. This is done by exposing the particles to a 
laser and analysing the intensity of scattered light at a fixed angle. The relationship between 
the diffusion coefficient corresponding to Brownian motion and the size of a spherical 
impenetrable particle is given in the Stokes-Einstein Equation  (Equation 4). 
    D =
RT
N
.
1
6πZr
     4 
Here, R is the gas constant, N is Avogadro's number, T is the temperature, Z is the viscosity of 
the solvent and r is the radius of the diffusing particle. There are a number of assumptions in 
this relationship, with the most relevant being that the particles are hard spheres. Because 
glycogen is not a hard sphere, DLS is only able to measure an apparent molecular size as 
opposed to an absolute size.  
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1.3.3 Transmission electron microscopy 
Transmission electron microscopy (TEM) uses electrons instead of light to obtain images with 
significantly higher resolution than light microscopes. This higher resolution results from the 
considerably shorter wavelength of electrons compared to visible light. Because electrons are 
used instead of light, a viewing screen that translates electron intensity to light intensity is 
required62. 
The image resolution of TEM can be expressed in terms of the Rayleigh equation for light 
microscopy (Equation 5), which gives the smallest distance able to be resolved,  
     δ =
0.61
μ sin β
     5 
Here,  is the refractive index of the viewing medium,  is the wavelength of the electrons and 
 is the semi-angle of the magnifying lens. The constant (0.61) comes from the Rayleigh 
criterion that estimates angular resolution based on diffraction patterns. This usually results in 
the resolution being approximately half of the wavelength62. 
1.4 Type 2 Diabetes 
Type 2 diabetes, a disease associated with poorly controlled blood-glucose levels, is one of the 
Australian Government’s National Health Priority Areas, with the prevalence of this disease in 
Australia expecting to increase from ~7.6 % in 2000 to ~11.4 % in 202563. Developing 
countries are also undergoing rapid increases in the incidence of type 2 diabetes64, with a recent 
survey showing that the prevalence and rate of increase in China is even greater than those in 
countries such as Australia and the United States65. Prevention, mitigation, and treatment are 
critical problems, which have attracted considerable research resources worldwide; despite this 
effort, problems associated with type 2 diabetes are increasing because of lifestyle changes. 
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Knowledge of the components that control the initiation and progression of type 2 diabetes is 
still limited and the elucidation of these factors is an active part of current global research. 
Reasons for the poor control of blood-glucose levels in type 2 diabetics are associated with the 
body's production and response to insulin, a hormone important for lowering blood-glucose 
levels and stimulating glycogen production. It has been shown that there is an increase in -
cell apoptosis in type 2 diabetic sufferers, resulting in a reduction of cell mass of ~20-40%66-
68.  cell dysfunction generally occurs in early stages of type 2 diabetes resulting in an impaired 
insulin release. This prevents the transitioning of the body into the fed state where hepatic 
glucose production is suppressed69. Not only is insulin secretion impaired in type 2 diabetic 
patients, but there is some evidence that glucagon secretion increases (see Figure 9)70. Because 
glucagon works in the opposite direction to insulin, this results in an even further increase in 
blood-glucose levels, as glycogenolysis is stimulated. 
One of the main differences between type 2 and type 1 diabetes is that type 2 diabetic sufferers 
not only have an impaired insulin release, but they are also resistant or less responsive to 
insulin. This effect is seen mainly in the muscle (see Figure 9), which relies significantly more 
on insulin to transport glucose than the liver, as muscle is unable to passively acquire 
glucose71,72. Initially insulin secretion is increased to respond to the lack of insulin sensitivity73-
75, but due to the damaged  cells associated with diabetes, this compensatory effect eventually 
decreases, leading to hyperglycemia. 
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Figure 970: A schematic diagram of how hyperglycemia is caused by type 2 diabetes. Decreased 
insulin and increased glucagon secretion from the pancreas result in an increased release of 
hepatic glucose and a decrease in glucose uptake from the muscle; this results in high blood 
glucose levels. 
There is extremely strong epidemiological evidence that obesity is linked to type 2 diabetes, 
with 80% of people with the disease being obese70. Specifically it has been statistically 
concluded that there is a very strong correlation between abdominal obesity and the onset of 
type 2 diabetes76. Obesity in both children and adults is a pandemic that is resulting partly due 
to our genetic ability to store energy efficiently77 (evolving over millions of years during times 
of less accessibility to large amounts of food) in combination with today's access to large 
amounts of high-calorie food78,79.  
Through a series of experiments it was shown that increased levels of diacylglycerol (resulting 
from high levels of free fatty acid concentrations) may activate specific protein kinases that 
lead to insulin resistance. This provides an explanation for the link between obesity and insulin 
resistance, since the adipose tissues in obese people have been shown to be dysfunctional, 
resulting in increased levels of free fatty acids19,20. 
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1.4.1 The discovery of the type 2 diabetic db/db mouse and leptin 
The diabetes (db) mutation in mice, occurring in an inbred mouse strain (C57BL/Ks) from the 
Jackson Laboratory, was first reported in 1966. This mutation is inherited as an autosomal 
recessive unit with complete penetrance, with homozygote (db/db) mice being infertile, having 
an increased fat accumulation, hyperglycemia and a shortened life span. Heterozygote (+/db) 
female mice however, cannot be distinguished physiologically from the wild type (+/+) mice80.  
This mutation exhibits a similar phenotype to the autosomal recessive obese gene (ob), reported 
approximately 17 years earlier (from the inbred C57BL/6 strain at the Jackson Laboratory),81 
which also results in infertility, increased fat accumulation and hyperglycemia; however the 
lifespan of ob/ob mice is longer than that of db/db mice. While causing similar phenotypes, the 
ob mutation is on chromosome 6 and results in the inability to produce the satiety factor, now 
called leptin82,83; the db gene however, is located on chromosome 4 and results in a 
dysfunctional leptin receptor84,85. The elegant experiments that led to the elucidation of the 
mechanism behind these phenotypes has been outlined in a review by Coleman86. In summary, 
the determination that ob/ob mice lacked a certain blood-borne satiety factor and that db/db 
mice, while producing an excessive amount of this factor were unable to effectively respond to 
it, was determined using a number of parabiosis experiments. This involved the surgical 
combining of pairs of mice, which upon healing established cross circulation, allowing any 
potential blood-borne factors to be exchanged. A summary of the parabiosis experiments 
performed is given in Figure 10. One of the key insights, that db/db mice contain an excessive 
amount of a satiety factor in the blood, but are resistant to it, was deduced from the parabosis 
of db/db mice with wild type (+/+) mice87. As seen in Figure 10A, when joined with db/db 
mice, wild type mice drastically reduced their food intake to such an extent that they died of 
starvation. After it was subsequently shown that ob/ob mice, when parabiotically combined 
with db/db mice (Figure 10B) also died of starvation88, it was clear that ob/ob mice were able 
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to respond to this satiety factor. When surgically joined with wild type mice (Figure 9C), ob/ob 
mice began to consume approximately the same amount of food as wild type mice, leading to 
a reduction in obesity, insulinemia and blood-glucose levels. This indicated that ob/ob mice 
did not produce the satiety factor observed both in wild type, and in elevated levels in db/db 
mice88.  
 
Figure 10:86 A summary of the key parabiotic experiments performed to elucidate the 
mechanism behind the phenotypes of ob/ob and db/db mice. 
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1.5 Glycogen and Diabetes 
Comparisons of the liver-glycogen content of non-diabetic and db/db mice has been 
inconsistent in the past, with some studies reporting similar levels89, while others have reported 
diabetic mice having a 2-3 fold increase in hepatic glycogen levels90,91. It was suggested that 
perhaps the discrepancies arose due to an inconsistency in the time of which tissue samples 
were collected92. Given the diurnal nature of glycogen metabolism in many animals such as 
mice55,93-95, it is possible that at some stages of this cycle the liver-glycogen content is similar 
between diabetic and non-diabetic mice, whereas at other stages the diabetic mice have 
significantly more liver glycogen. This was shown to be the case, as shown in Figure 11, with 
the liver-glycogen content between db/db and non-diabetic mice being similar sometimes 
during the diurnal cycle, while being much higher in the db/db mice at other time points92. 
While non-diabetic mice have a steady decrease in liver-glycogen levels during the light period 
of a light/dark (day/night) cycle, db/db mice consistently have high levels. One suggested 
reason for this maintained level of hepatic glycogen is that db/db mice continue to eat during 
the light hours92. 
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Figure 1192. The hepatic glycogen content of control (white circles) and db/db (black circles) 
mice over the course of one diurnal light/dark cycle. 
The first indication that db/db (on the C57BL/KsJ background) mice may have a different 
glycogen structure to that of control mice, was the observation that the activity of glycogen 
synthase was higher in the supernatants after sucrose density centrifugation (used to fractionate 
glycogen into different sizes) of db/db mouse glycogen compared to the controls. As the 
majority of glycogen synthase is bound to glycogen (diabetic and healthy glycogen having the 
same affinity for glycogen synthase20), this indicated that there were a higher proportion of 
glycogen molecules that did not sediment; as these are likely to be smaller molecules, this 
suggested db/db samples had a higher proportion of small molecules compared to  non-diabetic 
(db/+) glycogen96,97. This was then supported by further sucrose density centrifugation 
experiments, where it was observed that the glycogen from db/db mice was missing the 
“heavier” fraction that was present in the control mice96. However, one limitation with this 
observation was that only a small number of mice were compared (3 separate experiments of 
just one non-diabetic and one diabetic mouse each time). Also while qualitatively useful, as 
sucrose density centrifugation separates based on the size, density and the shape of particles, it 
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is unable to produce quantitative distributions. Size exclusion chromatography however, 
separates based on size (hydrodynamic volume) and thus, with careful calibration, is able to 
produce semi-quantitative distributions of glycogen7. Recently we compared the SEC 
distributions of db/db mice (females on the C57BL/6J background) to that of controls (db/+, 
+/+), showing that the diabetic glycogen consists of predominantly  particles, while non-
diabetic glycogen varied greatly between mouse samples. Some control mouse samples had 
similar distributions to the db/db mice (with few  particles), while others consisted of a large 
proportion of  particles38. This indicates that glycogen is not just simply larger in non-diabetic 
mice, compared to these diabetic mice, but that non-diabetic mice have a more flexible 
glycogen metabolism, in which the size distribution of glycogen molecules is dynamic. 
Diabetic mice however, appear to be locked into having a distribution of small glycogen 
molecules. It is possible that the small variation in the liver-glycogen content of db/db mice 
(see Figure 11) partially explains the similar lack of variation in glycogen size distributions.  
Figure 12(A-C) shows the SEC weight distributions of healthy (db/+, blue, A; +/+, green, B) 
liver glycogen, compared to type 2 diabetic liver glycogen (db/db, red, C). Figure 12D shows 
the weight distribution of liver glycogen from young db/+ (blue) and young db/db (red) mice. 
The young db/db mice were not yet obese or diabetic and were still able to make larger  
particles. This provides some evidence that the lack of -particle formation seen in adult db/db 
mice is not simply a result of having a dysfunctional leptin receptor (the genotypic 
characteristic of the db/db mouse), but is a result of the obesity/diabetes caused by this 
mutation98. 
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Figure 1298: SEC weight distributions of liver glycogen from adult non-diabetic mice (db/+, 
blue, A; +/+, green, B), adult diabetic mice (db/db, red, C) and young non-diabetic (db/+, blue, 
D) and diabetic (db/db, red, D) mice. Inserted in A is a TEM image of healthy mouse liver 
glycogen (showing a large  particle ~ 150 nm in diameter that is an assembly of smaller  
particles). 
Figure 13 shows the weight-average molecular weight of non-diabetic and diabetic mouse-liver 
glycogen. This also shows how diabetic mice seem unable to produce large  particles (with 
weight-average molecular weights ~107, typical of  particles). Again, non-diabetic glycogen 
shows a much higher variability indicating more flexibility. 
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Figure 1398: The weight-average molecular weight of glycogen from non-diabetic (db/+, 
blue) and diabetic (db/db, red) mouse liver. 
We suggested38 that a population of small  particles would be more susceptible to enzymatic 
degradation, due to the increased surface area to volume ratio and thus exposed chain ends 
available to be hydrolyzed. This hypothesis is supported by a study that showed that glycogen 
phosphorylase did indeed have a higher activity for smaller glycogen particles. While this was 
in the direction of synthesis, it still supports the idea of surface area to volume ratio being 
important for glycogen phosphorylase action, with a similar trend expected to be seen in the 
direction of degradation99. Glycogen phosphorylase has also been shown to be more associated 
with100, and have a higher in vitro activity for31, smaller glycogen particles. 
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2. Chapter 2: Molecular Insights into Glycogen -Particle 
Formation 
2.1 Introduction 
This section focuses on obtaining a better understanding of the fundamental characteristics of 
glycogen structure, with a particular emphasis on determining how  particles are held 
together. By increasing our understanding of glycogen’s structure, we can gain insight into its 
biosynthesis and degradation. Past discrepancies in the literature regarding the bonding in  
particles, explained in section 1.1.4, are resolved here using dynamic light scattering (DLS) 
and SEC to examine the effects of various reagents designed to test a number of postulated 
links between β particles. The Supporting Information is given in Appendix 1. 
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ABSTRACT: Glycogen, a hyperbranched complex glucose polymer, is an intracellular
glucose store that provides energy for cellular functions, with liver glycogen involved in blood-
glucose regulation. Liver glycogen comprises complex α particles made up of smaller β
particles. The recent discovery that these α particles are smaller and fewer in diabetic,
compared with healthy, mice highlights the need to elucidate the nature of α-particle
formation; this paper tests various possibilities for binding within α particles. Acid hydrolysis
effects, examined using dynamic light scattering and size exclusion chromatography, showed
that the binding is not simple α-(1→4) or α-(1→6) glycosidic linkages. There was no
significant change in α particle size after the addition of various reagents, which disrupt
disulfide, protein, and hydrogen bonds and hydrophobic interactions. The results are
consistent with proteinaceous binding between β particles in α particles, with the inability of
protease to break apart particles being attributed to steric hindrance.
■ INTRODUCTION
Glycogen is a hyperbranched glucose polymer with an assembly
of linear chains of α-(1→4)-linked D-glucose residues
connected via α-(1→6) branching linkages. Glycogen com-
prises smaller glycogen β particles (∼106−107 Da), which can
also form much larger rosettes denoted as α particles.1,2
Whereas α particles are often regarded as a special feature of
liver glycogen structure, they have been reported to exist in
insect flight muscle,3 rat muscle,4 mouse cardiac tissue5 and
even the brain tissue of an infant suffering from glycogenosis.6
Although several studies have provided clues into the
formation of and binding in α particles, there are conflicting
data and theories regarding both how these particles form and
what bonds hold them together. It has been acknowledged in a
recent review that the chemical basis for the holding together of
α particles is not well understood.2 Possibilities include
disulfide linkages and other binding arising from the protein
scaffold present in glycogen,7,8 hydrogen bonding and hydro-
phobic interactions (addressed by Orrell and Bueding9),
glycosidic linkages,10 and chain entanglement.
Liver glycogen, with a molecular size distribution ranging
from small β to large α particles,11−13 acts as a blood glucose
buffer, playing a significant role in maintaining blood glucose
homeostasis.14,15 After the recent discovery12 that db/db mice,
a mouse model for type 2 diabetes, are unable to form many
large α particles, the question of how these particles form and
what holds them together has become of particular interest
because it is likely that degradation of α particles into glucose
would be slower (and hence more controlled) than in the same
mass of β particles due to a lower amount of exposed chains.
There are a number of possibilities for this binding, given in the
following short overview.
Hydrogen Bonding and Hydrophobic Effects. Past
studies have tested a range of disaggregating (hydrogen-bond
and hydrophobic disrupting) agents on α particles and have
found no effect on overall molecular weight.9 The number size
distributions of liver glycogen16 are found to be monotonically
decreasing in size. This suggests that the process resulting in
combined β particles is not aggregation, which would instead
give a number distribution with a maximum occurring at some
optimal aggregation size. Furthermore, if glycogen was
aggregated due to hydrogen-bonding or hydrophobic effects
then this would also be expected to occur in the muscle, but
muscle glycogen generally comprises few, if any, α particles. If α
particles were, however, covalently connected, then there could
be a difference in the regulation of the glycogen-producing
enzymes causing the differences in glycogen molecular size
distributions observed in different tissues such as liver and
muscle.
Protein and Disulfide Bonding. After the determination
that a gluco-protein (glycogenin) is the precursor for glycogen
synthesis and the suggestion7 that this protein may be involved
in the binding in α particles, it was reported8 that there was an
elimination of large glycogen particles upon treatment with 2-
mercaptoethanol. This reagent disrupts disulfide bonds, with
the reduced sulfhydryl groups being subsequently blocked by
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the addition of iodoacetamide. This resulted in the conclusion
that α particles are composed of β particle units attached by
disulfide linkages.8,17 It was, however, suggested18 that the
reported reduction in α particles could be caused by a
byproduct of the reaction, hydroiodic acid, which may have
hydrolyzed the α particles.
Glycosidic Linkages. Another study10 constructed size
frequency histograms from transmission electron micrographs
(TEMs) of glycogen treated with 2-mercaptoethanol and
iodoacetamide and reported no significant size decrease; these
authors suggested that α particles are created on elongated
exterior chains, implying an α-(1→4) link between β particles.
It has been suggested19 that in β particles the local molecular
density becomes so high after ∼12 layers of glucose monomer
units that further growth cannot occur (perhaps due to
inaccessibility to glycogen synthase). It is also noted that it is
extremely difficult20 to obtain, even semiquantitatively, reliable
size distributions by TEM in a system as heterogeneous as
extracted glycogen.
Crowding/Budding Mechanism. One can combine these
ideas into a “crowding/budding” mechanism, where occasional
exterior chains in a β particle are less crowded and can form
new “buds” of growing branches via glycogen synthase; these
branches themselves propagate, branch, and thus grow to β
particles bonded to the original one. We had suggested12 that
this “crowding/budding” postulate was inconsistent with the
observed glycogen number size distribution,13 which does not
show the maximum that might be expected at a size
corresponding to the onset of crowding. However, we now
point out that because new β particles can start after molecules
reach this size, a shoulder rather than a maximum is more likely,
as was observed.13 Possible support for such a model, as
opposed to one where β particles or β particle units come
together to form α particles, is that it has been suggested that
there is approximately one glycogenin molecule for every α
particle in the liver.21 If free β particles, each needing an
initiating glycogenin molecule, were synthesized separately and
then joined then there should be many more glycogenin
molecules than α particles.
Crowding/Budding Model with Protein “Glue”. A new
“crowding/budding” model is presented here that maintains the
idea that α particles are synthesized as one molecule (as
opposed to being an aggregation of previously formed β
particles). Our model, however, requires the link between β
particles to be less stable to acid hydrolysis than the inherent α-
(1→4) glycosidic linkages, with protein being the most likely
candidate. Another model that consists of proteins on the
outside of already formed β particles, joining them together to
form α particles, is also supported by the acid hydrolysis results
presented here; this model still needs to explain how β particles
are initially formed given the low glycogenin levels that have
been reported in liver glycogen.21 A recent review of glycogen
metabolism2 reports a large number of proteins found to be
associated with glycogen, making the idea of a protein “glue”
reasonable. Interestingly, a recent study22 found that there is a
significant amount of glycogenin-1 associated with the surface
of liver glycogen. The name glycogenin-1 is now used to
differentiate this protein, which represents the glycogenin
protein generally referred to in the literature (for which a
crystal structure is available),23 from the more recently
discovered glycogenin-2. Given that the past studies that have
observed approximately one glycogenin per glycogen mole-
cule21,24 used 10% trichloroacetic acid (TCA) in their glycogen
extraction, which is shown to degrade glycogen9,25,26 and
precipitate protein,27 it is likely that any glycogenin outside (or
between) β particles was removed.
The present article systematically tests each of these
possibilities by obtaining data on the size of particles resulting
from treatment with reagents that would be expected to disrupt
each suggested type of bonding. Glycogen was obtained from
two sources: extracted from pig liver (performed at the
University of Queensland Centre for Advanced Animal
Science), which is expected to contain a large amount of α
particles, and commercial oyster glycogen, which is expected to
contain largely β particles.
■ MATERIALS AND METHODS
Extraction and Purification of Liver Glycogen. Glycogen was
extracted from pig liver as follows: the procedures were approved
through the University of Queensland animal ethics procedures. A
liver sample (∼25 g) was extracted from a 106 day old male pig (Large
White breed) reared at the University of Queensland Centre for
Advanced Animal Science. The pig had been fed a diet composed of
wheat flour (59%), egg powder (15%), casein and sucrose (5% each),
and palm (6%) and sunflower (4%) oils. The pig was sedated and
humanely euthanized prior to sample extraction. The liver sample was
cut from the central lobe of the liver and immediately frozen in dry ice
and kept at −80 °C for 6 weeks before glycogen analysis. The
procedure for liver-glycogen extraction and purification with minimal
degradation was similar to that described previously.28 Liver (4 g) was
homogenized in five volumes of glycogen isolation buffer, an inhibitor
of glucosidase activity (50 mM Tris, pH 8, 150 mM NaCl, 2 mM
EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, and protease-
inhibiting phenylmethanesulfonylfluoride (PMSF)). The sample was
centrifuged at 6000g for 10 min at 4 °C with the resulting supernatant
centrifuged further at 50 000g for 30 min at 4 °C. The pellet was
resuspended in 3 mL of glycogen isolation buffer and layered over an
18 mL, stepwise sucrose gradient (25, 50, and 75% in glycogen
isolation buffer). The sample was centrifuged at 300 00g for 2 h at 4
°C. The glycogen fraction pelleted through all three sucrose layers,
whereas the microsomal layer penetrated only to the 25−50% sucrose
fraction. The supernatant was discarded, and the pellet was
resuspended in 1 mL of 80% ethanol. The sample was then
centrifuged at 4000g for 10 min at 4 °C, and the supernatant was
discarded. This ethanol precipitation step was repeated once more; the
pellet was resuspended in 1 mL of deionized water and then
lyophilized (freeze-dried; VirTis, Benchtop K).
Characterization of Glycogen. It is essential for these experi-
ments that the oyster glycogen particles comprise largely β particles
and that the pig-liver glycogen contains a significant number of α
particles. The characterization of these was performed using
transmission electron microscopy (TEM), size-exclusion chromatog-
raphy (SEC) with differential refractive index (DRI) detection, and
multiple-angle laser light scattering without size separation (“batch
MALLS”). Batch MALLS is necessary because some shear scission of
larger molecules will occur in SEC.29
TEM images of glycogen were obtained by a method similar to that
used elsewhere.28 Oyster type III glycogen (from Sigma) and pig-liver
glycogen were resuspended in 50 mM Tris buffer (pH 7.4) at ∼1 mg
mL−1. This suspension was then diluted 10-fold and applied onto a
glow discharged copper grid (400 mesh). After 2 min, excess sample
was drawn off with filter paper, and two to three drops of 1% uranyl
acetate was used to stain the sample. The preparations were examined
using a JEOL 1010 transmission electron microscope operating at 100
kV. Micrographs were recorded digitally using a SIS Veleta CCD
camera and reports and measurements were prepared using the
AnalySiS image management software.
SEC requires a molecularly dispersed solution of the analyte
prepared without degradation, which was implemented following a
previous procedure.30,31 Glycogen was dissolved in the desired SEC
eluent of dimethyl sulfoxide (DMSO; HPLC grade, Sigma-Aldrich)
Biomacromolecules Article
dx.doi.org/10.1021/bm3012727 | Biomacromolecules 2012, 13, 3805−38133806
with 0.5 wt % LiBr (ReagentPlus) on a thermomixer at 80 °C for 6 h;
this gives complete molecular dissolution. The glycogen concen-
trations were ∼1.5 g L−1. SEC separates by hydrodynamic volume or
the corresponding hydrodynamic radius Rh; SEC data are reported
here as the SEC weight distribution w(log Rh).
Utilizing a procedure described in the literature,13 samples were
injected into an Agilent 1100 Series SEC system (PSS, Mainz,
Germany) using a GRAM preColumn, 30 and 3000 columns (PSS) in
series, in a column oven at 80 °C. The chromatography was carried
out at a flow rate of 0.3 mL min−1 to minimize shear scission of the
glycogen.29 The system used a refractive index detector (RID)
(Shimadzu RID-10A, Shimadzu, Japan) to allow the determination of
SEC weight distributions.
Pullulan standards (PSS), with an MW range of 342 Da to 2.35 ×
106 Da, were directly dissolved into eluent and run through the system
to generate a universal calibration curve, allowing the determination of
the hydrodynamic volume from the elution volume. The Mark−
Houwink parameters for pullulan in DMSO/LiBr (0.5 wt %) at 80 °C
are K = 2.427 × 10−4 dL g−1 and α = 0.6804 (Kramer and Kilz, PSS,
private communication). Whereas this means that all samples with a
hydrodynamic radius above 55 nm were outside of the calibration
limit, we are still able to compare relative differences in the total
weight of molecules because any inaccuracies will be consistent for all
samples.
Oyster glycogen was dissolved for batch MALLS in 0.5 wt % LiBr/
DMSO at concentrations ranging from 0.1 to 0.3 g L−1. Pig-liver
glycogen was dissolved in 0.5 wt % LiBr/DMSO at concentrations
ranging from 0.02 to 0.05 g L−1. These concentrations gave the best
signal without overloading the MALLS. The MALLS (BIC-MwA7000,
Brookhaven Instrument, New York,) was then run in batch mode, with
detectors at angles 35, 50, 75, 90, and 130°. Each sample was repeated
on a different day to determine a more accurate weight-average
molecular weight (M̅w). Data were analyzed with Berry plots (see the
Supporting Information).
Effects of Low pH on α Particles. To see the effects of acid on
glycogen size, we dissolved pig-liver and oyster glycogen in aqueous
solvent with a range of pH values and heated them in a thermomixer at
80 °C for 26 h. The apparent z-average diameter of molecules was
determined at different times by dynamic light scattering (DLS) with a
Zetasizer Nano (Malvern Instruments, Malvern, U.K.) after allowing
the samples to equilibrate to room temperature. The different solvents
used were distilled water (pH ∼7), 0.1 M sodium acetate buffer (pH
∼3.5), and HCl solution (pH 0.25 to 0.5).
For acid hydrolysis with SEC characterization, pig-liver and oyster
glycogen were dissolved in 0.1 M sodium acetate buffer (2 mg mL−1;
pH ∼3.5) and heated to 80 °C in a thermomixer for 10 min, 30 min, 2
h, 1 day, 2 days, 3 days, and 1 week. Pig-liver and oyster glycogen were
also dissolved in deionized water (2 mg mL−1) and heated in a
thermomixer at 80 °C for 1 week. All samples were run in duplicate.
After samples were removed from the thermomixer, four volumes of
ethanol were added to each to precipitate the glycogen. Samples were
centrifuged at 4000g for 10 min, and the supernatants were discarded.
The centrifugates were dissolved in 1 mL of deionized water and
lyophilized (VirTis, Benchtop K). Samples were then dissolved in the
SEC eluent and characterized with the same SEC procedure as the
starting materials. Pig-liver and oyster glycogen was also directly
dissolved in the SEC eluent to act as an initial time point (with no acid
hydrolysis). SEC results are presented as the SEC weight distribution
w(log Vh), which is the weight of particles of hydrodynamic volume Vh
(the SEC size separation parameter). Data are presented in terms of
the corresponding hydrodynamic radius Rh (Vh =
4/3πRh
3).
Using a similar preparative SEC setup to that used in the
literature,32 samples at the initial time point, 2 h acid hydrolyzed,
and 1 day acid hydrolyzed were run through PREP GRAM 30 and
PREP GRAM 3000 columns from PSS (Mainz, Germany) in an
AF2000 setup (Postnova Analytics, Landsberg-Lech, Germany) at 80
°C with a flow rate of 1.5 mL min−1 in the SEC eluent. Samples were
manually injected using a Rheodyne 7000 high-pressure switching
valve (IDEX Health & Science, Rohnert Park, CA). A DRI detector
(RI 3140, Postnova) was used to obtain the weight distribution of
molecules at each elution time. This preparative column setup, giving
slightly better separation than the other SEC column, was employed to
confirm further SEC results. Whereas it is generally necessary to
calibrate SEC data to make it reproducible, because we were just
interested in the shape of the elugram and all three samples were run
in succession, we are able to present the data as raw signal in relation
to elution time.
DLS of Glycogen Exposed to a Range of Conditions. Effects
of disrupting disulfide linkages were examined as follows. As
previously,8 liver glycogen was dissolved to a concentration of 2 g
L−1 in 0.1 M Tris buffer (pH 8.5) containing 8 M urea. Nitrogen was
then bubbled through the solution for 30 min. The sample was then
divided into three parts: one without further treatment (the control);
one treated with 2-mercaptoethanol (0.1 mL per mL of Tris buffer,
Sigma) for 30 min; and the last treated with 2-mercaptoethanol and
subsequently with iodoacetamide (0.3 g mL−1, Sigma). To determine
whether hydrophobic interactions were important, glycogen was also
dissolved in 2 wt % sodium dodecyl sulfate (SDS) in 8 M urea.
Effects of disrupting a protein scaffold were examined as follows.
Glycogen (4 mg mL−1) in 250 mM tricine buffer (pH 7.5) was
incubated at 37 °C with 0.9 units mL−1 protease (bacterial type XIV,
Sigma) for 30 min. Samples were then centrifuged (4000g, 10 min),
and the supernatant was discarded. Half of the samples were
subsequently treated with 0.45% bisulfite solution and incubated at
37 °C for 30 min. These samples were centrifuged again (4000g, 10
min), and the supernatant was discarded. All samples were then
dissolved in DMSO with 0.5 wt % LiBr,30 which disrupts hydrogen
bonding.
To test whether α particles were held together by hydrogen
bonding, glycogen dissolved in DMSO and in DMSO + 5 wt % LiBr
(which disrupts very strong H-bonding) were examined.
All samples were measured in quadruplicate.
The apparent z-average diameter of molecules was determined by
DLS with a Zetasizer Nano (Malvern Instruments). This DLS
instrument uses back scattering (173°) to infer an apparent molecular
size. A major problem with applying this to a dissolved complex
branched molecule such as glycogen is that DLS probes not only
overall center-of-mass motion (whence a z-average size is inferred) but
also all types of local motions and sensitivity to the latter (which are, in
general, unrelated to overall size) increase with increasing scattering
angle, which should be <35° to minimize this artifact.33−35 It has also
been shown that α particles and β particles exhibit different internal
dynamical properties, which would affect the DLS data interpretation
due to the local mode artifact.36
■ RESULTS AND DISCUSSION
Characterizing Starting Materials. Figure 1A shows a
TEM image of oyster glycogen, with particle sizes correspond-
ing to that of β particles at ∼20−30 nm in diameter. Figure 1B
shows a TEM image of pig-liver glycogen, showing that this
contains glycogen particles ranging from β particles up to large
α particles ∼200 nm in diameter. The SEC distribution given in
Figure 1C and the batch MALLS M̅w data in Table 1 confirm
the TEM results.
Effects of Low pH on α Particles. Figure 2 shows the
change of the apparent z-average size of both pig and oyster
glycogen exposed to a range of pH values.
Figure 3 shows SEC elugrams of pig-liver glycogen initially
(A), after 2 h (B), and after 1 day (C) of being exposed to pH
∼3.5 at 80 °C. Because larger particles elute first in SEC, the α-
particle peak comes before the smaller (largely β-particle) peak.
Calibrated SEC was used to characterize both pig-liver and
oyster glycogen before acid hydrolysis and at 10 min, 30 min, 2
h, 1 day, 2 days, 3 days, and 1 week after being exposed to pH
∼3.5 at 80 °C. Data for the first 2 h of digestion are given in
Figure 4, with the final time points between 1 day and 1 week
being presented in Figure 5.
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Figure 2 shows pig-liver glycogen under acidic conditions (at
80 °C) degrading over time, with the apparent z-average size of
particles approaching that of the oyster β particles after ∼26 h.
The fact that these molecules appear to be degraded much
more than the oyster glycogen suggests that the links between β
particles are more susceptible to acid hydrolysis than glycogen
α-(1→4) linkages. This is in agreement with early centrifuga-
tion experiments9 and TEM images that found no α particles at
pH < 4.16
To confirm this finding, SEC distributions of both pig-liver
and oyster glycogen exposed to pH ∼3.5 (at 80 °C) for
different times between 10 min and 1 week were obtained
(Figures 3−5). The advantages of using SEC are that DLS
artifacts33−35 are avoided and also that each sample is dissolved
Figure 1. TEM of oyster glycogen (A) and of pig-liver glycogen (B).
SEC weight distribution (C) of oyster glycogen (red) and pig-liver
glycogen (blue). Both SEC distributions are normalized to equal area.
Table 1. Batch MALLS Results Giving Weight-Average
Molecular Weights for Pig-Liver and Oyster Glycogen
sample M̅w/10
6 Da
pig-liver glycogen 28.7 ± 0.26
oyster glycogen 7.1 ± 0.74
Figure 2. Apparent z-average of pig-liver and oyster (green, pH ∼7; orange, pH ∼3.5; red, pH 0.25 to 0.5).
Figure 3. Raw SEC DRI signal of samples separated using preparative
SEC separation, with all data obtained in the same run; samples are
pig-liver glycogen with no acid hydrolysis (A) after 2 h of acid
hydrolysis (B) and after 1 day of acid hydrolysis (C).
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in the same solvent. Whereas the DLS results show what
appears to be degradation at low pH, it may be that the
negative charge acquired by glycogen following incubation in
low pH buffers37 may be disrupting any noncovalent interaction
such as hydrogen bonding.
It can be seen clearly from the elugram in Figure 3 that α
particles are degrading preferentially, although smaller (largely
β) particles still experience some hydrolysis. Calibrated SEC
was also used to obtain confirm that α particles are
preferentially degraded by acid hydrolysis.
Confirming DLS and preparative SEC results, the pig-liver
glycogen (Figure 4A) shows a significant decrease in α particles
after being exposed to low pH for 2 h, with smaller (largely β)
particles, both pig-liver (A) and oyster (B), remaining relatively
undegraded. If α particles were connected via α-(1→4)
linkages, then the distributions would be expected to maintain
the same shape as the particles degrade, as all molecules should
decrease in size (as a proportion of the whole molecule) at the
same rate. This, however, is not seen, with the shape of the
distributions being altered as α particles degrade at a faster rate
than that of β particles.
For the final stages of acid hydrolysis (1 day to 1 week) both
pig-liver (Figure 5A) and oyster glycogen (B) show very similar
degradation behavior, which is to be expected, because after 1
day pig-liver glycogen appears to comprise smaller (largely β)
particles exclusively and is then thus similar to oyster glycogen.
Figure 6 shows the effect of heating pig-liver (6A) and oyster
(6B) glycogen in deionized water at 80 °C for 1 week. These
results show that α particles are also hydrolyzed by water at this
temperature and that this neutral water hydrolysis at elevated
temperatures, as with the acid hydrolysis, preferentially
degrades the link between α particles.
Because a protein backbone is covalently linear and glycogen
after acid hydrolysis is dissolved in DMSO/LiBr, a potent
disrupter of hydrogen bonds, hydrolysis of just one peptide
bond would be sufficient to sever completely any link
potentially provided by this protein “glue”. Glycogen, however,
is a highly branched molecule, so any single breakage of an α-
(1→4) or α-(1→6) bond will remove only a part of the
molecule, and with ∼50% of the molecule being present in
outer chains,38,39 the amount of molecule to be separated from
one bond breakage is likely to be relatively small. This means
that ∼50% of bonds being hydrolyzed will result in the
Figure 4. SEC weight distributions for first the 2 h of acid hydrolysis; pig liver (A) and oyster (B) glycogen before acid hydrolysis and after 10 min,
30 min, and 2 h of acid hydrolysis. Curves are normalized to equal areas. Replicate experiments show the same trend. (See the Supporting
Information.)
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production of a small chain and a molecule that is of
approximately the same size as the molecule before this
hydrolysis. As this continues, the SEC-distribution maximum
would decrease with the formation of more and more smaller
molecules. The hydrolysis of inner glycogen chains will also
occur, causing an even greater decrease in the SEC-distribution
maximum. This predicted trend is consistent with Figure 5,
with the maximum steadily decreasing and the gradual
formation of a small shoulder of molecules. It should be
noted that many of the small molecules will have been removed
in the ethanol precipitation step40−42 during sample prepara-
tion and thus are not seen in the SEC distribution. The minimal
degradation of β particles in the first 2 h of exposure to an
acidic environment (Figure 4B) indicates that this hydrolysis is
relatively slow compared with the degradation of α particles.
It should also be noted that α-(1→6) bonds are much more
resistant to acid hydrolysis than α-(1→4),43,44 making it less
likely for whole branches to be removed. This may seem
contradictory to the observation that high amylose starches,
which contain fewer α-(1→6) linkages, are more acid-resistant
than starches with lower amylose contents. However, the
analysis of the chain length distributions of different acid-
hydrolyzed starches has shown that amylose chains are more
susceptible to acid hydrolysis than the shorter amylopectin
chains and that a possible reason for the increased acid
resistance of high amylose starches is that their hydrolysis
results in the production of larger nanoparticles.45
It is also unlikely that α particles are held together by other
glycosidic linkages because the kinetics for the acid hydrolysis
of α-(1→2) and α-(1→3) are very similar to that of α-(1→4),
and the acid hydrolysis of the anomeric β glycosidic linkages,
while more thermodynamically favorable, occurs at slower rates
than glycosidic linkages.43,46
It is well-established that peptide hydrolysis is catalyzed by
acid,47 and whereas complete hydrolysis of proteins into single
amino acids requires very low pH values at high temperatures,
partial hydrolysis occurs under much milder conditions48 and
even occurs spontaneously in water at neutral pH.49 The first-
order rate coefficient for the hydrolysis of internal peptide
bonds (exemplified using acetylglycylglycine N-methylamide)
under neutral conditions has been studied over a range of
temperatures.49 By assuming an Arrhenius form and extrapolat-
ing their results to 80 °C (see the Supporting Information), the
rate coefficient is estimated to be ∼2.0 × 10−8 s−1,
corresponding to a half-life of ∼401 days. This is approximately
four orders of magnitude faster than hydrolysis at this
temperature of the glycosidic bonds that join polysacchar-
ides.35,36 Using the same first-order kinetics, it can be calculated
Figure 5. SEC weight distributions for final stages of acid hydrolysis; pig liver (A) and oyster (B) glycogen after 1 day, 2 days, 3 days, and 1 week of
acid hydrolysis. Curves are normalized to equal areas. Replicate experiments show the same trend. (See the Supporting Information.)
Biomacromolecules Article
dx.doi.org/10.1021/bm3012727 | Biomacromolecules 2012, 13, 3805−38133810
that after 7 days ∼1.2% of peptide bonds will have been
hydrolyzed; given the covalently linear nature of protein, this
should be sufficient to sever many of the links between β
particles. Consistent with this approximate calculation, Figure
6A shows how α particles are hydrolyzed when heated to 80 °C
in deionized water for 7 days, a result consistent with the
hypothesis that protein holds α particles together.
α Particles Exposed to a Variety of Conditions.
Comparing the z-average diameter (obtained with DLS) of
pig-liver to oyster glycogen (which essentially contains only β
particles)50 for each treatment suggests whether or not α
particles are degraded into β particles. While there is a
significant amount of overlap between the oyster and the pig-
liver glycogen size distributions (see Figure 1C), the intensity
of scattered light measured in DLS is proportional to the sixth
power of the diameter, making it highly sensitive to higher
molecular sizes.
Exposing β particles to the same procedure as the liver
glycogen gives the apparent z-average diameter of β particles in
each solvent. This allows us to infer whether α particles break
up under a range of solvents and reagents, in which case the
apparent z-average size would be similar to that of the oyster
glycogen. Because β particles from oyster glycogen may be
slightly different from those in pig liver, only large differences in
the z-average diameter between the liver and oyster glycogen
can be used to infer whether α particles are or are not broken
apart. Because β and α particles have different dynamical
properties in solution,51 the degradation of α particles to β
particles would have large effects not only on center-of-mass
motion but also on all but the shortest local modes.
The results in Figures 7 and 8 show that β particles (typically
∼30 nm in diameter) gave a large range of apparent z-average
diameters in different solvents, ranging from 56 to 171 nm.
Because it is unconceivable that a β particle could swell to a size
of 171 nm or preferentially form aggregates in the much more
solvating LiBr/DMSO (which is not seen in SEC when β
particles are dissolved in this solvent), it is very likely that the
varied apparent sizes are artifacts arising from DLS being
sensitive to local motion at high angles. These results
emphasize that DLS of complex branched molecules can give
artifactual results.
Figure 6. Pig-liver (A) and oyster glycogen (B) dissolved directly in SEC eluent (time zero) and after being heated at 80 °C in deionized water for 1
week (curves overlap entirely in panel B). Curves are normalized to equal areas.
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Figure 7 shows that there is a moderate time-dependent
decrease in the apparent (DLS) size of glycogen treated with 2-
mercaptoethanol and iodoacetamide (D−F), whereas 2-
mercaptoethanol without iodoacetamide gave a moderate
increase (C). Figure 7B shows that the introduction of the
surfactant SDS, introduced to disrupt any hydrophobic
interactions, has no significant effect on the apparent size of
the glycogen (consistent with past experiments).9
Figure 8 shows the apparent size of untreated glycogen in
DMSO with two LiBr concentrations, treated with protease and
treated with both protease and bisulfite. In agreement with
previous results,13 5% LiBr caused a slight increase in apparent
size. Protease-treated liver glycogen also showed a moderate
increase in apparent size. When treated with protease and
bisulfite, a reducing agent that disrupts disulfide bonds, the
apparent particle size decreased slightly for the liver glycogen.
When treated with protease and bisulfite, the oyster glycogen
formed aggregates: there were two peaks in the apparent size
distribution obtained from the DLS software, at 100 and ∼3000
nm. Whereas one must be extremely cautious with distribution
reported by the DLS manufacturer’s software, because there are
major assumptions involved in inferring them from the raw
data, they are suggestive. Consistent with this, after
centrifugation this apparent 3000 nm peak was not present in
the supernatant, with just a single peak at ∼100 nm being
observed using DLS. This aggregate formation of β particles,
given that the α particles did not under the same conditions,
suggests a difference in the nature of the surfaces of β and α
particles. It should be noted, however, that it is possible that
this difference is not between β and α particles per se but is
instead a species-specific difference.
These results in Figure 7 show that α particles are not held
together by disulfide bonds, as once reported by Chee and
Geddes.8 A possible reason for that reported degradation of
glycogen particles may be that the byproduct hydroiodic acid
caused hydrolysis.18 We confirmed the possibility that the size
diminution reported by Chee and Geddes8 was caused by
adventitious hydroiodic acid by testing the pH after the
introduction of iodoacetamide, with the pH dropping from 8.5
to ∼1, while the apparent size changed from 170 to 105 nm
after 24 h.
Treatment with protease does not lead to a significant
change in apparent size (Figure 8), consistent with past
experiments.10 Whereas the formation of free β particles from
liver glycogen α particles upon protease incubation would have
been strong evidence of a protein link between β particles, we
suspect that the protease would not be able to diffuse within the
glycogen α-particle structure because of steric hindrance.
■ CONCLUSIONS
Liver glycogen, a glucose polymer functioning as a blood-sugar
reservoir in animals, comprises small β particles that are linked
together to form larger, more complex α particles. It has
recently been found that liver glycogen in diabetic mice
contains fewer and smaller α particles than found in healthy
mice,12 and thus understanding the nature of the binding
between β particles has significance for diabetes. The present
study investigates the changes in overall size and size
distribution (using static light scattering, DLS, and SEC)
when glycogen is subjected to a range of reagents and
conditions that should selectively break the bonds that are
possible candidates for this binding. The results presented here
show that the link joining β particles together, within an α
particle, is more susceptible to acid hydrolysis than glycogen’s
inherent glycosidic α-(1→4) and α-(1→6) linkages. Hydrolytic
degradation of α particles at neutral pH is also observed, with
the rate of hydrolysis more consistent with protein, not
glycosidic, linkages being degraded. While having to be careful
when interpreting high-angle DLS data, it is clear that α
particles are not degraded by disulfide-bond-disrupting 2-
mercaptoethanol or hydrophobic-interaction-disrupting SDS.
Whereas protease treatment did not result in the breaking apart
of α particles, it is quite possible that steric hindrance prevented
the protease from accessing the proteins between the particles.
The data are therefore most consistent with proteinaceous links
between the β particles to form α rosettes. One possibility is for
this protein to be glycogenin-1, believed to be located within
the glycogen core, but recently this was shown to be an
abundant protein associating with the surface of liver glycogen
particles.22 Proteomics work directed at the question of
whether glycogenin-1 is as prevalent on the surface of liver
glycogen from diabetic mice may help explain their inability to
form as many large α particles as healthy mice. This knowledge
is of potential interest in improved understanding of Type 2
diabetes.
Figure 7. Apparent z-average diameter of untreated liver (blue) and
oyster (red) glycogen (A); glycogen treated with 2 wt % SDS (B);
glycogen treated with 2-mercaptoethanol (C); glycogen treated with 2-
mercaptoethanol and iodoacetamide (D); glycogen treated with 2-
mercaptoethanol, and iodoacetamide after 4 (E) and 24 h (F).
Figure 8. Apparent z-average diameter of pig-liver (blue) and oyster
(red) glycogen in DMSO (A); glycogen in DMSO with 0.5 wt % LiBr
(B); glycogen in DMSO with 5 wt % LiBr (C); glycogen in DMSO
with 0.5 wt % LiBr treated with protease (D); and glycogen in DMSO
with 0.5 wt % LiBr treated with protease and reducing agent bisulfite
(E).
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2.2 Outcomes 
This study has provided strong evidence that glycogen  particles are held together via a 
linkage more acid labile than glycosidic linkages. This has led to the hypothesis of a protein 
“glue” that is capable of linking  particles together. If this suspected protein is proven to exist, 
any regulator that decreases its expression may become a promising inhibitory drug target for 
diabetes management, based on the impaired -particle formation found in diabetic mice98. 
While the experiments here do not conclusively rule out long glucan chains that are more 
reactive to acid hydrolysis than the glucan chains within a glycogen  particle acting as the 
glue that holds  particles together, it is unlikley that chain length would have a significant, if 
any effect on the acid hydrolysis rate of the glycosidic linkages.  The results presented in 
Chapter 5 provide further evidence that the linkages holding  particles together to form larger 
 particles are not glycosidic. 
We also demonstrated that past studies observing the effect of 2-mercaptoethanol on glycogen 
structure, with the addition of iodoacetamide, did indeed result in low pHs (as Manners 
suggested3) and that it is the acidic environment, not the reducing effect of 2-mercaptoethanol 
that resulted in the reported degradation of glycogen  particles.  
3. Chapter 3: Changes in Glycogen Structure over Feeding 
Cycle Sheds New Light on Blood-Glucose Control 
3.1 Introduction 
While the previous chapter has indicated the potential of a protein “glue” in holding  particles 
together, it is still unclear when during the glycogen cycle these particles are formed. One 
significant limitation to our previous study that compared the structure of liver glycogen from 
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healthy and diabetic mice38, is that all of the mice were sacrificed at approximately the same 
time during the day (~9 am), instead of taking into account the whole diurnal cycle of glycogen 
metabolism.  
As described in section 1.2.4 above, there have been discrepencies in the literature regarding 
the metabolism of glycogen in terms of structure, with some studies32 seeing the structure 
varying significantly during glycogen synthesis and others seeing little difference59. This 
chapter analyzes the glycogen content and structure at various times over a diurnal cycle, with 
the aim being to characterize any structural changes that occur during synthesis and 
degradation. The Supporting Information is given in Appendix 2. 
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ABSTRACT: Liver glycogen, a highly branched polymer of glucose, is
important for maintaining blood-glucose homeostasis. It was recently shown
that db/db mice, a model for Type 2 diabetes, are unable to form the large
composite glycogen α particles present in normal, healthy mice. In this study,
the structure of healthy mouse-liver glycogen over the diurnal cycle was
characterized using size exclusion chromatography and transmission electron
microscopy. Glycogen was found to be formed as smaller β particles, and then
only assembled into large α particles, with a broad size distribution,
significantly after the time when glycogen content had reached a maximum.
This pathway, missing in diabetic animals, is likely to give optimal blood-
glucose control during the daily feeding cycle. Lack of this control may
contribute to, or result from, diabetes. This discovery suggests novel
approaches to diabetes management.
■ INTRODUCTION
Glycogen, a hyperbranched glucose polymer, is found in a
number of organisms; in the case of animals, including humans,
it is present in a variety of different tissues. Liver glycogen acts
as a blood-glucose buffer, helping the body maintain blood-
glucose homeostasis. Glycogen particles range from smaller β
particles (∼20−30 nm in diameter) to composite α particles as
large as 300 nm.1,2
Size exclusion chromatography (SEC) has recently been used
to compare the structure of nondiabetic liver glycogen with that
in db/db mice, a model for type 2 diabetes.3 The results show
that the size distribution of nondiabetic liver glycogen varies,
with a wide range of sizes in a given animal, but with a
predominance of very large glycogen α particles in many
individuals. However, liver glycogen in “diabetic” db/db mice
has relatively little size variation between mice, with all
glycogen consisting predominantly of β particles within a fairly
narrow size distribution, plus some small α particles. This is
consistent with the observation that db/db mice had fewer
“heavy particles”, as inferred using sucrose density centrifuga-
tion.4 If this is a general phenomenon, then there are potential
implications for elucidation of the molecular mechanisms
underlying diabetes and its management in humans.
The first step in understanding why db/db mice are unable to
form larger α particles is to gain a better understanding of the
formation and degradation of these particles in healthy,
nondiabetic mice.
Liver glycogen in mice, like many animal species,5−8 follows a
daily rhythm. This rhythm in rodents has been studied in some
detail during a 12 h light/12 h dark cycle, with glycogen
content peaking during the dark period and decreasing during
the light (due to their nocturnal nature).5,6,9−11 Previous results
and conclusions for glycogen structural changes during
synthesis and degradation have been conflicting. In 1967,
Parodi reported12 that, while glycogen content increased
significantly after administering glucose to overnight-fasted
mice, the glycogen size distributions (using sucrose gradient
centrifugation) remained almost unchanged. However, Geddes
in 197113 found that sucrose-density-centrifugation size
distributions varied significantly with glycogen content in
refed rabbits after 4 days of starvation.
Moreover, liver-glycogen contents after the refeeding of
starved rats14 and rabbits13 were significantly higher than those
of normal livers with an overproduction of low molecular
weight glycogen in rabbits. Thus, a starvation/refeeding
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method may not accurately reflect the process occurring during
a normal feeding cycle.
To better understand the dynamics of liver glycogen
formation, we characterized liver glycogen structure by SEC
and transmission electron microscopy (TEM), from mice
sacrificed at various times of the day, exploiting the natural
diurnal rhythms of feeding patterns in mice.
■ EXPERIMENTAL SECTION
Animals. Approval for the use of animals was from the University
of Sydney Animal Care and Ethics Committee. Male mice on an FVB/
NJ background were bred in-house and housed in standard cages (2−6
mice/cage). Temperature was controlled at 22° ± 1 °C with a 12 h
dark-light cycle (lights on at 6 am). Mice were given ad libitum access
to water and standard chow (6% kcal from fat, 14.3 MJ kg−1, Glen
Forest Specialty Feeds WA, Australia) until age 12 weeks.
At termination, 12 week old mice were anaesthetized with sodium
pentobarbitone (150 mg kg−1 intraperitoneal). Liver was rapidly
excised, snap frozen in liquid nitrogen, and stored at −80 °C.
Glycogen Extraction. Glycogen was extracted similarly to
previous studies.15,16 Approximately 200 mg of mouse liver was
homogenized in 3.2 mL of glycogen isolation buffer (50 mM Tris, pH
8, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, and 5 mM sodium
pyrophosphate). A total of 200 μL of this homogenate was removed
for glycogen content analysis. Samples were centrifuged at 6000 g for
10 min at 4 °C. The supernatants were then centrifuged at 300000 g
for 1 h at 4 °C. The pellet was then resuspended in glycogen isolation
buffer and layered over a 3 mL, stepwise sucrose gradient (37.5 and
75% in glycogen isolation buffer). These samples were then
centrifuged at 488300 g for 2 h at 4 °C. The pellet of glycogen at
the bottom of the tube was resuspended in 500 μL of water. Samples
were mixed with four parts absolute ethanol to precipitate glycogen.
The samples were centrifuged at 4000 g for 10 min and the pellets
were redissolved in 1 mL of deionized water and lyophilized (freeze-
dried; VirTis, Benchtop K). A small amount of sample was put aside
for TEM.
Size-Exclusion Chromatography. As shown previously in refs 17
and 18, mouse-liver glycogen was dissolved directly into the SEC
eluent, dimethyl sulfoxide (DMSO; HPLC grade, Sigma-Aldrich) with
0.5 wt % LiBr (ReagentPlus) on a thermomixer at 80 °C for 6 h, giving
complete molecular dissolution. The size separation method follows
that performed previously.17 Samples were injected into an Agilent
1100 Series SEC system (PSS, Mainz, Germany) using a GRAM
preColumn, 30 and 3000 columns (PSS) in a column oven at 80 °C
and a flow rate of 0.3 mL min−1. This flow rate was employed to
minimize shear scission of the molecules.19 SEC weight distributions
were determined by using a refractive index detector (RID; Shimadzu
RID-10A, Shimadzu, Japan).
A universal calibration curve was obtained using pullulan standards
(PSS), with a molar mass range of 342 to 2.35 × 106 Da, which were
directly dissolved into the DMSO/LiBr eluent. This allowed the
conversion of elution volume into hydrodynamic radius (Rh).
19 It is
noted that the IUPAC definition of hydrodynamic radius20 depends on
the technique used, and thus, Rh as defined by the SEC separation
parameter is a (hopefully only slightly) different quantity to that for,
for example, dynamic light scattering. While there are obvious
problems with this definition, it is the one that is internationally
agreed upon. It could be supplanted by adding a further subscript
indicating the technique in question, but to do that here, where only a
single type of Rh is under discussion, would introduce an unnecessary
clutter in notation. The Mark−Houwink parameters for pullulan in
DMSO/LiBr (0.5 wt %) at 80 °C are K = 2.427 × 10−4 dL g−1 and α =
0.6804 (Kramer and Kilz, PSS, private communication); this gives an
Rh upper limit of accurate calibration of ∼60 nm, with the size scale
above this being only semiquantitative.
Transmission Electron Microscopy. TEM images of glycogen
were obtained using a similar method to that employed previously.21
One glycogen sample from each of the mice sacrificed at 9 pm, 4 am,
12 noon, 4 pm, and after 16 h of starvation was dissolved into
deionized water (∼0.5 mg mL−1). This was then diluted 10-fold and
applied to a glow discharged 100 mesh copper grid (ProSciTech).
After 1 min, excess sample was drawn off with filter paper and 2−3
drops of 2% uranyl acetate was added to stain the sample. Excess
uranyl acetate was removed using filter paper after 45 s. The
preparations were then analyzed using a JEOL 1010 transmission
electron microscope (JEOL, Tokyo, Japan) operating at 100 kV. The
images were recorded digitally with a SIS Veleta CCD camera
(Olympus, Münster, Germany) and reports and measurements were
prepared using the AnalySiS image management software.
Glycogen Content Assays. The method employed, using
amyloglucosidase to degrade glycogen to individual glucose units
and then glucose oxidase/peroxidase (GOPOD) reagent to quantify
the amount of glucose, was similar to that used elsewhere.22 A total of
5 μL of amyloglucosidase (Megazyme), 20 μL of homogenate (from
Glycogen Extraction), and 100 μL of sodium acetate buffer (pH 6)
was made up to 0.5 mL with deionized water and incubated on a
thermomixer at 50 °C for 30 min. A control, with everything except
amyloglucosidase, was also analyzed. A 300 μL aliquot of each sample
was then added to 1 mL of glucose oxidase/peroxidase reagent
(GOPOD, Megazyme) and incubated for a further 30 min at 50 °C on
a thermomixer. The absorbance (510 nm) of each sample was then
analyzed on a UV-1700 PharmaSpec UV−vis spectrophotometer
(Shimadzu). The glycogen content was then calculated based on a
calibration curve (constructed by reacting D-glucose of various
concentrations with the same GOPOD reagent). All samples and
controls were run in duplicate with the absorbance values averaged.
■ RESULTS AND DISCUSSION
As shown in Figure 1, the amount of liver glycogen in the mice
followed a diurnal pattern, being synthesized during the dark
(feeding) period and subsequently degraded during the light
hours. This resembles the pattern reported in previous
studies.5,23,24 Glycogen structure was characterized at various
phases of this cycle, to examine changes during glycogen
synthesis, degradation, and after starvation.
SEC weight distributions of glycogen, as functions of
molecular size (the hydrodynamic radius Rh) at various time
points of the diurnal cycle, are given in Figure 2. The areas of
the curves were normalized to unity, to give an indication of the
relative structural changes. Distributions of glycogen are also
Figure 1. Liver-glycogen content of ad libitum fed wild-type mice at
various stages of a day/night cycle; shading represents night/feeding
period. Values shown are the mean ± SEM of 3−9 mice. The dashed
line represents the mean glycogen content of 7 mice starved for 16 h.
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normalized to their concentration in Figure 3, with the
synthesis and degradation phases represented in Figure 3a
and b, respectively.
Surprisingly, when glycogen reaches a maximum concen-
tration at 4 am (Figure 1), it consists almost entirely of β
particles, as seen in Figures 2c and 3a. This decrease in the
average size of glycogen particles between 4 pm and 4 am is
statistically significant (Figure S1 in Supporting Information).
The micrographs from TEM (Figure 4b) support the
suggestion that glycogen forms initially as separate β particles,
which later in some way form α particles.
It cannot be confirmed whether these mice were ever going
to form α particles, as approximately half of the distributions at
later time points during degradation (8 am and 12 noon) also
did not contain a significant population of α particles. Further
studies are required to properly understand the synthesis of
liver glycogen in terms of structure.
Figure 2f shows the glycogen size distributions of mice
sacrificed at 4 pm, toward the end of degradation. Interestingly,
large glycogen α particles still remain, with a greater proportion
of the smaller molecules having been degraded. This increase in
the average particle size from 12 to 4 pm is statistically
significant (Figure S1 in Supporting Information). TEM was
used to visualize these α particles (Figure 4d).
Where Parodi reported that the molecular weight of glycogen
did not significantly change after fasting,12 the mice were only
fasted for 5 h after sacrificing the controls early in the morning,
and the glycogen content decreased by ∼62%. If the highest
Figure 2. SEC weight distributions, w(log Rh; normalized to equal areas) as functions of molecular size (the hydrodynamic radius Rh) for wild-type
mice sacrificed at various stages of the day/night cycle: 9 pm, blue (a); midnight, black (b); 4 am, orange (c); 8 am, gray (d); 12 noon, purple (e); 4
pm, green (f); after 16 h starvation, red (g); and a magnified version of (g), (h). The multiple distributions for each time point represent replicates
with each distribution being from one mouse. A dashed line is added in a, f, g, and h to separate the glycogen peaks from the contamination peaks
(which are much more prominent when glycogen concentrations are low) of small molecules. Note the x axis is linear in Rh, not logarithmic as
normal for SEC weight distributions; the linear axis enables particular features to be distinguished for the present system. The mean values (and SEM
bars) for the Rh at which the maximum occurs and the average Rh are given in the SI (Figure S1a and S1b, respectively).
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glycogen content in the present study (∼5%, see Figure 1) were
to decrease by the same amount, there would be a glycogen
content of ∼2% (roughly that of mice sacrificed at 12 noon). It
can be seen from Figure 2e that this glycogen would more likely
have a distribution similar to the glycogen during the synthesis
phase, but Figure 2f shows that one only has significantly
different distributions at a glycogen content as low as ∼1%.
This suggests that if the past study had been for mice fasted for
longer, the results might have been very different.
Our results agree with Geddes’25 finding of a significant
differences in sucrose-density-centrifugation distributions of
liver glycogen at different times after starvation, with no large
glycogen molecules remaining after 16 h of fasting (Figure
2g,h); it is noted that one can only make qualitative inferences
from data obtained from sucrose-density centrifugation.
While liver glycogen reaches low levels after starvation, this
glycogen can persist for up to 72 h of starvation.26 Microscopy
studies on frog hepatocytes demonstrate that starved frogs only
have β particles as opposed to the α particles found in
hepatocytes of fed frogs.27 This is consistent with Figure 2g,h,
where only small β particles remain during the starvation phase.
These smaller β particles were visualized using TEM (Figure
4e). It is important to note that these small β particles (Rh ∼12
nm) started to form during fasting (Figure 2f) when there were
still large α particles present (which eventually degrade away).
This, as well as the fact these molecules are narrowly
distributed, suggests that they are more resistant to degradation
and are not just persisting because glycogen degradation
pathways are switched off.
Altogether, the size distributions of glycogen being
synthesized, degraded and after starvation have revealed a
number of interesting insights into glycogen metabolism,
leading to the proposed “recycling” model of glycogen
metabolism in terms of the tertiary structure (β and α
particles) presented in Figure 5.
When glycogen reaches its maximum concentration (“Late
synthesis” in Figure 5), it appears to consist almost entirely of β
particles. This result, which at first is surprising, shows that α
particles are formed following the formation of individual β
particles.
This pathway makes evolutionary sense, with the need to
rapidly synthesize large amounts of glycogen (when blood
sugar is rising from the digestion of food) being aided by the
higher surface area to volume ratio of the smaller β particles.
Indeed it has been shown in vitro with rabbit-liver glycogen
that, in the direction of synthesis, glycogen phosphorylase has a
higher activity for smaller glycogen molecules.28 Further
support for this hypothesis comes from a study demonstrating
a tendency for radiolabeled glucose to be incorporated more
readily into lower molecular weight material.25 Our data also
suggest that α particles remaining from the previous day/night
cycle appear to be degraded during glycogen synthesis (arrows
1 and 2 in Figure 5). If this were not the case, glycogen α
particles that were not degraded in one diurnal cycle would
continually grow during the following synthetic phase, making
even larger α particles than the previous cycle. This would
result in the average size of glycogen particles becoming larger
from one day to the next.
During fasting, however, it is desirable to have a slower, more
controlled, release of glucose back into the blood, which is
aided by the transformation of many β particles into larger α
particles. As stated, our results show an initial, preferential
degradation of smaller molecules in the liver (arrow 4 in Figure
5), which is consistent with past studies that show glycogen
phosphorylase is more associated with,29 and has a higher in
vitro activity for,30 lower molecular weight glycogen. A
radioactivity study also hinted that larger molecules may be
metabolized more slowly.13 These results and preliminary rate
Figure 3. Same SEC weight distributions of liver glycogen from Figure
2. These are separated into the phases of glycogen synthesis (a) and
degradation (b) with mice being sacrificed at 9 pm, blue (a); midnight,
black (a); 4 am, orange (a); 8 am, gray (b); 12 noon, purple (b); 4 pm,
green (b); after 16 h starvation, red (b). The multiple distributions
represent replicates with each distribution being from one mouse. All
distributions are now normalized to have an area equal to their
calculated concentration.
Figure 4. TEM images of liver glycogen at various stages of the day/night cycle: 9 pm (a); 4 am (b); 12 pm (c); 4 pm (d); and after 16 h of
starvation (e). Scale bar represents 200 nm.
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data from our laboratories (showing populations of large
glycogen particles degrading much slower than populations of
smaller β particles; see Figure S3 in SI) support the inference
that the rates of degradation per mass of glycogen of small
glycogen molecules are faster than those of large molecules,
consistent with the hypothesis that glycogen degradation is
controlled by surface area. The observation that diabetic mice
are unable to form as many large α particles as healthy mice3
therefore suggests that these smaller molecules are more
vulnerable to enzymatic degradation due to their lower ratio of
surface area to volume.3,31
Another interesting feature of our data is the narrowly
distributed small β particles that remain after starvation. An
evolutionary advantage of this resistant glycogen is clear, as
synthesizing a new glycogen molecule from the beginning
(involving the production of more initiating protein, glyco-
genin) would require more energy, and be much slower, than
building glycogen from this resistant “elementary” glycogen
molecule. While the mechanism for the resistance of these
molecules is unclear, it has been suggested that this remaining
liver glycogen may be denser, impeding the access of
degradative enzymes.13,32,33 Whether this glycogen bears any
relation to the proglycogen referred to in previous
publications34−36 is hard to determine due to the different
glycogen-extraction methods employed; however, it has been
suggested37 that the “proglycogen” inferred in these past studies
were artifacts of the extraction methods.
■ CONCLUSION
Size distributions of glycogen being synthesized, degraded, and
after starvation have revealed a number of interesting insights
into glycogen metabolism. When glycogen reaches its
maximum concentration it appears to consist almost entirely
of β particles. This surprising result suggests that α particles
may be formed after the formation of separate β particles. A
very important new discovery (consistent with past studies that
suggested this may be the case) is that as glycogen degrades the
larger α particles persist longer than the smaller particles and
that this glycogen is degraded to a more stable molecule with
an Rh of ∼12 nm. Given the lack of large α particles in diabetic
animals, these findings have potential application in drug targets
for diabetes management, through drugs which affect different
steps in the pathway of Figure 5, a pathway whose existence
was never previously suspected.
Figure 5. Proposed “recycling” model for the structural changes of glycogen over a diurnal cycle and after starvation.
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3.2 Outcomes 
The structural characterization of glycogen at various time points across a diurnal cycle has led 
to several interesting insights. First, when glycogen was at its peak concentration, it consisted 
almost entirely of β particles, indicating that glycogen is initially created as separate β particles 
which can later combine to form α particles. This was unexpected, it being hypothesized that 
most α particles would be present when the glycogen content was at a maximum. However, 
this unexpected result yielded important new insights. In evolutionary terms the prevalence of 
small β particles when glycogen content is high would be a strategy optimal with an animal’s 
need to quickly synthesize glycogen after food digestion. Assuming that the enzymatic kinetics 
of both synthesis and degradation of β particles are surface-area controlled (the enzymes are 
different, but both are much larger than the accessible spaces within a glycogen particle), rapid 
synthesis would be assisted by the greater surface area to volume ratio of the smaller molecules. 
An in vitro study101 with rabbit-liver glycogen supports this hypothesis, with glycogen 
phosphorylase having a higher activity for smaller glycogen particles in the direction of 
glycogen synthesis. In 1971 Geddes32 also found that glucose tended to be incorporated more 
into lower-weight material, which is consistent with smaller molecules being synthesized more 
rapidly. 
The second major insight resulting from the structural study of glycogen across a diurnal cycle, 
is that towards the end of glycogen degradation, there is a much greater proportion of large α 
particles remaining. This is consistent with the hypothesis that α particles degrade relatively 
slowly due to their decreased surface area to volume ratio; our preliminary in vitro kinetics 
data given in Appendix 2 and a past kinetics study31 support this hypothesis. Indeed we have 
suggested38 that this is why α particles have evolved; to give a slower, more controlled release 
of glucose back into the blood. It has also been observed102 that glycogen phosphorylase is 
more associated with lower-molecular-weight glycogen, again being consistent with the idea 
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of larger molecules being more resistant to degradation because of their lower surface area to 
volume ratio. 
The final insight into glycogen metabolism gained from this study is that after 16 hours of 
starvation, the liver glycogen of mice consisted of narrowly distributed, very small β particles, 
with a hydrodynamic radius Rh of ~12 nm. These particles started to form while there were still 
large α particles remaining, indicating that their persistence is attributable to the particles being 
resistant to degradation, as opposed to the degradative enzymes being “switched off”. Past 
studies have noted that glycogen can persist long after starvation, when no high molecular 
weight material remained103,104 and it has been suggested that perhaps these molecules have a 
high molecular density, impeding enzymatic access32. The synthetic pathway to create these 
small resistant molecules may have evolved as a more efficient mechanism for glycogen 
metabolism, with particles not having to be created completely ab initio, which involves the 
synthesis of the glycogen-initiating protein, glycogenin. 
4. Chapter 4: Improving size-exclusion chromatography 
separation for glycogen 
4.1 Introduction 
Given the pivotal role SEC has played in the analysis of glycogen structure, any 
improvements in the resolution and effectivness of this technique will benefit further research 
associated with the importance of glycogen structure on glycaemic control. While our past 
studies that have obtained size distributions of native glycogen using SEC have employed a 
dimethyl sulfoxide/lithium bromide (DMSO/LiBr) eluent, it has recently been shown for 
synthetic branched polysaccharides (with similar size ranges to glycogen) that aqueous SEC 
results in significantly improved resolution105. There are several other advantages to using an 
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aqueous system: water is cheaper, safer, easier to dispose of and is more physiologically 
relevant than DMSO. In this chapter we compare the size distributions of glycogen obtained 
from DMSO- and aqueous-SEC, and also analyze the effect of flow rate and column pore-
size. The Supporting Information is given in Appendix 3. 
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a  b  s  t  r  a  c  t
Glycogen  is  a hyperbranched  glucose  polymer  comprised  of  glycogen   particles,  which  can  also  form
much  larger  composite   particles.  The  recent  discovery  using  size-exclusion  chromatography  (SEC)  that
fewer, smaller,   particles  are  found  in  diabetic-mouse  liver compared  to  healthy  mice  highlights  the
need  to achieve  greater  accuracy  in  the  size  separation  methods  used  to analyze    and   particles.  While
past  studies  have  used  dimethyl  sulfoxide  as  the  SEC  eluent  to  analyze  the  molecular  size  and  structure  of
native  glycogen,  an aqueous  eluent  has  not  been  rigorously  tested  and  compared  with  dimethyl  sulfoxide.
The conditions  for SEC  of  pig-liver  glycogen,  phytoglycogen  and oyster  glycogen  were  optimized  by
comparing  two different  eluents,  aqueous  50 mM  NH4NO3/0.02%  NaN3 and  dimethyl  sulfoxide/0.5%  LiBr,
run  through  different  column  materials  and  pore  sizes  at various  flow  rates. The  aqueous  system  gave
distinct  size  separation  of - and  -particle  peaks,  allowing  for  a more  detailed  and  quantitative  analysis
and  comparison  between  liver  glycogen  samples.  This  greater  resolution  has  also revealed  key  differences
between  the  structure  of  liver  glycogen  and  phytoglycogen.
© 2014  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Glycogen functions as a glucose storage molecule in a wide range
of organisms, ranging from bacteria to animals, while some plant
varieties have a structurally similar glucan termed phytoglycogen
(which may  also play a role in starch biosynthesis).
Both glycogen and phytoglycogen consist of linear chains of
-(1 → 4)-linked d-glucose residues, with branching points being
connected via -(1 → 6) glycosidic linkages. Glycogen comprises
smaller molecules, termed  particles (∼20 nm in diameter with
molecular weights ∼106–107) [1,2] that can also form much larger
molecules, termed  particles (anywhere between 40 and 300 nm
in diameter with molecular weights reaching over 108) [3,4]. In
animals, glycogen is found in a number of organs, performing
various functions. Liver glycogen is essential in maintaining
blood-glucose homeostasis [5], whereas muscle glycogen provides
rapid energy during muscular activity [6]. While muscle glycogen
consists of  particles, liver [7] and cardiac [8] glycogen has been
∗ Corresponding author at: The University of Queensland, Centre for Nutrition and
Food Sciences, Queensland Alliance for Agriculture and Food Innovation, Brisbane,
Queensland 4072, Australia. Tel.: +61 412215144.
E-mail address: b.gilbert@uq.edu.au (R.G. Gilbert).
shown to contain  particles. These larger molecules are also seen
in phytoglycogen [9]. It is also noted that glycogen is not simply
a polysaccharide, as there is extensive evidence that all glycogens
contain small but significant amounts of protein [10,11].
Insight can be gained into the biosynthesis and degradation of
glycogen by analyzing glycogen’s macromolecular structure. Size-
exclusion chromatography (SEC) has been successfully used to
determine size distributions of starch and glycogen, as recently
reviewed [12–15], which has resulted in the discovery that db/db
mice (a model for type 2 diabetes) have impaired  particle forma-
tion [16]. Given the greater ratio of surface area to volume of smaller
molecules, it has been hypothesized that impaired -particle for-
mation, all other things being equal, may  impact on blood–glucose
homeostasis [8,16].
While dimethyl sulfoxide (DMSO)/LiBr has been used as the SEC
solvent in these past studies to characterize glycogen structure, to
date aqueous-SEC has not been employed for native liver glyco-
gen, although some encouraging analysis has been performed on
commercial oyster and rabbit-liver glycogen [17]. The DMSO/LiBr
system has been employed in the past because it has been shown
that this dissolves amylose and amylopectin (the two types of glu-
cans in starch, with the same glycosidic linkages as in glycogen)
molecularly and without aggregation [18]. However, there are a
number of potential benefits of using an aqueous system: the lower
0021-9673/$ – see front matter © 2014 Elsevier B.V. All rights reserved.
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viscosity of water should lead to better resolution and reduction of
shear scission; the characterization is more physiologically relevant
as glycogen is in an aqueous solvent in vivo; and water is a much
cheaper and safer solvent than DMSO. Aqueous SEC has recently
been successfully used for synthetic branched polysaccharides
(with similar size ranges to glycogen), where better separation was
found compared to a DMSO setup [19]. Additionally, the presence
of small amounts of proteins in glycogen will affect the solubility of
this molecule in water- and DMSO-based systems; if, as is usually
the case, the proteins are predominantly hydrophilic on the surface,
water solubilization will be increased. In this present study, the size
separation of glycogen from pig liver, sugary-1 (su-1) mutant maize
grain (termed phytoglycogen) and oyster glycogen were analyzed
using both aqueous (50 mM NH4NO3/0.02% NaN3) and DMSO/LiBr
SEC. Differential refractive index detection was used alone, as the
objective of improved separation is not aided by further knowledge
(which would be useful for mechanistic interpretation) that would
result from having additional detectors.
2. Method
2.1. Glycogen extraction and purification
2.1.1. Pig-liver glycogen
Pig-liver glycogen was extracted as previously described [20].
A sample from the central lobe of the liver (∼25 g) from a 106-
day old male pig (Large White breed), reared at the University of
Queensland Centre for Advanced Animal Science, was immediately
frozen in dry ice and kept at −80 ◦C for 6 weeks prior to glycogen
extraction. Liver (∼4 g) was homogenized with 5 volumes of glyco-
gen isolation buffer (50 mM Tris, pH 8, 150 mM NaCl, 2 mM EDTA,
50 mM NaF, 5 mM sodium pyrophosphate, and phenylmethanesul-
fonylfluoride (PMSF)). The homogenate was centrifuged at 6000 × g
for 10 min  at 4 ◦C with the resulting supernatant then being cen-
trifuged at 50,000 × g for 30 min  at 4 ◦C. The pellet was  resuspended
in glycogen isolation buffer (3 mL)  and layered over an 18 mL,  step-
wise sucrose gradient (25%, 50%, and 75% in glycogen isolation
buffer). The gradient was then centrifuged at 300,000 × g for 2 h
at 4 ◦C. The supernatant was discarded and the pellet was  resus-
pended in 1 mL  of 80% ethanol. The sample was then centrifuged at
4000 × g for 10 min  at 4 ◦C and the supernatant was discarded. This
ethanol precipitation step was repeated once more and the pel-
let was dissolved in 1 mL  of deionized water and then lyophilized
(freeze-dried; VirTis, Benchtop K).
2.1.2. Phytoglycogen
Extraction of phytoglycogen was performed following a tech-
nique developed in our laboratories, as done previously [21].
Kernels of su-1 mutant maize, obtained from Prof. Ian D. Godwin
(The University of Queensland, Brisbane, Australia), were ground
into a fine powder using a cryo-mill (Freezer/Mill 6870, SPEC
CertiPrep, Metuchen, NJ, USA) that used a 1 min  precooling step
followed by 5 min  grinding. This technique is used to minimize
mechanical and thermal damage and has been shown to be effec-
tive for starch extraction [22]. After grinding, 100 mg of kernel
flour was incubated in 2.5 mL  of tricine buffer for 30 min  at 37 ◦C
with protease (2.5 units mL−1; bacterial type XIV, Sigma-Aldrich).
An additional 2.5 mL  of ice-cold tricine buffer was  added to the
sample, followed by centrifugation at 4000 × g for 10 min. The
supernatant was precipitated with 4 volumes of absolute ethanol
and centrifuged for an additional 10 min  at 4000 × g. The pellet was
dissolved in 1 mL  of deionized water and then lyophilized (freeze-
dried; VirTis, Benchtop K).
Table 1
Column information.
Solvent Column Particle size (m)
Aqueous Suprema 30 5
Suprema 1000 5
Suprema 3000 5
Suprema 10,000 10
DMSO GRAM 30 10
GRAM 1000 10
GRAM 3000 10
GRAM 10,000 10
2.1.3. Oyster glycogen
Oyster type II glycogen was  purchased from Sigma-Aldrich. This
was used as a comparative tool as it consists only of  particles [20].
2.2. Size-exclusion chromatography using dimethyl sulfoxide
(DMSO)/LiBr as an eluent
Pig-liver glycogen, phytoglycogen and oyster glycogen were dis-
solved (2 g L−1) in DMSO with 0.5 wt% LiBr on a thermomixer at
80 ◦C and 350 rpm overnight.
Samples were injected into an Agilent 110 Series SEC system
(PSS, Mainz, Germany) using two  different column setups: GRAM
preColumn, 30 and 3000 columns (PSS); and GRAM preColumn,
1000 and 10,000 (PSS) (see Table 1 for column information). The
columns were kept at 80 ◦C using a column oven and 3 different
flow rates were tested (0.3, 0.6 and 0.9 mL  min−1). A refractive index
detector (RID) (Shimadzu RID-10A, Shimadzu, Japan) was used to
determine the SEC weight distributions. The detector temperature
was 45 ◦C. Because SEC weight distributions are based on the rel-
ative amount of DRI signal, any small difference in the refractive
index between the eluent in the column and in the detector due to
a temperature difference will remain constant.
Universal calibration curves were obtained for each column
setup and flow rate using pullulan standards (PSS), with a molar
mass range of 1080 Da to 2.35 × 106 Da, which were directly
dissolved into eluent. This allowed elution volumes to be con-
verted into hydrodynamic volumes (Vh), or equivalently the
hydrodynamic radius (Rh), where Vh = 4/3R3h [23], using the
Mark-Houwink relationship (see Eq. (1)).
Vh =
2
5
KM1+˛
NA
(1)
The hydrodynamic radius here is defined by IUPAC as the vol-
ume  of a hydrodynamically equivalent sphere [24], and thus the
meaning is dependent on the particular technique used: for exam-
ple, hydrodynamic radius in dynamic light scattering is a different
quantity to that for SEC.
The use of universal calibration in this study is based on the
assumption that SEC separates solely on hydrodynamic size, an
assumption which has been shown to be valid for molecules with
widely varied shapes [25–27]. As this study is aimed at improving
the separation of  and  particles and very accurate values of size
are not necessary for this goal, the universal calibration assump-
tion is used here with the caveat that calibration is not absolute
and may  not be completely reliable for glycogen.
The Mark-Houwink parameters for pullulan in DMSO/LiBr
(0.5 wt%) at 80 ◦C are K = 2.427 × 10−4 dL g−1 and  ˛ = 0.6804
(Kramer and Kilz, PSS, private communication; the number of sig-
nificant figures is that provided by Kramer and Kilz, and are given
in full to avoid the possibility of sensitivity of the data processing to
these values). No uncertainty (or rather, joint confidence interval)
is known for the two  Mark-Houwink parameters. These values give
an Rh upper limit of accurate calibration of ∼58 nm for this solvent.
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Fig. 1. A comparison of aqueous and DMSO systems at different flow rates for larger pore columns (10,000 and 1000). SEC weight distributions of pig-liver glycogen (A and
B),  phytoglycogen (C and D) and oyster glycogen (E and F) using a DMSO/LiBr (A, C and E) and an aqueous (B, D and F) eluent system. Each sample was run in duplicate (red
and  blue) and at 3 different flow rates (0.3 mL  min−1, full line; 0.6 mL min−1, dashed line; 0.9 mL  min−1, broken line). The concentration of all samples were ∼2 g L−1. The
normalization of these distributions is arbitrary and for convenience is chosen to have a maximum of 1.
2.3. Size-exclusion chromatography using aqueous (ammonium
nitrate) eluent
Pig-liver glycogen, phytoglycogen and oyster glycogen were
dissolved (2 g L−1) in 50 mM NH4NO3 with 0.02% sodium azide
(antimicrobial agent) in a thermomixer at 80 ◦C and 350 rpm
overnight. The ammonium nitrate was used to increase the ionic
strength of the solution, minimizing any potential interactions
between the glycogen and the column [28].
Dissolved samples were injected into an AF2000 SEC setup
(Postnova Analytics, Landsberg-Lech, Germany), with 2 different
columns setups being tested: SUPREMA preColumn, 30 and 3000
(PSS); and SUPREMA preColumn, 1000 and 10,000 (PSS) (see Table 1
for column information). The temperature was set at 80 ◦C and 3
flow rates (0.3, 0.6 and 0.9 mL min−1) were tested.
The same pullulan standards used for the DMSO SEC setup
were used to create universal calibration curves for each col-
umn  setup and flow rate. The Mark-Houwink parameters used
were the same as those used for an aqueous SEC set up that
used pullulan in 50 mM NaNO3 with 0.02% NaN3 at 50 ◦C [19],
as differences between the two  solvent setups were unable
to be determined beyond experimental error (see supporting
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Fig. 2. A comparison of aqueous and DMSO systems at different flow rates for smaller pore columns (3000 and 30). SEC weight distributions of pig-liver glycogen (A and B),
phytoglycogen (C and D) and oyster glycogen (E and F) using a DMSO/LiBr (A, C and E) and an aqueous (B, D and F) eluent system. Each sample was run in duplicate (red
and  blue) and at 3 different flow rates (0.3 mL  min−1, full line; 0.6 mL min−1, dashed line; 0.9 mL  min−1, broken line). The concentration of all samples were ∼2 g L−1. The
normalization of these distributions is arbitrary and for convenience is chosen to have a maximum of 1.
information Figure S1). The Mark-Houwink parameters (Prof. Katja
Loos, private communication) for pullulan in both these solvents
are K = 1.0176 × 10−3 dL g−1 and  ˛ = 0.525, giving an Rh upper limit
of calibration of ∼44 nm.
Pig-liver glycogen (a different pig sample from the same trial,
extracted exactly the same way as the previous sample) was  also
tested at various concentrations (5, 2, 1, 0.5 mg  mL−1) using a
SUPREMA preColumn, 30 and 3000 (PSS) setup at 80 ◦C and a flow
rate of 0.3 mL  min−1.
3. Results and discussion
3.1. Transmission electron microscopy (TEM) images of glycogen
While this study focuses on optimizing SEC for glycogen, TEM
images were obtained to visualize the glycogen being tested. Typ-
ical images have been presented in previous publications [2,4,20].
Similar images of  and  particles were also obtained in the
present work.
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Fig. 3. The calculated plate height (A) and reduced plate height (B) using oyster glycogen peaks at various flow rates for larger pore DMSO columns (purple circles), smaller
pore  DMSO columns (blue diamonds), larger pore aqueous columns (red squares), and smaller pore aqueous columns (green triangles). While the dispersity of the oyster
glycogen leads to the calculation of lower plate heights, using this peak gives the relative column efficiency of the columns at different flow rates.
3.2. SEC of glycogen
SEC weight distributions of pig-liver glycogen, phytoglycogen
and oyster glycogen were obtained for both DMSO/LiBr and aque-
ous (50 mM NH4NO3/0.02% NaN3) setups with large (10,000 and
1000) and small (3000 and 30) column pores at three different flow
rates (0.3, 0.6 and 0.9 mL  min−1) (Figs. 1 and 2). While SEC elutes
approximately linearly in log Rh, we have found that features are
more easily distinguished for  particles with a linear size axis.
Each SEC distribution is also provided in the supporting informa-
tion with a logarithmic X-axis to aid in the visual observation of any
differences at lower Rh values.
3.3. Comparing different solvents and flow rates
Figs. 1 and 2 compare the SEC weight distributions of glyco-
gen obtained using DMSO/LiBr and aqueous (50 mM NH4NO3/0.02%
NaN3) setups for the larger (Fig. 1) and smaller (Fig. 2) pore
columns at three different flow rates. There is a striking difference
between the distributions of pig-liver glycogen from DMSO/LiBr
(Figs. 1A and 2A) and aqueous (Figs. 1B and 2B) SEC setups. In the
aqueous systems there are two distinct peaks, each corresponding
to the sizes of  and  particles. This represents greatly improved
separation over the DMSO/LiBr system, where there is only one
peak corresponding to the size of  particles (with only a shoul-
der being present in the  particle region). While the differences
between pig-liver glycogen, phytoglycogen and to a lesser extent
oyster glycogen are less obvious when analyzed using SEC with
DMSO/LiBr (Figs. 1A, C and E and 2A, C and E), it is clear, using
aqueous SEC, that pig-liver glycogen is unique in having two  dis-
tinct peaks. This explains why this difference was not seen in a
recent paper comparing pig-liver glycogen to phytoglycogen, as a
DMSO/LiBr system was employed [21].
The resolution of SEC for a polymer with a given size distribution
depends both on the intrinsic separation capacity of the stationary
phase under the specific elution conditions (determined by the cal-
ibration curve) and the peak variance (related to band broadening).
This dependence of the SEC resolution on both the calibration curve
and the peak variance can be mathematically described using Eq.
(2) [29,30]:
Rsp ∝ 1
 × b × √L
(2)
Here Rsp is the specific SEC resolution, b the slope of
the calibration curve (as approximated by a linear expression
log M = log a − bVel, L the length of the column set, and  is the peak
variance (band broadening).
The quantity  is related to the plate number, N, a dimension-
less quantity [30] indicative of the system efficiency. Assuming the
elution peak is Gaussian, their relation is described by Eq. (3):
 = VR
√
p
N
(3)
Here p is the fraction of solute in the stationary phase and VR is
the peak retention volume.
To determine the relative contribution of  for each column set,
the number of theoretical plates, N, were calculated from the elu-
tion profiles of oyster glycogen at each of the 3 flow rates. As the
peaks were close to being symmetrical and Gaussian-shaped, Eq.
(4) can be employed [30]:
N = 5.54
(
VR
W1/2
)2
(4)
Here W1/2 is the width of the peak at one-half the height.
While this leads to a greatly reduced calculated N due to the
disperse oyster glycogen (the true N would be calculated using a
mono-disperse sample), the use of oyster glycogen allows a direct
comparison of the relative broadening effect experienced by glyco-
gen in each column. The calculated values for N could then be
converted to the theoretical plate height, H, which is simply N
divided by the added length of the columns in the setup. Fig. 3,
which is effectively a van Deemter analysis, gives the theoretical
plate height, HOYS (Fig. 3A), and reduced plate height, hOYS (Fig. 3B),
calculated using oyster glycogen elution peaks for the four different
column setups at the three different flow rates. For the aqueous-
SEC SUPREMA 3000 and 30 setup, nine flow rates ranging from 0.1
to 0.9 mL  min−1 were employed, confirming that the longitudinal
diffusion (commonly referred to as the B-term of the van Deemter
equation) was  insignificant, as is generally the case with SEC [30].
Therefore resolution will improve gradually as the flow rate is
decreased. It should be noted however that these improvements
are very small, with very little flow-rate effects being observed
for oyster glycogen (see Figs. 1E and F and 2E andF). Therefore,
the main consideration for choosing a flow rate is to minimize
shear scission, while maintaining a flow rate that allows reason-
able throughput of samples. The plate height, Fig. 3A, is lowest for
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Fig. 4. The slope between each consecutive two points in the calibration curve of
the larger pore DMSO columns (purple circles), smaller pore DMSO columns (blue
diamonds), larger pore aqueous columns (red squares) and smaller pore aqueous
columns (green triangles).
the aqueous 3000 and 30 setup; however when adjusting for the
particle size of the column packing material (given in Table 1), the
reduced plate height (Fig. 3B) is more similar to that of the DMSO
10,000 and 1000 setup. The least efficient column setup at a flow
rate of 0.3 mL  min−1 is the aqueous 10,000 and 1000. This indicates
that the better resolution obtained in aqueous columns is not due
to the column efficiency, or the peak variance of the column·
Given the length of all column setups is equal, any difference
in the resolution is therefore most likely due to b, the slope of
the calibration curve. A comparison of the calibration curves for
each setup is given in supporting information (Figure S2A). A plot
of the derivation of the calibration plot is also given in the support-
ing information (Figure S2B); however because the larger pullulan
standards deviate substantially from the calibration curve, this plot
does not adequately represent the effectiveness of the columns at
these larger sizes.
To properly compare the separation of the larger standards in
the different column setups, the slope b between each two con-
secutive pullulan standards was calculated (see Fig. 4). The slope
of the calibration curve is dramatically higher in the DMSO setups
for larger sized molecules, indicating that the largest pullulan stan-
dard is approaching the exclusion limit of the columns. However
with the aqueous setups, the slopes of the calibration curves remain
low, indicating that the columns are still separating effectively
at these sizes. This key difference between DMSO and aqueous
setups explains the significantly improved separation of - and
-particle peaks observed in the aqueous systems. One  reason
for this difference in exclusion limits (other than the possibility
that a GRAM column of a particular pore size is not equivalent to
the corresponding SUPREMA column) is that pullulan of the same
molecular weight will have a larger hydrodynamic radius in the
DMSO setups (∼58 nm)  then in the aqueous setups (∼44 nm). This
difference in hydrodynamic volume (and intrinsic viscosity) may
also affect glycogen in a similar manner, leading to a higher pro-
portion of the molecules being larger than the exclusion limit in
DMSO/LiBr.
This would also have the effect of increasing the amount shear
scission, as larger molecules experience more shear [23].
Another factor that influences the amount of shear scission is the
viscosity of the solvent, with the more viscous solvents resulting in
a higher shear force. The viscosity of DMSO at 80 ◦C is ∼0.8 mPa s
(as estimated in a previous publication [23] from an Arrhenius fit
to literature viscosity data), while the viscosity of water at 80 ◦C is
∼0.36 mPa  s [31,32], meaning glycogen will be less susceptible to
shear scission in aqueous SEC. It can be seen in Figs. 1 and 2 that
this appears to be the case; however there still seems to be some
shear scission of molecules in the aqueous setups at higher flow
rates, emphasizing the risk of using high flow rates when looking
at macromolecules such as glycogen.
One of the concerns when using aqueous-based solvents for
the analysis of large polysaccharides is the effect of aggregation.
There is the possibility that the separate peak representing the 
particles in the pig-liver glycogen is due to aggregation, which is
then broken in higher shear environments. This was tested using a
variety of concentrations of pig-liver glycogen; those with higher
concentrations should display higher aggregation, and therefore
a greater proportion of large molecules. As seen in Fig. 5, this
is not the case, indicating that the  particle peak is not due
to aggregation. This is consistent with a light scattering study
of glycogen at different concentrations in water, with aggrega-
tion only becoming obvious at a concentration of around 8% (w/v)
[33].
Furthermore, the observation that phytoglycogen has some par-
ticles that correspond to the size of small  particles, but remains
mono-modal, is strong evidence that this second peak present in
pig-liver glycogen is not due to anomalous separation at this size
range. An overlay of all pullulan standard peaks is given in the
supporting information (Figure S7) to highlight that all peaks are
symmetrical, indicating normal SEC separation.
Fig. 5. Pig-liver glycogen samples at different concentrations (5 mg  mL−1, blue; 2 mg mL−1, red; 1 mg mL−1, black; 0.5 mg mL−1, green) in the aqueous 3000 and 30 columns.
These  were done in duplicate from the same glycogen sample. The normalization of these distributions is arbitrary and for convenience is chosen to have a maximum of 1.
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Fig. 6. Comparison of SEC weight distributions (3000 and 30, complete line; 10,000 and 1000, dashed line) using a DMSO/LiBr (A, C and E) and an aqueous (B, D and F) eluent
system  of pig-liver glycogen (A and B), phytoglycogen (C and D) and oyster glycogen (E and F). Each sample was run in duplicate (red and blue). The normalization of these
distributions is arbitrary and for convenience is chosen to have a maximum of 1.
3.4. Comparing columns with different pore sizes
A comparison of large- and small-pore column setups is given
in Fig. 6. For all glycogen types in the DMSO/LiBr column setups
(Fig. 6A, C and E), the larger pore columns (10,000 and 1000) result
in a narrower distribution with smaller Rh values. In the aqueous
setups the resolution is qualitatively similar between the SUPREMA
10,000 and 1000 and SUPREMA 3000 and 30; however, with the
pig-liver glycogen, the  particle peak in the SUPREMA 10,000 and
1000 is shifted down to lower sizes. Because a greater proportion
of the distribution for the aqueous SUPREMA 10,000 and 1000 is
below the calibration upper limit (Rh ∼ 44 nm), it is probably more
accurate than the SUPREMA 3000 and 30 setup. For example, the
 particle peak maximum is within the calibration upper limit for
the SUPREMA 10,000 and 1000 setup, but is significantly outside
this limit in the SUPREMA 3000 and 30 setup, causing problems of
inaccurate extrapolation (see Figure S3 in supporting information).
For all types of glycogen however, the column pore-size does not
significantly change the shape of the distribution.
3.5. Parameterization of distributions
While information can be gained by looking at qualitative
differences between curves when comparing SEC distributions
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Fig. 7. Useful parameters that can be obtained from the aqueous SEC distributions of pig-liver glycogen: (A) peak heights allowing the determination of ˛h/ˇh; (B)  ˛ and ˇ
particles fitted with Gaussian distributions (red and black, respectively) allowing the proportion of  ˛ and  ˇ particles to be estimated.
(for example the observation that there are more  particles in
healthy mice than diabetic [16]), having the ability to reduce the
distributions to meaningful parameters is beneficial, especially
when looking for statistical relevance between samples. Param-
eterization of distributions obtained using DMSO/LiBr for liver
glycogen is very limited, with the most obvious parameter being
the Rh at which the maximum occurs. The average, R¯h, can also be
calculated [34] as given in Eq. (5):
log R¯h =
∫ ∞
−∞ w(log Rh)dlog Rh∫ ∞
−∞(w(log Rh)/ log Rh) dlog Rh
(5)
While these parameters are useful, they do not necessarily give
a good indication of the relative amount of  and  particles in a
sample. Although there is no clear distinction seen under electron
microscopy of small particles always being individual  particles,
it is useful to have an approximate metric. The improved separa-
tion obtained using aqueous SEC allows for the determination of
a number of useful parameters regarding the proportion of  to 
particles. The ratio of the peak heights (Fig. 7A), here denoted ˛h/ˇh,
is a useful way to get insight into the relative amount of  particles,
if any, in a sample. Another useful parameter is the area under the
curve (AUC) of the -particle peak as a proportion of the total area
(Fig. 7B), ˛area, with the -particle peak being fitted with a Gaussian
distribution (here done using Fityk software). Similarly the propor-
tional AUC of the estimated -particle peak, ˇarea, can be calculated.
It should be noted that there is still a significant proportion of the
SEC distribution lying between the - and -particle peaks that is
not included in either estimated Gaussian curves. While this also
creates the possibility of another parameter, that being the propor-
tional AUC in this intermediate region, this is perhaps excessive.
An improved fit can be obtained using two exponentially-modified
Gaussians, but this is merely what would be expected given the
additional parameters, and such a fit has no obvious relation to
physical/biological processes.
In this way, any distribution with a significant  particle peak
can now be reduced to six simple, meaningful parameters: the Rh
value at which the  particle peak occurs (ˇRh); the Rh value at
which the  particle peak occurs (˛Rh); the average Rh (Rh); the
peak-height ratio of  to  particles (˛h/ˇh); the estimated AUC
of  particles as a proportion of the total area, ˛area; and similarly
the estimated AUC of the -particle peak, ˇarea. This will allow for
quantitative and statistical comparison between samples. The five
most useful of these parameters (with ˇarea being excluded due to
its strongly inverse relationship with ˛area) have been calculated
for pig-liver glycogen, phytoglycogen and oyster glycogen for both
aqueous-SEC setups using the blue duplicates from Figs. 1B and 2B
(see Table 2).
Table 2
Parameterization of aqueous-SEC distributions.
SUPREMA Sample ˇRh (nm) ˛Rh (nm) R¯h (nm) ˛h/ˇh ˛area
10,000 and 1000 Pig 16.4 42.5 24.3 0.417 0.255
Phyto 19.9 – 20.6 – –
Oys 14.2 – 15.6 – –
3000 and 30 Pig 19.0 56.8 33.0 0.460 0.262
Phyto 19.5 – 20.0 – –
Oys 14.30 – 15.0 – –
4. Conclusion
SEC weight distributions of pig-liver glycogen, phytoglyco-
gen and oyster glycogen were obtained using both aqueous
50 mM NH4NO3/0.02% NaN3 and DMSO/0.5% LiBr setups, employ-
ing various pore columns and three flow rates. A considerable
improvement in resolution, explained by differences in the slopes
of the calibration curves, was obtained through the use of aque-
ous SEC, with pig-liver glycogen being separated into two distinct
peaks. Structural differences between liver glycogen and phyto-
glycogen, while hard to observe in SEC-DMSO/LiBr, are clearly
identifiable using SEC-50 mM NH4NO3/0.02% NaN3. In contrast to
pig-liver glycogen, phytoglycogen only exhibited one peak. This
single peak however, still consists of some molecules that are of a
similar size to small  particles, making the differences between
pig-liver glycogen and phytoglycogen less obvious in TEM. The
slowest flow rate employed for all columns (0.3 mL min−1) was
shown to be optimal, resulting in reduced shear scission and
slightly better resolution. While the pore size had little effect on
the shape of the distributions, the larger pores resulted in distribu-
tions having smaller Rh values. Given the results shown here, it is
of benefit to employ an aqueous SEC system with a low flow rate
when analyzing glycogen that may  have  particles. This has poten-
tial applications in human health, given the recent observation that
there are significant differences in the size distributions of  and 
particles in healthy compared to diabetic animals [16].
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4.2 Outcomes 
We discovered that there is a considerably enhanced resolution obtained when analyzing 
glycogen with aqueous-SEC compared to using DMSO, with there being a significantly 
improved separation of α- and β-particle peaks. 
It was revealed here that the predominant reason for the differences between the SEC 
distributions acquired from aqueous and DMSO setups, was the superior separation of the 
aqueous systems for larger molecules (in the α-particle region). It was clear that the largest 
pullulan standard (2.35 × 106 Da) was approaching the exclusion limits of the DMSO column 
setups, but not for the aqueous setups. It is important to note that pullulan swells to a larger 
hydrodynamic size in DMSO/LiBr compared with the aqueous (50 mM NH4NO3/0.02 % NaN3) 
solvent, with the largest pullulan standard being ~58 nm compared with ~44 nm, respectively. 
If glycogen also swells more in DMSO/LiBr, a larger proportion of the distribution will be 
excluded in these setups, given the same pore sizes in the aqueous and DMSO columns. 
While size distributions of liver glycogen using DMSO-SEC are qualitatively useful, with the 
inability to separate α- and β-particle peaks, the parameterization and thus quantitative 
comparison of these distributions is limited. Two obvious parameters that can be used are the 
Rh at which the peak maximum occurs, βRh, as well as the average Rh ( hR ) given by Equation 
6106: 
h h
h
h
h
h
(log )d log
log
(log )
d log
log
w R R
R
w R
R
R







     6 
While useful, these parameters do not give a good indication of the relative amount of α-
particles in a particular sample. The ideal would be if a theory were available giving the size 
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distribution in terms of the rate parameters of the underlying biosynthetic processes, as has 
been developed for the distribution of chain lengths of amylopectin107,108. This is work for the 
future, which will be spurred by the availability of more accurate data using the technique 
reviewed here. 
With the increased resolution obtained using aqueous SEC, leading to a separation of these α- 
and β-particles peaks, the determination of at least six simple empirical parameters is now 
possible109. The first two parameters are the Rh values at the β-particle and α-particle peak 
maxima, βRh and αRh, respectively. As with DMSO-SEC, hR  can also be determined (see 
Equation 6).  A parameter that gives a good indication of the proportion of α-particles is the 
ratio of the α-particle peak height to that of the β-particle peak (αh/βh), as seen in Figure 14. 
Another parameter, αarea, is determined by fitting the α-particle peak with a Gaussian 
distribution, and then determining the area under the curve (AUC) of this peak in relation to 
the AUC of the whole distribution, plotted with a conventional log axis (see Figure 14, with 
the estimated α-particle distribution in red). Similarly, βarea can be calculated by fitting a 
Gaussian curve to the β-particle peak (black curve in Figure 14) and dividing the area under 
the curve (AUC) by the distribution’s total AUC.  
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Figure 14: Parameterization of distributions by taking the ratio of peak heights and by fitting 
Gaussian curves to the distribution to separate the - and -particle components. 
Unfortunately aqueous-SEC, which has been shown here to be superior to a DMSO-SEC setup, 
was not available for the experiments carried out in Chapter 2 and Chapter 3. It may be 
interesting to repeat the experiments performed in these chapters with the new system, as the 
improved resolution between the - and -particle peaks may provide greater insight into the 
nature of what is holding  particles together and the formation and degradation of these 
particles across a diurnal cycle. 
5. Chapter 5: A Rapid Extraction Method for Glycogen 
from Formalin-fixed Liver 
5.1 Introduction 
While the use of mouse models is an extremely useful way of studying the metabolism of 
glycogen in terms of structure, the translation of this research into human liver-tissues will 
automatically enhance the physiological relevance of any further discoveries. Given pathology 
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laboratories’ routine method of chemically fixing human liver samples with formalin, the 
development of a method to extract glycogen from formalin-fixed tissue would allow for the 
analysis of these human samples. In this chapter we compare the size distributions of glycogen 
extracted from frozen liver tissue via sucrose gradient centrifugation to that extracted from 
formalin fixed tissues. We also assess the potential for doing mass spectroscopy (MS) 
proteomics on glycogen extracted via both methods. The Supporting Information is given in 
Appendix 4. 
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Abstract 26 
Liver glycogen is necessary for maintaining glucose homeostasis. It has recently been 27 
discovered that diabetes alters hepatic glycogen structure in mice, but it is not known if this is 28 
also the case for human liver glycogen. While past structural studies have extracted glycogen 29 
from fresh or frozen tissue using a cold-water, sucrose-gradient centrifugation technique, a 30 
method for the extraction of glycogen from formalin-fixed liver would allow the analysis of 31 
glycogen from human tissues that are routinely collected in pathology laboratories. In this 32 
study, both sucrose-gradient and formalin-fixed extraction techniques were carried out on 33 
piglet livers, with the yields, purities and size distributions (using size exclusion 34 
chromatography) compared. The formalin extraction technique, when combined with a 35 
protease treatment, resulted in higher yields (but lower purities) of glycogen with size 36 
distributions similar to the sucrose gradient centrifugation technique. This formalin extraction 37 
procedure was also significantly faster, allowing glycogen extraction throughput to increase 38 
by an order of magnitude. Both extraction techniques were compatible with mass spectrometry 39 
proteomics, with SWATH-MS analysis showing the two techniques were highly complementary. 40 
This new procedure can thus be used to examine differences in glycogen molecular structure 41 
in healthy and diabetic human livers. 42 
Introduction 43 
Glycogen is a highly branched glucose polymer which functionally stores energy in a state 44 
which can be rapidly mobilized in response to hypoglycaemia. The highest concentration of 45 
glycogen is present in the liver; glycogen is also found in skeletal muscle,1 heart,2 adipose3 and 46 
brain tissues.4 Liver glycogen consists of glucose units that are attached to form linear chains 47 
via -(1→4) linkages. These chains are connected via -(1→6)-linked branch points to form 48 
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highly branched glycogen “” particles (~20 nm in diameter) that can further join to form much 49 
larger “” particles (~100 – 200 nm).5  50 
Glycogen was first isolated by Claude Bernard in 1857 from dog liver, employing a method of 51 
heating liver tissue in an alkaline solution.6 This method was shown to degrade the glycogen, 52 
making the exploration of milder techniques advantageous.7 Later methods employing cold 53 
trichloroacetic acid (TCA)8 isolated glycogen with less degradation. Since then extraction 54 
methods have become progressively milder, with a cold water extraction method coupled with 55 
ultracentrifugation being shown to extract much larger, intact glycogen  particles.9,10 56 
More recent cold-water extraction techniques have used a Tris buffer,11-13 which is a potent 57 
inhibitor of glucosidase activity.14 These techniques have also used sucrose-density gradient 58 
centrifugation to aid in the separation of the glycogen particles from the contaminating 59 
microsomal layer.  60 
Liver glycogen undergoes rapid enzymatic degradation post-mortem under ambient 61 
conditions.15 Therefore unless glycogen can be immediately extracted from fresh liver tissue, 62 
which is usually an unfeasible arrangement for human samples, characterization requires a 63 
method for preserving the tissue. Two common ways to do this are by rapidly freezing the 64 
samples or by chemically fixing them in a solution such as formalin. However, it is important 65 
to ensure that it is possible to extract glycogen from samples that have been so preserved 66 
without significant loss or degradation of the glycogen (and any glycogen-bound proteins), 67 
compared to the parent glycogen from the liver extracted immediately after sacrifice. 68 
A method employing formalin (which can dissolve glycogen and precipitate protein) to extract 69 
liver glycogen, while initially promising,16 was shown to be inferior to the cold-water 70 
extraction techniques, with a product of lower purity being obtained.17 It was however noted 71 
that this method may be useful for recovering glycogen from tissues already stored in formalin. 72 
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It was shown that the formalin method extracts glycogen with larger particle sizes than the 73 
alkali and TCA methods (as inferred from having higher sedimentation coefficients), indicating 74 
less degradation; however, a comparison with the cold-water extraction technique has not yet 75 
been performed. One potential problem with the formalin technique is the acidity of 76 
formaldehyde;17 however the use of neutral-buffered formalin (NBF), a common reagent used 77 
today for fixing tissue samples, can avoid potential acid degradation. 78 
A comparison of glycogen extracted from modern cold-water extraction techniques that utilize 79 
Tris buffers, ultracentrifugation and sucrose density gradients with a formalin method that uses 80 
NBF would determine the potential of extracting glycogen from formalin-fixed tissues, 81 
allowing for the analysis of glycogen from the vast source of human tissues currently fixed 82 
with NBF in pathology laboratories.18 The extension of this work into human samples would 83 
allow for a more detailed study of liver glycogen and its role in type 2 diabetes. This is 84 
especially relevant given the discovery19 that liver glycogen from healthy and diabetic mouse 85 
livers shows significant molecular structural differences, from which a number of deductions 86 
can be made5,20 of potential relevance to diabetes in humans. For example, the prevalence of α 87 
particles comprising tightly bound β  particles in healthy livers is likely to cause slower glucose 88 
release under glycolysis, which would lead to better control of blood sugar; elucidating the 89 
nature of the structural difference between healthy and diabetic α particles might then suggest 90 
novel drug targets for diabetes management. 91 
The efficacy of different glycogen extraction techniques, with and without formalin, is 92 
explored here, using liver from healthy piglets. Efficacy is judged by comparing the molecular 93 
size distributions from the various extraction techniques using size-exclusion chromatography, 94 
which can show if there is a systematic loss of particles of  different sizes. Mass spectroscopy 95 
proteomics was also performed on mouse-liver glycogen, confirming the ability to identify 96 
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glycogen-associating proteins from glycogen extracted via both cold-water sucrose-gradient 97 
centrifugation and formalin techniques. 98 
Materials and Methods 99 
Animals 100 
Glycogen was extracted from two piglet livers following a procedure similar to that used 101 
previously20 (The University of Queensland animal ethics approval certificate 102 
CNFS/217/11/PORK CRC). Two male, 34 day-old piglets (Large White breed), reared at the 103 
UQ Gatton piggery, were sedated and euthanized prior to sample extraction. The piglets were 104 
fed a standard nursery diet consisting of wheat (68.6%); fishmeal (6.8%); whey powder (5.0%), 105 
soybean meal (4.0%) and soy protein concentrate (4.0%). A sample of liver from each (~10 g) 106 
was obtained from the central lobe of the liver and immediately frozen in liquid nitrogen and 107 
stored at −80 °C. Each following procedure was first performed with one liver sample and then 108 
repeated 2 days later with the other, acting as an experimental replicate. 109 
For the proteomics analysis, one male 24-week old, non-fasted C57BL6/J mouse was 110 
euthanazed via CO2 inhalation. Following this, the liver was divided into two and either 111 
immediately snap frozen for the sucrose method or placed in 10% NBF for ~48 h. Small animal 112 
studies were performed in accordance with guidelines from the University of Queensland 113 
Ethics Committee and the National Health and Medical Research Council of Australia.  114 
Cold-water extraction using sucrose density ultracentrifugation (“sucrose method”) 115 
The procedure for liver-glycogen extraction and purification using sucrose density 116 
ultracentrifugation was similar to that used previously.5 Approximately 1.2 g of frozen liver 117 
was homogenized in 18.2 mL of glycogen isolation buffer, an inhibitor of glucosidase activity 118 
(50 mM Tris, pH 8, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 5 mM sodium pyrophosphate, 119 
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and protease-inhibiting cocktail (Roche)). Then 200 L of the homogenate was removed and 120 
frozen at −20 °C for glycogen content analysis. The remaining homogenate was divided into 121 
six equal portions and was centrifuged at 6000 g for 10 min at 4 °C with the resulting 122 
supernatants centrifuged further at 488 300 g for 1 h at 4 °C. The pellets were resuspended in 123 
400 L of glycogen isolation buffer and layered over a 3-mL stepwise sucrose gradient (37.5% 124 
and 75% in glycogen isolation buffer). The samples were then centrifuged at 488 300 g for 2 h 125 
at 4 °C. The supernatants were discarded and the resulting pellets were resuspended in 200 L 126 
of deionized water. 1 mL of absolute ethanol was added to the samples and centrifuged at 4000 127 
g for 10 min, with the supernatants being discarded. The pellets were resuspended in 500 L 128 
of deionized water and then lyophilized (freeze-dried; VirTis, Benchtop K).  129 
Preparation of 10% neutral-buffered formalin 130 
While technically 3.7% formaldehyde, historically the preparation of this fixative chemical has 131 
been achieved by diluting commercial-grade stock formaldehyde (37-40% formaldehyde, 132 
generally referred to as formalin when in solution) 10-fold in a phosphate buffer; hence the 133 
name 10% neutral-buffered formalin (NBF). A 10% NBF solution (pH 7) was prepared by 134 
diluting 37% formaldehyde (formalin) 10-fold and adding 4% sodium dihydrogenphosphate 135 
monohydrate and 6.5% anhydrous sodium hydrogenphosphate. 136 
Extraction of glycogen from formalin-fixed tissue (“formalin method”) 137 
The method used was modified from that employed previously.16 Approximately 1.2 g of 138 
frozen liver was divided into 6 portions (~200 mg each). These samples were taken from the 139 
same piglets as for the “Cold-water extraction using sucrose density ultracentrifugation” 140 
section. To these samples, 2 mL of 10% NBF was added, with the liver tissues being fully 141 
immersed. These samples were left at room temperature for ~48 h, which has been shown to 142 
be an adequate time to form protein crosslinks when using NBF at ~25 °C,21 and then 143 
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homogenized. The homogenate was subsequently centrifuged at 4000 g for 10 min. The 144 
supernatant of each sample was added to 10 mL of absolute ethanol and the samples were 145 
centrifuged at 4000 g for 10 min. The pellet was resuspended in 500 L of deionized water and 146 
then lyophilized (freeze-dried; VirTis, Benchtop K). 147 
Measuring the liver-glycogen content 148 
The glycogen content of the liver was determined using a glucose oxidase/peroxidase 149 
(GOPOD) assay procedure, similar to that used previously.5,22 Firstly, six 20 L aliquots of 150 
liver-glycogen homogenate (from Cold-water extraction using sucrose density 151 
ultracentrifugation (“sucrose method”)) were separated, allowing for a more accurate 152 
determination of the liver-glycogen content and determination of the statistical error in the 153 
analysis. To each of these 6 samples was added 5 L of amyloglucosidase (3260 U mL-1, 154 
Megazyme) and 100 L of sodium acetate buffer (pH 6), with the solution being made up to 155 
500 L with deionized water and incubated on a thermomixer (50 °C) for 30 min. A control for 156 
each of the samples, containing everything except amyloglucosidase, and a blank containing 157 
everything except the glycogen homogenate, were also analyzed. A 300 L aliquot of each 158 
sample was added to 1 mL of  GOPOD reagent (Megazyme) and incubated at 50 °C for a further 159 
30 min on the thermomixer. The absorbance (510 nm) of each sample was analyzed on a UV-160 
1700 PharmaSpec UV-vis spectrophotometer (Shimadzu). The glycogen content was 161 
determined by constructing a calibration curve that analyzed the absorbance of various 162 
concentrations of D-glucose that had been reacted with the same GOPOD reagent. All samples 163 
including controls were run in duplicate. Various concentrations of sucrose (up to a 164 
concentration of 1 mg mL–1) were also tested, showing no reaction with GOPOD, confirming 165 
that there is no additional absorbance resulting from sucrose contamination. 166 
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The liver glycogen content, given in Table 1, is presented as the mean ± standard error of the 167 
mean (SEM) of the 6 samples. 168 
Measuring crude glycogen yield 169 
The crude yield from both of the glycogen extraction methods, given in Table 1, was 170 
determined by weighing the amount of sample remaining after being freeze-dried. There were 171 
6 samples from each method, allowing the yield to be presented as the mean  ±  standard error 172 
of the mean (SEM). 173 
Measuring glycogen purity 174 
The purity of glycogen can also be determined using the same assay used to measure the 175 
glycogen content of the liver. Briefly, 100 L of extracted-glycogen solution (~0.006 mg mL–176 
1) was added to 5 L of amyloglucosidase (3260 U mL–1, Megazyme) and 100 L of sodium 177 
acetate buffer (pH 6), with the solution being made up to 500 L with deionized water. The 178 
rest of the procedure is identical to that in the section “Measuring the liver-glycogen content”, 179 
with the glycogen purity being calculated as a percentage of the determined glycogen content 180 
to that of the intial amount of sample used in the assay. Because there were 6 samples for each 181 
extraction procedure, the glycogen purity is given as the mean  ± standard error of the mean 182 
(SEM); see Table 1. 183 
Protease treatment of formalin-extracted glycogen (“formalin/protease method”) 184 
Approximately 3 mg of the glycogen extracted using the formalin-extraction method was 185 
subjected to protease treatment as follows. Glycogen was dissolved in 0.5 mL of protease 186 
solution (2.5 U mL–1; bacterial type XIV, Sigma-Aldrich) in tricine buffer (pH 7.5, 250 mM) 187 
and incubated at 37 °C for 4 h. Samples were then lyophilized (freeze-dried; VirTis, BTP-9EL). 188 
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Size-exclusion chromatography (SEC) of glycogen 189 
An aqueous SEC setup similar to that recently employed for glycogen characterization was 190 
used here.23 Glycogen samples were dissolved in a thermomixer overnight at 25 °C in 50 mM 191 
ammonium nitrate/0.02% sodium azide at ~2 g L–1. The effect of heating the samples overnight 192 
at 80 °C in a thermomixer was also tested. As previously stated,23 the ammonium nitrate is used 193 
to minimize any potential interactions between the glycogen and the column by increasing the 194 
solution’s ionic strength. Sodium azide acts as an antimicrobial agent. 195 
Dissolved glycogen samples were injected into an Agilent 1260 infinity SEC system (Aglient, 196 
Santa Clara, CA, USA) using a column setup of SUPREMA pre-column, 1000 and 10000 197 
columns (Polymer Standard Service, Mainz, Germany). The columns were kept at 80 °C using 198 
a column oven and the flow rate was set to 0.3 mL min−1. A refractive index detector (RID) 199 
(Optilab UT-rEX, WYATT, Santa Barbara, CA, USA) was used to determine the SEC weight 200 
distributions. 201 
Pullulan standards (PSS), with a molar mass range of 342 Da to 2.35 × 106 Da, were dissolved 202 
into the 50 mM ammonium nitrate/0.02% sodium azide solution and run through the SEC 203 
system, allowing the construction of a universal calibration curve. While this assumes that the 204 
SEC is separating solely on hydrodynamic size, a valid assumption shown for molecules with 205 
widely varied shapes,24,25 the purpose of this study was to compare the relative structure of 206 
glycogen obtained from different extraction methods, with any inaccuracies in calibration 207 
being equal for all of the samples as they were run consecutively. 208 
Mass Spectrometry 209 
Mouse-liver glycogen was extracted via both the sucrose and formalin methods, as was 210 
performed with the piglet livers (see Cold-water extraction using sucrose density 211 
ultracentrifugation (“sucrose method”) and Extraction of glycogen from formalin-fixed tissue 212 
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(“formalin method”)). For glycogen extracted from the formalin method, two treatments that 213 
have been previously employed for formalin-fixed tissue were trialled.26 2 mg mL–1 of 214 
glycogen was treated with either 6 M guanidine-HCl or 2% SDS, then heated at 100 °C for 1 215 
h. Samples without either treatment were also tested as a control. Glycogen extracted from the 216 
sucrose method also did not undergo these additional treatments. 217 
Extracted glycogen samples containing ~50 g protein were resuspended in 50 mM Tris HCl 218 
buffer (pH 7.5) and 10 mM DTT with 1 g trypsin (proteomics grade, Sigma-Aldrich) and 219 
incubated at 37 °C with constant mixing for 16 h. Insoluble material was removed by 220 
centrifugation at 18 000 g for 10 min, and peptides were desalted with C18 ZipTips (Millipore). 221 
Peptides were analyzed as described previously27 by LC-ESI-MS/MS using a Prominence 222 
nanoLC system (Shimadzu) and TripleTof 5600 mass spectrometry with a Nanospray III 223 
interface (AB SCIEX). Identical LC conditions were used for SWATH-MS, with an MS-TOF 224 
scan from an m/z of 350-1800 for 0.05 s followed by high sensitivity information-independent 225 
acquisition with 26 m/z isolation windows with 1 m/z window overlap each for 0.1 s across an 226 
m/z range of 400 – 1250. Collision energy was automatically assigned by Analyst software (AB 227 
SCIEX) based on m/z window ranges.  228 
Peptides were identified essentially as described.28 using ProteinPilot (AB SCIEX), searching 229 
the UniProt database (downloaded from www.uniprot.org/ as at 4th March 2014) with standard 230 
settings: Sample type, identification; Instrument, TripleTof 5600; Species, Mouse with 231 
common contaminants; ID focus, biological modifications; Enzyme, Trypsin; Search effort, 232 
thorough ID. False discovery rate analysis using ProteinPilot was performed on all searches, 233 
and peptides identified with greater than 99% confidence and with a local false discovery rate 234 
of less than 1% were included for further analysis. ProteinPilot search results were used as ion 235 
libraries for SWATH analyses. The abundance of proteins were measured automatically using 236 
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PeakView (AB SCIEX) with standard settings. Comparison of protein relative abundance was 237 
performed with the MSstats package in R.29 Gene ontology analysis was performed using the 238 
DAVID bioinformatics resource.30 239 
Results 240 
The extraction of liver-glycogen using different techniques was performed on the same liver 241 
samples, allowing the direct comparison of the methods. Because the trend was the same for 242 
both pigs, the main text contains results from a single pig, with those for the corresponding 243 
size-exclusion chromatography data for the other in the SI.  244 
The yields and purities of glycogen extracted with the sucrose and formalin methods are given 245 
in Table 1. 246 
Table 1. Glycogen content, purity and yield.  247 
 Liver-Glycogen 
Content (%) 
Crude yield 
(%) 
Purity 
(%) 
Glycogen Yield 
(%) 
Sucrose 4.31 ± 0.022 3.6 ± 0.15 55 ± 5.30 46 ± 4.65 
Formalin 11.8 ± 0.45  31 ± 5.42 85 ± 16.94 
Samples are given as the mean  ± standard error of the mean (SEM), n = 6. 248 
 249 
While the purity of the glycogen extracted using the formalin method is lower than that of the 250 
sucrose method (~31% compared to ~55%), the amount of glycogen extracted (the glycogen 251 
yield) is significantly higher with the formalin method, which extracted ~85% of the glycogen 252 
present in the liver (as calculated in “Measuring the liver-glycogen content”), compared to the 253 
~46% from the sucrose method. Because the formalin/protease method consists of taking 254 
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formalin-extracted glycogen and adding protease, the glycogen yield is the same as for the 255 
formalin method. The crude yield and purity will change as a direct result of how much protease 256 
is added to the samples. 257 
Size distributions of the glycogen extracted by the sucrose method, the formalin method and 258 
the formalin/protease method are given in Figure 1. 259 
 260 
Figure 1. SEC weight distributions, w(log Rh; normalized to have equal heights for the 261 
maximum glycogen peak) as a function of molecular size (the hydrodnamic radius Rh) for pig-262 
liver glycogen extracted via the sucrose method (blue), formalin method (black) and 263 
formalin/protease method (red). The same data are provided with a linear X-axis in Rh (A) and 264 
a logarithmic X-axis (B), aiding in the visual observation of this large range of molecular sizes. 265 
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While there are 6 replicates for each extraction technique, there is significant overlap between 266 
distributions of the same method. The SEC samples were also run at a concentration 5 times 267 
more dilute, with no changes occuring in the distribution, indicating no aggregation (see SI). 268 
 269 
As shown in Figure 1A, each of the three extraction methods have a similar and relatively  good 270 
level of repeatability, with little variation between the six distributions within each extraction 271 
method. There is however some variation so care must be taken when drawing conclusions 272 
from very similar distibutions.  273 
The effect of dissolving samples at 80 °C overnight (compared to the much milder 25 °C) was 274 
also tested, as this method has been employed previously.23 As can be seen in Figure 2, 275 
glycogen from all extraction methods showed some level of degradation when dissolved at 80 276 
°C compared to 25 °C.  277 
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 278 
Figure 2. SEC weight distributions, w(log Rh), normalized to have equal heights for the 279 
maximum glycogen peak, as a function of molecular size (the hydrodnamic radius Rh) for pig-280 
liver glycogen dissolved overnight at 25 °C (full line) and 80 °C (broken line) extracted via the 281 
sucrose method (A, blue), formalin method (B, black) and formalin/protease method (C, red). 282 
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While there are 6 replicates for each extraction technique, there is significant overlap between 283 
distributions of the same method. 284 
 285 
Mass spectroscopy (MS) proteomics was also performed on mouse-liver glycogen extracted 286 
via the sucrose and formalin methods. Proteins were digested with trypsin and detected by LC-287 
ESI-MS/MS. This identified 147 proteins with guanidine-HCl treatment, 40 with SDS 288 
treatment and 137 with no additional treatment (Supplementary Tables 1-4). Glycogenin and 289 
glycogen phosphorylase, proteins associated with glycogen biosynthesis, were confidently 290 
identified in formalin-extracted glycogen after guanidine-HCl treatment (Table 2).  291 
Table 2. Peptides identified from glycogen-associated proteins enriched from formalin 292 
fixed tissue. 293 
Sequence ∆Mass m/z z Score 
PYGL_MOUSE 
ARPEFMLPVHFYGR -0.0043 430.7241 4 7 
DIWNMEPSDLK 0.0025 674.3174 2 8 
GIVGVENVAELK 0.0006 614.3511 2 8 
HLEIIYEINQK -0.0032 467.2564 3 8 
ISLSNESSNGVSANGK 0.0027 783.3694 2 10 
IVALFPK -0.0026 394.2562 2 5 
LHSFVSDDIFLR 0.0017 483.5898 3 9 
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TFAYTNHTVLPEALER -0.0050 621.3179 3 9 
VFADYEAYVK 0.0009 602.7983 2 8 
VLYPNDNFFEGK -0.0005 721.8510 2 10 
YEYGIFNQK 0.0556 581.3102 2 9 
GLYG_MOUSE 
MVVLTSPQVSDSMR 0.0034 775.3909 2 13 
 294 
 295 
However, as expected by the measured purity of the samples, many non-glycogen associated 296 
proteins were also identified in these preparations. To compare formalin-extracted glycogen 297 
with standard sucrose enriched glycogen, we performed semi-quantitative proteomics with 298 
SWATH-MS. Proteomic analysis of glycogen enriched using the sucrose method identifyed 299 
290 proteins. SWATH-MS comparison of sucrose and formalin extracted glycogen found 72% 300 
of proteins had significantly different relative abundances (adjusted P < 0.05), suggesting that 301 
these extraction methods are qualitiatively complementary (Figure 3 – volcano plot).  302 
 303 
 304 
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Figure 3. Volcano plot comparing differences in relative protein abundances in glycogen 305 
samples enriched via the sucrose method and the formalin method. Technical triplicates of each 306 
enrichment method were compared with SWATH-MS. Each data point represents an 307 
independent protein. 308 
Gene ontology analysis was peformed to compare the proteins enriched by the sucrose and 309 
formalin extraction methods (see Table 3).  310 
Table 3. Gene ontology analysis of proteins enriched by sucrose versus formalin methods 311 
Keyword Count % Adjusted P-value 
Enriched in Sucrose preparation  
ribosomal protein 67 31 8.20E-18 
ribonucleoprotein 71 32.9 4.80E-13 
acetylation 157 72.7 7.70E-05 
ribosome 17 7.9 1.50E-02 
Enriched in Formalin preparation  
cytoplasm 95 47.5 2.60E-06 
hydrolase 40 20 3.70E-03 
Secreted 23 11.5 2.30E-02 
disulfide bond 32 16 3.30E-02 
metal-binding 52 26 3.80E-02 
 312 
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 313 
Discussion 314 
While a cold-water extraction method that utilizes sucrose density centrifugation has been 315 
shown to be effective in extracting glycogen with minimal degradation,11,12,31 a method that 316 
allows glycogen to be extracted from formalin-fixed tissues would permit the study of glycogen 317 
from formalin-fixed human tissues in pathology laboratories. The analysis of human glycogen 318 
would result in studies that are more physiologically relevant to human health. Given the 319 
discovery that the glycogen from diabetic (db/db) mice has a significantly different structure 320 
to that of the non-diabetic controls19 and the evidence that glycogen structure may be important 321 
in its metabolism,5 the potential impacts of having a better undertstanding of glycogen 322 
metabolism in terms of structure for humans is considerable. 323 
Because the normalization of these distributions is arbitrary, one cannot say, for example, that 324 
one technique or other results on more or less extraction of α particles; however, comparison 325 
of relative amounts is meaningful. 326 
The distributions of glycogen extracted using the formalin method (without protease) have 327 
relatively fewer  particles then the sucrose method; however, when treated with protease, 328 
there is a substantial increase in the relative height of the  particle peak (see Figure 1A). While 329 
there are still more  particles in relative terms from the sucrose method, it is possible that this 330 
is due to a loss of  particles from this method, as opposed to a loss of  particles in the 331 
formalin/protease method. Indeed, the preferential loss of  particles in the sucrose method 332 
appears to be more likely, both because the total yield is lower (see Table 1) and because, given 333 
the method’s reliance on the larger, denser particles forming a pellet after the sucrose-gradient 334 
centrifugation step, it is more likely that smaller particles would be lost. The shift of the -335 
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particle peak from the sucrose method to higher sizes is consistent with the prefential loss of 336 
smaller particles. 337 
One possible explanation for the increased amount of  particles in the formalin/protease 338 
method, compared to the formalin method (see Figure 1A), is that a significant amount of  339 
particles may be left insoluble after formalin fixation, most likely due to glycogen-associating 340 
proteins being linked together to form large insoluble aggregates which can be liberated when 341 
exposed to protease. This may suggest that there are significantly more proteins on the outside 342 
of  particles than  particles; however this is only speculation. Another possibility is that there 343 
is a network of proteins that are not connected to the larger glycogen  particles, but form a 344 
physical barrier that allows smaller  particles, but not  particles, to pass into solution. Here 345 
protease would be able to destroy this barrier, allowing these glycogen  particles to be 346 
analyzed using SEC. 347 
If the predominant aim of an experiment is to analyze the size distributions of the liver 348 
glycogen, then small contaminant molecules (such as sucrose or small proteins) that do not 349 
overlap with the glycogen in the size distribution are inconsequential. As can be seen in Figure 350 
1B, there are a large amount of non-glycogen contaminants for all extraction methods; however 351 
these do not overlap in molecular size with the glycogen distributions. There is a large 352 
contaminant peak of small molecules in the formalin/protease extracted samples resulting from 353 
the tricine that was used in the buffer for the protease treatment. 354 
If higher purities are required, the use of an S500 chromatography column has been shown to 355 
be effective at removing smaller particles such as free sugars and protein contaminants; 356 
however as is common with additional purification techniques, this leads to lower yields and 357 
also may affect the size distributions.11,12 358 
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The effect of heating samples at 80 °C was also analyzed, with the results showing that care 359 
must be taken when dissolving glycogen in an aqueous solvent, with lower temperatures being 360 
preferable (see Figure 2). Of particular interest is that the  particles of glycogen extracted via 361 
the formalin and formalin/protease method are much more susceptible to degradation than 362 
glycogen extracted via the sucrose method. Glycogen extracted using these methods should 363 
therefore always be dissolved at mild temperatures. The pH of the samples from all of the 364 
extraction methods was ~7, ruling out acid hydrolysis as the reason for degradation. 365 
Inferences for bonding between β particles in α particles 366 
The difference in degradation rates of glycogen extracted via the different methods may shed 367 
some light on the bond that holds glycogen  particles together, the nature of which there is as 368 
yet no unambiguous evidence. The fact that the formalin extraction technique leads to a 369 
significant weakening of the bonds holding  particles together provides further evidence (in 370 
addition to that reported previously20) that glycogen  particles are not held together via 371 
glycosidic linkages. While at room temperature protein reacts relatively quickly with 372 
formaldehyde, carbohydrates are unreactive with formaldehyde at this temperature,32 373 
remaining chemically unaltered unless exposed to fixation for several weeks.33 Therefore the 374 
preferential degradation of  particles in the presence of formaldehyde is additional evidence 375 
that the bond holding them together is different to glycosidic linkages. Given the well 376 
established ability of formaldehyde to form both inter- and intra-molecular crosslinks between 377 
protein residues, it is possible that the conformation of this hypothesized protein “glue” is 378 
altered by reacting with formaldehyde. It has been shown that whether a protein maintains its 379 
native confirmation after treatment in 10% NBF depends on that protein. For example, in one 380 
study RNase A maintained a conformation almost identical to the native, untreated protein 381 
while myoglobin showed significant stuctural changes after treatment with formalin.34 382 
However when heated, in both cases the formalin-treated proteins behaved differently to the 383 
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untreated controls, having a broad and non-cooperative thermal transition as opposed to the 384 
cooperative, relatively sharp transitions of the native proteins. It is therefore entirely possible 385 
that any protein “glue” would be in a significantly different conformation at 80 °C when the 386 
glycogen was extracted with the formalin method as opposed to the sucrose method. How this 387 
difference would affect the ability of the protein to join the  particles together can only be 388 
speculated at this point and is beyond the scope of this study; however we will offer a brief 389 
description of two possibilities. Firstly, if there is a protein linked covalently to join together  390 
particles, it is possible that denaturing this protein will make the protein backbone more 391 
susceptible to shear scission; given the relatively large molecular weights of  particles (106 – 392 
107), the amount of shear scission during SEC characterization that could be subjected to a 393 
single-molecule glue holding these together may be sufficient to cleave a bond. While such 394 
shear scission is very unlikely in small molecules, it becomes increasingly likely with larger 395 
molecules, and certainly occurs with amylopectin, which is of a size commensurate with that 396 
of glycogen α particles.35 Secondly, while the possibility of a non-covalent protein linkage has 397 
been inconsistent with a number of studies that have used powerful denaturants,10 the presence 398 
of a highly resistant protein cannot be completely disregarded. If so, it is possible that this 399 
resistant protein is denatured to the extent of failing as a glue when treated with formalin and 400 
heated to 80 °C. 401 
Identification of glycogen-associated proteins 402 
Further investigations of the regulation of the structure of glycogen would require identification 403 
and measurement of the proteins physically associated with glycogen particles. Mass 404 
spectrometry proteomics would be a useful approach for this purpose. We therefore tested if 405 
formalin-extracted glycogen was compatible with MS proteomic analyses. Several sample 406 
preparation methods were tested, including denaturing proteins in formalin-extracted glycogen 407 
samples with guanidine-HCl or SDS, compared with no additional treatment. It has been shown 408 
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here that formalin-extracted glycogen can be analyzed successfully for associated proteins 409 
when using guanidine-HCl; however due to the low purity of the samples, there is a large amout 410 
of contaminating proteins. Again this problem can be largely circumvented by employing 411 
further purification with an S500 gel chromatography column. Gene ontology analysis of the 412 
differentially abundant proteins showed that the sucrose method enriched contaminating 413 
proteins from intracellular ribosomes, whereas the formalin method enriched secreted proteins, 414 
confirming the complementarity of these methods for glycogen enrichment (see Table 3). The 415 
volcano plot (Figure 3) illustrates these differences between the two methods.  Future studies 416 
aimed at identifying bona fide glycogen-associated proteins would require additional 417 
purification steps to remove contaminating proteins. 418 
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5.2 Outcomes 
Liver glycogen extracted from both sucrose-gradient centrifugation and formalin-fixed 
techniques were carried out, comparing the yields, purities and SEC size distributions. The 
formalin extraction technique, when combined with an additional protease treatment step, 
resulted in higher yields (but lower purities) of glycogen with size distributions similar to the 
sucrose gradient centrifugation technique. This formalin extraction procedure was also 
significantly faster, allowing the throughput of glycogen samples that can be extracted to 
increase by an order of magnitude. Both the sucrose gradient centrifugation and formalin 
techniques were compatible with MS proteomics, with SWATH-MS analysis showing the two 
techniques to be highly complementary. This new procedure can thus be used to examine 
differences in glycogen molecular structure in human livers, allowing the link between diabetes 
and liver glycogen to be further explored. 
6. Chapter 6: Thesis discussion and future work 
6.1 Discussion 
The work described in this thesis has resulted in a richer understanding of liver-glycogen 
metabolism in terms of structure, an aspect of glycaemic control that has often been 
overlooked.  Given the building evidence that smaller glycogen particles: 1) have a higher 
association with glycogen phosphorylase102, a key enzyme involved in glycogen degradation; 
and 2) are degraded more rapidly in vitro31,110, the inability to form larger glycogen  particles 
is predicted to result in a faster, less controlled degradation into glucose. This is hypothesized 
to be the reason why evolution has favored the formation of large α particles in the liver, where 
glucose release needs to be relatively slow and tightly controlled, as opposed to the smaller β 
particles found in muscle tissue where glycogen needs to be broken down rapidly during 
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exercise. It is therefore conceivable that poor blood-glucose control is at the very least 
exacerbated in db/db mice by impaired α particle formation. 
The question of what holds α particles together has proven to be difficult to resolve, with a 
number of past studies coming to conflicting conclusions. The possibility of hydrogen bonding 
has been consistently negated by experimental evidence7,31, suggesting a covalent link. While 
the disulfide-disrupting reagent 2-mercaptoethanol appeared to cause α particles to break down, 
we have shown in Chapter 2 that this is an artifact. Another study also used 2-mercaptoethanol 
and iodoacetamide and reported no change in the size of liver glycogen35. The authors 
suggested that the link between β particles may just be α-(1→4) glycosidic linkages, the same 
bond used to connect glucose units in a glycogen chain. Again, Chapter 2 sheds light on this 
issue. Here, SEC was used to obtain the weight distributions of glycogen at various times after 
being exposed to a relatively low pH (~3.5). While it is well known that acid can hydrolyze 
glycogen31,111, only when these semiquantitative distributions were obtained did it become 
clear that the bonds holding α particles together were degraded much faster by acid hydrolysis 
than the normal glycosidic linkages in glycogen. This was consistent with past sucrose density 
centrifugation data112. Furthermore, it was shown in this recent SEC study that, even at a neutral 
pH, α particles can degrade into β particles. The degradation rates of α particles to β particles 
in both acidic and neutral pHs were found to be consistent with the hydrolysis of protein113,114: 
the “glue” whereby the β particles in α particles are held together is therefore hypothesized to 
be proteinaceous and covalently linked to the glycogen.  
One major implication of α particles being held together by protein (as suggested although not 
proven by experiment), as opposed to simply α-(1→4) or α-(1→6) glycosidic linkages, is a 
new potential target for clinical intervention. Approximately half of the orally dosed drugs used 
clinically are small molecules that inhibit the action of enzymes115,116. Therefore, any enzyme 
Page 60 
that may be linked to impaired α particle formation (or increased α particle degradation) may 
potentially become a new drug target for inhibition. If a “glue” protein is found, a new drug 
that upregulates this protein to increase the synthesis rate and the molecular size of α particles 
becomes a possible intervention for diabetic patients. 
It should be noted however, that there is also evidence that is not consistant with a 
proeteinaceous linkage, with the most obvious being that protease does not have an effect on 
the size of glycogen  particles. Another important consideration is the lack of reactivity of the 
non-reducing end of the glycogen chains, making it unlikely that any protein “glue” is able to 
directly react with the end of a glycogen chain. One possibility is that the phosphorylation of 
glycogen plays an important role in forming a covalent link with a protein glue. Another 
possibility (not yet tested) is that there is a direct link between  particles via phosphodiesters. 
While significant progress has been made in this study, future work is required to determine 
what links  particles together to form these larger  particles. 
One important aspect of analyzing the effect glycogen structure has on glycaemic control is to 
determine when in the diurnal cycle of glycogen metabolism these  particles form. Equally 
important is to determine when these particles begin to degrade. To answer this, as given in 
Chapter 3, we exploited the natural diurnal cycle of glycogen metabolism in mice, sacrificing 
wild-type mice at various times during a 12 hour light/12 hour dark cycle. By analyzing the 
glycogen content and structure for each mouse we were able to form a much more detailed 
understanding of the role structure plays in liver-glycogen metabolism. This study revealed 
three key insights: 1) glycogen initially forms as separate  particles, only to be subsequently 
joined together to form larger  particles after the glycogen content has reached its maximum 
concentration; 2) during glycogen degradation the larger particles were much more resistant to 
glycogenolysis, persisting significantly longer than the smaller  particles; and 3) glycogen 
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particles are finally degraded to a small but resistant particle with a hydrodynamic radius of ~ 
12 nm. Not only does this data support the theory that glycogen particle size influences the rate 
of glycogenolysis, but it strongly suggests that there is a mechanism in which separate  
particles are able to conglomerate to form an  particle. 
Given the critical role SEC plays in our understanding of glycogen structure, allowing us to 
probe aspects of glycogen metabolism previously unexplored due to technological limitations, 
any improvements made in the effectiveness of this method will be invaluable to further 
research into the role of glycogen structure in glycaemic control. After the recent finding that 
an aqueous-SEC system achieved significantly improved resolution, when compared to a 
DMSO-SEC system for synthetic, branched polysaccharides105, it became clear that a 
comparison between our past DMSO-SEC system with the newer aqueous-SEC system could 
give us an improved method for analyzing glycogen’s structure. While temporarily delaying 
the search for answers regarding glycogen structure’s role in glycaemic control, an 
improvement in our analysis techniques could greatly increase the efficiency in which we 
subsequently answer these questions. Indeed, as described in Chapter 4, we found a 
significantly improved resolution in the SEC distributions obtained using aqueous-SEC in 
comparison to our previous DMSO-SEC setup. This improved resolution greatly increases the 
power of our SEC analyses, resulting in separation of - and -particle peaks. This separation 
is not achieved using DMSO-SEC, with the  particles forming a shoulder on the -particle 
peak. As explained in greater detail in Chapter 4, there are considerable benefits to being able 
to separate the maxima of the - and -particle peaks, one being the increased ability to 
effectively parameterize and thus statistically compare distributions. Aqueous-SEC should 
therefore be used for all future work requiring glycogen SEC distributions. 
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Another important aspect of characterizing the structure of glycogen is being able to extract 
glycogen with minimal degradation. Since the initial isolation of glycogen from dog liver in 
1857117, the search for extraction techniques that result in decreased damage to the native 
structure has resulted in the progression of milder methods. After glycogen was shown to be 
degraded by both hot-alkaline118 and cold trichloroacetic acid31 extraction methods, the 
development and improvement of cold-water techniques1,7,31,119,120 has allowed for the 
extraction of glycogen with minimal degradation. Given the extensive practice in pathology 
laboratories of chemically fixing liver tissue in a solution of dissolved formaldehyde, known 
as formalin121, the development of an extraction method that can isolate glycogen from these 
tissues with minimal degradation would allow this vast source of human tissues to be analyzed. 
This extension of glycogen research into human tissues will greatly enhance the physiological 
relavance, in terms of human health, of further investigations into the role of glycogen structure 
in maintaining blood-glucose homeostasis. 
Here we developed a method of extracting glycogen from formalin-fixed liver tissue. While 
the purity of the glycogen is lower than when compared with the cold-water sucrose gradient 
centrifugation method, the glycogen yield is greater. Because the impurities from both methods 
consist of small molecules, there is no overlap between contaminants and glycogen in the SEC 
distributions, making their presence irrelevant to the determination of accurate size 
distributions. As discussed in Chapter 5, the sucrose gradient method appears to result in the 
preferential loss of smaller  particles, making the formalin method preferable when needing 
to obtain accurate size distributions. However one disadvantage with this method is that the 
glycogen particles are much more vulnerable to being degraded in water. Care must therefore 
be taken, with glycogen being dissolved at room temperature. This unexpected difference in 
susceptibilty of degradation between glycogen extracted via the formalin and sucrose gradient 
techniques gives us further insight into the bond holding particles together. The preferential 
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degradation of  particles into  particles (compared to the degradation of  particles) 
following the formalin extraction method is further evidence that glycosidic linkages do not 
hold  particles together. Given carbohydrates are unreactive to formalin122, but that formalin 
reacts rapidly with protein123, it is possible that the inter-molecular and intra-molecular 
crosslinks formed during formalin fixing affect the proposed protein “glue”, making it more 
susceptible to degradation when being heated at 80 °C. Again further research is required to 
test this protein “glue” hypothesis. 
6.2 Future Research 
While there have been a number of important advancements in our knowledge on glycogen’s 
structure and the role this plays in its metabolism, this research is still in its infancy. There are 
a number of projects currently underway to further progress this research and a large amount 
of future projects that have been conceived to help answer the plethora of questions arising 
from the work presented here. In brief, here are some of the more pertinent questions remaining 
unanswered: What is the bond holding  particles together?; If the bond is proteinaceous, what 
is this protein?; Is the difference in glycogen structure seen in db/db mice present across the 
whole diurnal cycle?; Why is -particle formation impaired in db/db mice?; Can a “healthy” 
glycogen structure be rescued in db/db mice with the administration of suitable type 2 diabetic 
drugs? and; Is this impaired  particle formation seen in other models for type 2 diabetes and 
most importantly, in humans? 
A detailed project proposed for an NHMRC fellowship is given in Appendix 5. Below are 
summaries for other potential projects aimed to answer some of the above unanswered 
questions. 
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6.2.1 Proteomic analysis of fractionated glycogen 
If there is a proteinaceous link holding  particles together, this protein should be able to be 
detected using mass-spectroscopy-based proteomics. While mass spectroscopy (MS) has been 
used to successful identify proteins associated on the surface of liver glycogen19, here we 
propose to degrade glycogen with -amylase and identify any proteins trapped inside the 
glycogen particles. Theoretically any protein “glue” should be more abundant in the  patricles 
than in the  particles. Therefore, by performing MS proteomics on glycogen that has been 
fractionated based on size and treated with -amylase to liberate any trapped proteins, we can 
identify potential proteins involved in binding the larger  particles together. The absence of 
any suitable proteins would be strong evidence against the protein “glue” hypothesis. 
Fractionation of the glycogen can be performed using preparative SEC. 
6.2.2 Analyzing glycogen structure across a diurnal cycle for healthy and db/db mice 
The discovery98 that db/db mice had fewer  particles than healthy mice only analyzed samples 
at one time point during the day (9 am). Given the diurnal nature of glycogen synthesis 
(discussed in Chapter 3), it is important to determine whether db/db mice are able to synthesize 
 particles at any stage across the 24 h cycle. The project proposed here is to repeat the 
experiments outlined in Chapter 3 but to also analyze db/db mice, with the wild-type mice 
acting as a control. 
6.2.3 Analyzing glycogen structure across a diurnal cycle for healthy and high-fat diet 
mice 
To determine whether glycogen structure plays a role in glycaemic control and diabetes, more 
than one dibetic model needs to be analyzed. An alternative to the db/db mouse as a model for 
type 2 diabetes is the high-fat diet mouse. While genetically identical to the controls, these 
mice are given a diet that has a higher fat content than the controls, causing them to become 
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obese and eventually insulin resistant. Again it would be ideal to analyze the glycogen content 
and structure over the course of a diurnal cycle. 
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New Molecular Insights into Glycogen Alpha-
Particle Formation 
Supporting Information 
Acid hydrolysis repeat experiments 
 
Figure 1. First 2 h of acid hydrolysis repeat; pig liver (A) and oyster (B) glycogen before acid 
hydrolysis (blue), and after 10 min (red), 30 min (green) and 2 h (black) of acid hydrolysis. 
Shows the same trend as the figure presented in the main text. 
 
Figure 2. Final stages of acid hydrolysis repeat; pig-liver (A) and oyster (B) glycogen after 1 
d (blue), 2 d (red), 3 d (green) and 1 week (black) of acid hydrolysis. 
 
 
 
  
Batch MALLS Berry Plots 
 
 
Figure 3. Replicate Berry plots of pig-liver (A) and oyster glycogen (B). Extrapolated values to zero 
concentration are coloured in black. 
Calulation of rate constant  for the hydrolysis of AcG-­‐GNHMe	  at	  neutral	  pH 
 
The following calculation uses data taken from the literature for the hydrolysis of AcG-­‐GNHMe 
(representative of a protein peptide bond).1 
By assuming the reacton rate is of Arhenius form, the rate constant of hydrolysis can be estimated at 80 oC. 
 
At 150 oC the rate constant of AcG-GNHMe hydrolysis is 5.1 × 10-6 s-1. The activation energy was 
calculated to be 98.3 kJ mol-1.1 The pre-exponential factor can then be calculated from the above 
equation to be ~ 7.1 × 106 s-1  . This gives an estimated hydrolysis rate of 2.0 × 10-8 s-1 at 80 oC. 
 
 
	   (1)	   Radzicka,	  A.;	  Wolfenden,	  R.	  Journal	  of	  the	  American	  Chemical	  Society	  1996,	  118,	  6105.	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control 
Mitchell A. Sullivan, Samuel T. N. Aroney, Shihan Li, Frederick J. Warren, Jin Suk Joo, Ka 
Sin Mak,  David I. Stapleton, Kim S. Bell-Anderson & Robert G. Gilbert 
  
 
 
 
Figure S1. The mean hydrodynamic radius (Rh) at which the maximum occurs (a) and the 
average hydrodynamic radius (b) (calculated as previously)1 for SEC weight distributions of 
glycogen at various times during a light/dark cycle. Values shown are the mean ± S.E.M. of 
3–9 mice. Different letters indicate statistical significance (p < 0.05). 
 
Preliminary kinetics studies 
Materials 
Potassium phosphate, ethylenediaminetetraacetic acid (EDTA), magnesium chloride, α-D 
glucose 1,6-diphosphate, β-nicotinamide adenine dinucleotide phosphate (β-NAPD), glucose-
6-phosphate dehydrogenase, phosphoglucomutase, glycogen phosphorylase b from rabbit 
muscle and adenosine 5′-monophosphate (AMP) were purchased from Sigma-Aldrich.  
Diabetic C57BL/6j-db/db and wild-type female mice were sacrificed at either ~1.5 months 
(“young”) or ~3 months (“old”). Glycogen extraction was performed using established 
methods.2,3 Glycogen was extracted from the livers of eight mice with 4 non-diabetic (3 old 
and 1 young) and 4 diabetic (2 old and 2 young).  The important factor is that there are a 
range of glycogen sizes to test the dependence of size on the initial rate of phosphorylase 
degradation; this range of sizes was achieved (see Figure S2). 
Preparation of Digestion Buffer 
A solution containing 500 mM potassium phosphate, 300 mM magnesium chloride and 100 
mM EDTA (adjusted to pH 6.8) was prepared. The digestion buffer was obtained by mixing 
this solution (1.5 mL) with deionized water (10 mL), NADP 0.08 mg mL–1 (1 mL) and α-D 
glucose 1,6-diphosphate 0.08 mg mL–1 (30 µL).  
Glycogen Phosphorylase Assay 
The phosphorylase assays were performed on mouse-liver glycogen using a similar assay to a 
past study.4  0.8 mg of mouse-liver glycogen was dissolved into 0.2 mL of digestion buffer. 
Samples were then dissolved in a thermomixer at 80 °C and 350 rpm for 4 h. Samples were 
then diluted to 0.1125 mg mL–1 with the digestion buffer. .  
A microplate reader (BMG FLUOstar OPTIMA) was used to measure the absorbance of β-
NADPH, which is produced during the reaction. The following reagents were placed into 
each well: 180 μL glycogen solution, 6 μL of glycogen phophorylase (0.75 U mL–1), 6 μL of 
phosphoglucomutase (10 U mL–1), 6 μL glucose-6-phosphate dehydrogenase (10 U mL–1) 
and 2 μL of 100 mM 5 ′ AMP. Absorbance of the samples at 37 °C was measured at 340 nm 
every 90 s. A standard curve of known concentrations of β-NADPH was used. Initial rates for 
the reaction were obtained from the linear region of a plot of product concentration against 
time. 
 
 
Figure S2. SEC weight distributions, w(log Rh) (normalized to equal areas) of young non-
diabetic (green), old non-diabetic (blue), young diabetic (orange) and old diabetic (red) mice. 
 
 Figure S3. Initial rate v of glycogen phosphorylase degradation of glycogen from young non-
diabetic (green square), old non-diabetic (blue diamond), young diabetic (orange triangle) 
and old diabetic (red circle) mice. 
 
 (1) Vilaplana, F.; Gilbert, R. G. J. Chromatography A 2011, 1218, 4434. 
 (2) Ryu, J.-H.; Drain, J.; Kim, J. H.; McGee, S.; Gray-Weale, A.; Waddington, L.; 
Parker, G. J.; Hargreaves, M.; Yoo, S.-H.; Stapleton, D. International Journal of Biological 
Macromolecules 2009, 45, 478. 
 (3) Sullivan, M. A.; Li, J.; Li, C. Z.; Vilaplana, F.; Stapleton, D.; Gray-Weale, A. 
A.; Bowen, S.; Zheng, L.; Gilbert, R. G. Biomacromolecules 2011, 12, 1983. 
 (4) Thomas, D. A.; Wright, B. E. Journal of Biological Chemistry 1976, 251, 
1253. 
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Figure	  S1.	  Calibration	  curves	  of	  pullulan	  in	  50	  mM	  NH4NO3/0.02%	  NaN3	  at	  80	  
oC	  and	  50	  mM	  
NaNO3/0.02%	  NaN3	  at	  50	  oC.	  These	  were	  run	  in	  duplicate	  with	  the	  variation	  between	  duplicates	  
being	  as	  large	  as	  between	  different	  solvent	  systems.	  	  
	  
	  Figure	  S2.	  Comparison	  of	  calibration	  curves	  for	  pullulan	  in	  aqueous	  (50	  mM	  NH4NO3/0.02%	  NaN3)	  
and	  DMSO/LiBr	  setups	  for	  the	  different	  pore	  sizes.	  τ is	  the	  elution	  time	  divided	  by	  that	  of	  the	  
smallest	  standard.	  
	  
	  
Figure	  S3.	  Comparison	  of	  aqueous	  calibration	  curves	  with	  the	  elution	  time	  (presented	  in	  terms	  of	  
τ, where τ is	  the	  elution	  time	  divided	  by	  that	  of	  the	  smallest	  standard)	  corresponding	  to	  the	  α	  
particle	  peak	  maxima	  being	  given	  (black).	  Trend	  lines	  have	  been	  extended.	  
	  
Figure	  S4.	  Equivalent	  to	  Figure	  4	  in	  main	  article	  with	  the	  X	  axis	  being	  changed	  to	  a	  logarithmic	  scale.	  
	  Figure	  S5.	  Equivalent	  to	  Figure	  5	  in	  the	  main	  article	  with	  the	  X	  axis	  being	  changed	  to	  a	  logarithmic	  
scale.	  
	  Figure	  S6.	  Equivalent	  to	  Figure	  4	  in	  main	  article	  with	  the	  X	  axis	  being	  changed	  to	  logarithmic.	  
	  
	  Figure	  S7.	  An	  overlay	  of	  the	  elution	  plots	  for	  pullulan	  standards	  in	  the	  aqueous	  3000	  and	  30	  setup.	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Figure S1. Equivalent to Figure 1 in the main article but with a different pig-liver sample. This 
repeated experiment shows the same trends as the initial pig sample. 
 
 
 
  
Figure S2. Equivalent to Figure 2 in the main article but with a different pig-liver sample. This 
repeated experiment shows the same trends as the initial pig sample. 
 
 Figure S3. SEC weight distributions, w(log Rh; normalized to have equal heights for the maximum 
glycogen peak) as a function of molecular size (the hydrodynamic radius Rh) for 2 pig-liver glycogen 
samples at  2 mg mL-1 (full line) and 0.4 mg mL-1 (broken line) extracted via the sucrose method (A), 
formalin method (B) and formalin/protease method (C).  
 
  
Table S1. Proteins identified by LC-ESI-MS/MS after glycogen enrichment from formalin fixed 
tissue. 
Accession Protein Score % Cov (95%) Peptides (95%) 
P07724 ALBU_MOUSE 175.39 74.18 136 
Q63836 SBP2_MOUSE 83.96 78.39 61 
P02762 MUP6_MOUSE 82.07 76.11 67 
P04938 MUP8_MOUSE 82.07 90.73 67 
B5X0G2 MUP17_MOUSE 79.89 70.56 65 
Q00897 A1AT4_MOUSE 79.21 64.41 47 
Q61838 A2M_MOUSE 68.89 28.56 35 
Q9QXD6 F16P1_MOUSE 56.12 78.11 31 
P12710 FABPL_MOUSE 54.82 92.13 66 
Q921I1 TRFE_MOUSE 51.42 39.17 29 
Q64374 RGN_MOUSE 46.36 66.22 28 
P07759 SPA3K_MOUSE 40.25 51.44 25 
Q8C196 CPSM_MOUSE 39.63 17.87 21 
P16015 CAH3_MOUSE 38.39 61.92 27 
Q8R0Y6 AL1L1_MOUSE 36.96 25.61 18 
P16460 ASSY_MOUSE 36.36 43.69 21 
Q8QZR3 EST2A_MOUSE 36.23 30.29 18 
Q9D0F9 PGM1_MOUSE 35.84 43.24 18 
P60710 ACTB_MOUSE 33.45 54.67 20 
P63260 ACTG_MOUSE 31.01 50.13 19 
P19157 GSTP1_MOUSE 32.88 65.24 22 
O35215 DOPD_MOUSE 32.22 83.05 20 
Q63880 EST3A_MOUSE 32.02 29.42 18 
P35505 FAAA_MOUSE 32 51.55 16 
P16858 G3P_MOUSE 31.19 51.05 16 
Q00623 APOA1_MOUSE 29.76 49.24 16 
O08709 PRDX6_MOUSE 29.06 69.64 14 
P28665 MUG1_MOUSE 31.16 11.79 15 
Q91X72 HEMO_MOUSE 27.06 30.22 14 
P30115 GSTA3_MOUSE 27.02 49.32 15 
P11352 GPX1_MOUSE 27.02 65.17 14 
P23953 EST1C_MOUSE 26.48 27.08 14 
P17182 ENOA_MOUSE 24.94 39.63 13 
P20029 GRP78_MOUSE 24.85 20.61 12 
P24549 AL1A1_MOUSE 26.26 36.33 16 
P00329 ADH1_MOUSE 24.04 46.13 14 
P10649 GSTM1_MOUSE 23.88 48.62 14 
O35490 BHMT1_MOUSE 23.55 37.10 16 
Q8VCT4 CES1D_MOUSE 25.35 25.84 13 
Q91Y97 ALDOB_MOUSE 22.66 42.58 12 
P52760 UK114_MOUSE 22 82.22 12 
P08228 SODC_MOUSE 22 67.53 16 
Q61176 ARGI1_MOUSE 20.08 47.99 11 
Q9JII6 AK1A1_MOUSE 20.06 37.23 10 
Q9WVL0 MAAI_MOUSE 19.99 57.87 11 
P14152 MDHC_MOUSE 19.8 44.01 13 
Q91YI0 ARLY_MOUSE 19.54 26.08 10 
P50247 SAHH_MOUSE 19.47 28.47 10 
P09103 PDIA1_MOUSE 18.58 24.95 9 
Q00898 A1AT5_MOUSE 69.25 50.61 44 
O88844 IDHC_MOUSE 18.44 34.30 11 
P05201 AATC_MOUSE 16.58 29.78 8 
P11499 HS90B_MOUSE 16.39 14.09 8 
P06151 LDHA_MOUSE 16.23 26.20 8 
Q8VC30 DHAK_MOUSE 16.01 21.80 8 
P07309 TTHY_MOUSE 14.89 57.82 8 
P02535 K1C10_MOUSE 14.83 18.77 10 
P02088 HBB1_MOUSE 14.33 47.62 10 
P63017 HSP7C_MOUSE 15.38 14.86 9 
P27773 PDIA3_MOUSE 13.47 20.99 8 
P09411 PGK1_MOUSE 13.47 28.78 8 
P70694 DHB5_MOUSE 13.08 29.72 7 
Q78JT3 3HAO_MOUSE 12.77 30.77 8 
P08113 ENPL_MOUSE 14.72 12.72 8 
P17751 TPIS_MOUSE 12.28 26.42 6 
P35700 PRDX1_MOUSE 12.08 27.14 6 
Q64442 DHSO_MOUSE 12.04 23.25 6 
P49429 HPPD_MOUSE 11.79 18.07 6 
Q91WG0 EST2C_MOUSE 16.61 16.76 8 
Q9DBE0 CSAD_MOUSE 11.59 14.00 6 
P48036 ANXA5_MOUSE 11.41 21.63 6 
P10126 EF1A1_MOUSE 11.26 19.26 7 
Q9CXN7 PBLD2_MOUSE 10.96 23.61 6 
Q9DBJ1 PGAM1_MOUSE 10.86 37.40 6 
Q91X83 METK1_MOUSE 10.62 18.94 6 
P34914 HYES_MOUSE 10.15 12.64 5 
P68372 TBB4B_MOUSE 10 14.38 5 
Q9D6F9 TBB4A_MOUSE 8 10.36 4 
P99024 TBB5_MOUSE 8 11.04 4 
P29391 FRIL1_MOUSE 10 39.89 7 
P09813 APOA2_MOUSE 10 33.33 6 
P01027 CO3_MOUSE 9.9 4.09 5 
Q91X91 NADC_MOUSE 9.84 19.06 5 
P14211 CALR_MOUSE 9.79 14.18 5 
P01942 HBA_MOUSE 9.73 31.69 7 
Q8BVI4 DHPR_MOUSE 9.38 34.02 5 
P63101 1433Z_MOUSE 9.26 25.71 5 
Q9QXF8 GNMT_MOUSE 9 26.28 5 
P28271 ACOC_MOUSE 8.95 9.45 5 
Q8VCU1 EST3B_MOUSE 22.93 17.34 13 
P56480 ATPB_MOUSE 8.54 13.61 5 
O08677 KNG1_MOUSE 8.21 9.53 6 
Q5FW60 MUP20_MOUSE 14.91 44.75 9 
P07758 A1AT1_MOUSE 75.31 57.63 49 
P04104 K2C1_MOUSE 8.06 7.06 4 
Q8VCM7 FIBG_MOUSE 8.03 12.84 4 
P29699 FETUA_MOUSE 8.02 17.97 4 
P62962 PROF1_MOUSE 8 40.00 4 
Q9D819 IPYR_MOUSE 8 16.26 4 
P97328 KHK_MOUSE 7.7 17.45 4 
Q8BH00 AL8A1_MOUSE 7.73 13.14 4 
G3X982 AOXC_MOUSE 7.45 4.72 4 
Q9ET01 PYGL_MOUSE 7.06 5.06 4 
Q8VCN5 CGL_MOUSE 7.04 13.57 4 
P21614 VTDB_MOUSE 6.86 11.55 4 
P55264 ADK_MOUSE 6.52 12.19 3 
Q9CPY7 AMPL_MOUSE 6.35 6.17 3 
P06801 MAOX_MOUSE 6.29 8.22 3 
P61458 PHS_MOUSE 6.16 25.00 3 
Q9CPU0 LGUL_MOUSE 6.11 21.20 3 
P32261 ANT3_MOUSE 6.09 8.39 3 
O09131 GSTO1_MOUSE 6.03 18.75 3 
P70296 PEBP1_MOUSE 6.02 28.34 3 
Q8BK48 EST2E_MOUSE 14.73 14.67 8 
P01872 IGHM_MOUSE 6 8.59 3 
Q923D2 BLVRB_MOUSE 6 30.58 3 
P68373 TBA1C_MOUSE 6 10.02 4 
P68368 TBA4A_MOUSE 6 10.04 3 
P05213 TBA1B_MOUSE 6 9.98 4 
P68369 TBA1A_MOUSE 4 6.87 3 
Q01853 TERA_MOUSE 5.82 4.72 3 
Q8VCR7 ABHEB_MOUSE 5.77 15.71 3 
Q9QYG0 NDRG2_MOUSE 5.72 10.78 4 
P06728 APOA4_MOUSE 5.68 8.61 3 
P53657 KPYR_MOUSE 5.62 8.36 3 
P17742 PPIA_MOUSE 5.51 23.17 3 
Q8QZR5 ALAT1_MOUSE 5.27 7.06 3 
P40936 INMT_MOUSE 5.1 13.64 3 
P24472 GSTA4_MOUSE 4.94 20.27 3 
Q91ZJ5 UGPA_MOUSE 4.8 8.07 3 
Q8BWT1 THIM_MOUSE 4.34 10.08 3 
Q91V76 CK054_MOUSE 4.32 9.21 2 
P99029 PRDX5_MOUSE 4.11 11.90 2 
P31786 ACBP_MOUSE 4.08 34.48 2 
Q03265 ATPA_MOUSE 4.05 4.70 2 
P54869 HMCS2_MOUSE 4.05 4.13 2 
Q9D0J8 PTMS_MOUSE 4.03 16.83 3 
Q8K0E8 FIBB_MOUSE 4.01 6.45 3 
P11589 MUP2_MOUSE 72.47 76.11 61 
Q920E5 FPPS_MOUSE 4 8.21 2 
Q9DBF1 AL7A1_MOUSE 4 6.12 2 
Q64105 SPRE_MOUSE 4 10.73 2 
P15105 GLNA_MOUSE 4 9.92 2 
P08226 APOE_MOUSE 4 7.07 2 
P01898 HA10_MOUSE 4 7.08 2 
 
 
 
 Table S2. Proteins identified by LC-ESI-MS/MS after glycogen enrichment from formalin fixed 
tissue with SDS. 
Accession Protein Score % Cov (95%) Peptides (95%) 
P07724 ALBU_MOUSE 61.98 50.0 40 
Q63836 SBP2_MOUSE 45.49 51.3 26 
P12710 FABPL_MOUSE 26.10 71.6 26 
P60710 ACTB_MOUSE 24.25 40.0 15 
P63260 ACTG_MOUSE 22.24 35.5 13 
P04938 MUP8_MOUSE 20.60 69.5 13 
P02762 MUP6_MOUSE 20.60 58.3 13 
B5X0G2 MUP17_MOUSE 20.60 58.3 13 
P11588 MUP1_MOUSE 19.17 51.7 12 
P11352 GPX1_MOUSE 16.18 53.2 9 
Q00896 A1AT3_MOUSE 15.82 17.2 9 
P22599 A1AT2_MOUSE 13.61 14.8 8 
P19157 GSTP1_MOUSE 15.78 26.7 11 
Q64374 RGN_MOUSE 14.14 29.4 7 
Q91X72 HEMO_MOUSE 13.86 19.1 8 
Q8VCU1 EST3B_MOUSE 12.71 14.7 8 
Q8C196 CPSM_MOUSE 12.18 4.3 6 
P35505 FAAA_MOUSE 12.13 17.7 6 
P07759 SPA3K_MOUSE 12.00 18.9 6 
Q91WG0 EST2C_MOUSE 10.00 12.5 6 
Q8VCT4 CES1D_MOUSE 10.00 11.2 5 
P56480 ATPB_MOUSE 10.00 11.7 5 
P52760 UK114_MOUSE 10.00 25.9 5 
P10649 GSTM1_MOUSE 10.00 27.5 5 
P08228 SODC_MOUSE 10.00 29.9 5 
P02088 HBB1_MOUSE 10.00 47.6 5 
Q91Y97 ALDOB_MOUSE 8.00 15.7 4 
O35490 BHMT1_MOUSE 7.59 12.0 4 
Q8QZR3 EST2A_MOUSE 9.10 12.4 5 
Q61176 ARGI1_MOUSE 6.59 11.8 3 
Q00623 APOA1_MOUSE 6.02 12.5 3 
P16858 G3P_MOUSE 6.00 15.6 3 
Q03265 ATPA_MOUSE 6.00 6.5 3 
P14152 MDHC_MOUSE 6.00 8.4 3 
P05201 AATC_MOUSE 6.00 9.2 3 
P01942 HBA_MOUSE 6.00 25.4 4 
O35215 DOPD_MOUSE 6.00 30.5 4 
P16015 CAH3_MOUSE 4.57 10.0 2 
Q61838 A2M_MOUSE 4.04 1.7 2 
P04939 MUP3_MOUSE 4.02 10.9 2 
P11725 OTC_MOUSE 4.00 6.2 2 
Q921I1 TRFE_MOUSE 4.00 3.3 2 
P31786 ACBP_MOUSE 4.00 33.3 2 
P07309 TTHY_MOUSE 4.00 17.0 2 
P05202 AATM_MOUSE 4.00 7.0 2 
P14211 CALR_MOUSE 2.19 4.6 2 
 
  
Table S3. Proteins identified by LC-ESI-MS/MS after glycogen enrichment from formalin fixed 
tissue with guanidine-HCl. 
Accession Protein Score % Cov (95%) Peptides (95%) 
P07724 ALBU_MOUSE 143.85 62.66 129 
P22599 A1AT2_MOUSE 77.27 61.99 57 
Q63836 SBP2_MOUSE 76.38 68.64 62 
Q61838 A2M_MOUSE 75.2 28.09 41 
P02762 MUP6_MOUSE 57.54 69.44 56 
P04938 MUP8_MOUSE 57.54 82.78 56 
P11588 MUP1_MOUSE 57.4 69.44 56 
B5X0G2 MUP17_MOUSE 56.99 63.89 54 
P07759 SPA3K_MOUSE 55.16 51.44 37 
Q8R0Y6 AL1L1_MOUSE 47.15 33.70 24 
Q921I1 TRFE_MOUSE 41.78 32.86 25 
Q64374 RGN_MOUSE 40.66 51.51 29 
P28665 MUG1_MOUSE 41.52 18.09 20 
Q9QXD6 F16P1_MOUSE 39.28 60.36 26 
P12710 FABPL_MOUSE 36.46 85.83 62 
Q8QZR3 EST2A_MOUSE 35.94 35.48 18 
P16015 CAH3_MOUSE 35.81 60.77 23 
P16460 ASSY_MOUSE 35.48 39.81 21 
Q63880 EST3A_MOUSE 35.22 36.08 23 
P20029 GRP78_MOUSE 34.93 29.47 18 
P63260 ACTG_MOUSE 33.46 52.80 23 
P60710 ACTB_MOUSE 33.46 52.80 23 
P35505 FAAA_MOUSE 32.91 53.46 19 
Q9D0F9 PGM1_MOUSE 31.43 38.26 16 
P23953 EST1C_MOUSE 26.56 27.98 15 
P16858 G3P_MOUSE 26.15 45.65 14 
P11352 GPX1_MOUSE 26.07 60.70 16 
O08709 PRDX6_MOUSE 24.73 52.23 14 
Q61176 ARGI1_MOUSE 24.48 48.30 15 
P52760 UK114_MOUSE 24.02 76.30 13 
O35215 DOPD_MOUSE 23.93 65.25 14 
P19157 GSTP1_MOUSE 23.66 53.33 16 
P05201 AATC_MOUSE 23.16 46.73 13 
P09103 PDIA1_MOUSE 22.71 29.08 12 
P10649 GSTM1_MOUSE 22.64 48.62 13 
Q8VCT4 CES1D_MOUSE 27.51 29.38 16 
P24549 AL1A1_MOUSE 23.02 24.95 13 
Q91WG0 EST2C_MOUSE 24.75 36.19 14 
Q00898 A1AT5_MOUSE 74.21 59.56 57 
Q00623 APOA1_MOUSE 20.84 41.67 12 
P11499 HS90B_MOUSE 20.77 20.86 11 
P14152 MDHC_MOUSE 20.35 35.33 16 
O88844 IDHC_MOUSE 20.6 36.23 12 
P17182 ENOA_MOUSE 20.03 39.86 13 
Q91X72 HEMO_MOUSE 19.69 19.35 11 
P08228 SODC_MOUSE 19.66 61.04 14 
P00329 ADH1_MOUSE 19.27 31.73 13 
P50247 SAHH_MOUSE 18.55 29.17 10 
Q91YI0 ARLY_MOUSE 17.93 24.78 10 
Q9JII6 AK1A1_MOUSE 17.91 37.23 11 
Q91Y97 ALDOB_MOUSE 17.37 37.64 12 
P30115 GSTA3_MOUSE 17.03 35.75 9 
P08113 ENPL_MOUSE 19.12 19.20 11 
P06151 LDHA_MOUSE 16.63 25.60 8 
Q8VC30 DHAK_MOUSE 16.63 25.78 9 
Q78JT3 3HAO_MOUSE 16.55 45.45 11 
P63017 HSP7C_MOUSE 18.6 19.50 12 
P53657 KPYR_MOUSE 16.22 21.08 8 
O35490 BHMT1_MOUSE 15.97 31.94 12 
P49429 HPPD_MOUSE 15.88 26.72 9 
P27773 PDIA3_MOUSE 15.71 21.78 8 
Q9ET01 PYGL_MOUSE 15.33 13.06 9 
Q8C196 CPSM_MOUSE 15.02 5.80 7 
P01027 CO3_MOUSE 14.44 6.13 8 
P09411 PGK1_MOUSE 14.01 27.10 8 
P10126 EF1A1_MOUSE 13.73 26.41 10 
G3X982 AOXC_MOUSE 13.7 9.51 8 
P02088 HBB1_MOUSE 13.49 47.62 8 
Q9CXN7 PBLD2_MOUSE 13.34 27.43 6 
P07309 TTHY_MOUSE 13.29 57.82 7 
Q01853 TERA_MOUSE 12.92 13.03 7 
Q9WVL0 MAAI_MOUSE 12.69 39.35 6 
Q9DBE0 CSAD_MOUSE 12.63 15.21 6 
Q64442 DHSO_MOUSE 12.11 23.53 7 
Q00897 A1AT4_MOUSE 69.98 64.16 53 
P06801 MAOX_MOUSE 11.66 14.16 6 
P35700 PRDX1_MOUSE 11.51 29.65 7 
P68372 TBB4B_MOUSE 11.47 19.78 7 
Q9D6F9 TBB4A_MOUSE 9.35 15.77 6 
P55264 ADK_MOUSE 11.22 20.22 7 
P14211 CALR_MOUSE 11 23.08 8 
P17751 TPIS_MOUSE 10.96 32.78 7 
P34914 HYES_MOUSE 10.84 16.25 6 
P28271 ACOC_MOUSE 10.8 12.15 6 
P70694 DHB5_MOUSE 10.22 24.46 6 
P02535 K1C10_MOUSE 10.15 12.28 5 
P01942 HBA_MOUSE 10.1 30.28 5 
Q8BK48 EST2E_MOUSE 17.21 20.04 11 
P09813 APOA2_MOUSE 9.42 33.33 6 
Q9DBJ1 PGAM1_MOUSE 9.3 36.22 5 
Q8VCM7 FIBG_MOUSE 9 18.81 6 
Q91X83 METK1_MOUSE 8.85 16.92 5 
P48036 ANXA5_MOUSE 8.72 19.12 5 
P17742 PPIA_MOUSE 8.44 23.17 4 
Q8VCU1 EST3B_MOUSE 24.14 24.17 14 
Q8BVI4 DHPR_MOUSE 8.1 30.29 4 
P62962 PROF1_MOUSE 8 40.00 4 
P68373 TBA1C_MOUSE 8 12.03 4 
P05213 TBA1B_MOUSE 8 11.97 4 
P68369 TBA1A_MOUSE 6 8.87 3 
Q9CPY7 AMPL_MOUSE 7.92 12.52 6 
P32261 ANT3_MOUSE 7.69 12.26 4 
P62259 1433E_MOUSE 7.53 22.75 4 
Q8VCN5 CGL_MOUSE 7.43 13.82 4 
Q9QXF8 GNMT_MOUSE 7.29 21.16 4 
Q91ZJ5 UGPA_MOUSE 7.22 12.20 4 
Q91X91 NADC_MOUSE 7.13 24.41 6 
Q8VCC2 EST1_MOUSE 7.7 9.20 5 
P24369 PPIB_MOUSE 6.99 21.76 4 
P04104 K2C1_MOUSE 6.89 7.06 4 
Q8BH00 AL8A1_MOUSE 6.93 13.35 4 
Q923D2 BLVRB_MOUSE 6.79 34.47 4 
O08677 KNG1_MOUSE 6.64 9.53 5 
P07758 A1AT1_MOUSE 67.94 60.05 57 
Q00896 A1AT3_MOUSE 71.67 62.86 59 
Q8K0E8 FIBB_MOUSE 6.52 10.81 4 
Q9D819 IPYR_MOUSE 6.29 17.99 5 
Q9CPU0 LGUL_MOUSE 6.12 21.20 3 
P16331 PH4H_MOUSE 6.06 6.84 3 
P28474 ADHX_MOUSE 8.16 15.78 4 
Q91XD4 FTCD_MOUSE 6 11.65 3 
P70296 PEBP1_MOUSE 5.92 28.34 3 
P01872 IGHM_MOUSE 5.85 10.79 3 
P40142 TKT_MOUSE 5.85 6.90 3 
P21614 VTDB_MOUSE 5.82 9.45 3 
Q9QYG0 NDRG2_MOUSE 5.42 10.78 3 
P06728 APOA4_MOUSE 5.37 8.61 3 
Q91V76 CK054_MOUSE 5.02 13.33 3 
Q922D8 C1TC_MOUSE 4.93 3.96 3 
Q8K157 GALM_MOUSE 4.8 13.45 3 
Q06890 CLUS_MOUSE 4.71 10.04 3 
Q8VCR7 ABHEB_MOUSE 4.7 14.76 3 
Q9DBB8 DHDH_MOUSE 4.63 13.81 3 
O09131 GSTO1_MOUSE 4.57 18.75 3 
Q9DCQ2 ASPD_MOUSE 4.49 16.38 3 
P01898 HA10_MOUSE 4.29 8.31 2 
P14430 HA18_MOUSE 2.23 4.29 1 
P58252 EF2_MOUSE 4.19 3.38 2 
Q9DCG6 PBLD1_MOUSE 12.81 27.43 6 
P04939 MUP3_MOUSE 4.15 22.83 4 
Q8QZR5 ALAT1_MOUSE 4.1 4.64 2 
P35492 HUTH_MOUSE 4.08 4.57 2 
P19096 FAS_MOUSE 4.04 1.68 2 
Q9JMD3 PCTL_MOUSE 4.03 8.59 2 
P40936 INMT_MOUSE 4.02 13.26 2 
P29699 FETUA_MOUSE 4.02 11.01 2 
Q99J08 S14L2_MOUSE 4.01 7.94 2 
P17563 SBP1_MOUSE 64.96 59.96 54 
P11589 MUP2_MOUSE 49.35 76.11 52 
P63101 1433Z_MOUSE 6.47 17.55 3 
Q9JLJ2 AL9A1_MOUSE 4 4.86 2 
Q7TPR4 ACTN1_MOUSE 4 2.47 2 
P57780 ACTN4_MOUSE 4 2.41 2 
Q99PT1 GDIR1_MOUSE 4 15.20 2 
Q64105 SPRE_MOUSE 4 10.73 2 
Q922R8 PDIA6_MOUSE 4 7.05 2 
Q61598 GDIB_MOUSE 4 6.74 2 
  
Table S4. Proteins identified by LC-ESI-MS/MS after sucrose glycogen enrichment. 
Accession Protein Score % Cov (95%) Peptides (95%) 
Q8C196 CPSM_MOUSE 444.1 73.07 257 
Q9ET01 PYGL_MOUSE 122.53 57.88 74 
P16460 ASSY_MOUSE 117.46 64.56 71 
P19096 FAS_MOUSE 114.15 31.91 61 
Q922D8 C1TC_MOUSE 91.85 63.21 50 
Q8R0Y6 AL1L1_MOUSE 83.69 61.75 45 
Q05920 PYC_MOUSE 81.36 47.37 46 
P47738 ALDH2_MOUSE 71.52 64.55 39 
P56480 ATPB_MOUSE 68.67 62.76 35 
P16858 G3P_MOUSE 60.75 53.45 32 
Q03265 ATPA_MOUSE 52.95 51.18 30 
P68372 TBB4B_MOUSE 50.55 65.39 32 
P20029 GRP78_MOUSE 50.01 43.36 25 
P26443 DHE3_MOUSE 49.16 39.78 29 
Q8BWT1 THIM_MOUSE 48.67 63.48 27 
Q8BMS1 ECHA_MOUSE 47.44 34.47 23 
P24549 AL1A1_MOUSE 46.91 59.68 28 
P68373 TBA1C_MOUSE 38.87 48.11 22 
P15105 GLNA_MOUSE 36.41 40.75 20 
Q91VS7 MGST1_MOUSE 36.11 61.94 20 
P53395 ODB2_MOUSE 35.75 45.85 19 
P41216 ACSL1_MOUSE 35.46 30.04 18 
P10126 EF1A1_MOUSE 34.86 52.81 28 
P14148 RL7_MOUSE 34.31 50.00 22 
P12970 RL7A_MOUSE 34.29 42.86 18 
P25444 RS2_MOUSE 33.47 40.96 22 
O35490 BHMT1_MOUSE 33.05 53.81 22 
Q63880 EST3A_MOUSE 32.88 38.18 19 
P60710 ACTB_MOUSE 32.27 57.33 19 
Q8CGC7 SYEP_MOUSE 31.88 15.74 16 
Q9D8E6 RL4_MOUSE 30.58 35.32 19 
Q91XD4 FTCD_MOUSE 29.34 45.29 16 
P09103 PDIA1_MOUSE 28.34 32.81 15 
P63038 CH60_MOUSE 28 35.43 15 
P07724 ALBU_MOUSE 27.77 26.64 13 
P24270 CATA_MOUSE 27.42 37.38 14 
P80315 TCPD_MOUSE 27.09 34.32 13 
P97351 RS3A_MOUSE 26.12 42.42 13 
P14869 RLA0_MOUSE 25.37 44.48 14 
P11352 GPX1_MOUSE 25.33 78.61 14 
P17717 UDB17_MOUSE 24.97 30.00 14 
P62908 RS3_MOUSE 24.91 52.26 13 
P47911 RL6_MOUSE 24.43 31.08 14 
P63017 HSP7C_MOUSE 32.19 33.13 17 
P80318 TCPG_MOUSE 24.15 30.83 12 
P53657 KPYR_MOUSE 24.04 31.36 12 
P00329 ADH1_MOUSE 23.8 37.87 14 
P33267 CP2F2_MOUSE 23.21 31.36 12 
P38647 GRP75_MOUSE 23.57 26.36 15 
P08113 ENPL_MOUSE 22.96 19.20 12 
Q9QXD6 F16P1_MOUSE 22.8 49.70 13 
P50247 SAHH_MOUSE 22.44 30.79 13 
P62082 RS7_MOUSE 22.43 43.81 13 
P11983 TCPA_MOUSE 24.02 28.06 12 
Q01853 TERA_MOUSE 22 20.72 11 
Q8BH00 AL8A1_MOUSE 22.16 32.24 11 
Q99K67 AASS_MOUSE 21.59 14.90 11 
P51410 RL9_MOUSE 21.17 64.06 11 
P11714 CP2D9_MOUSE 21.04 25.40 11 
P62702 RS4X_MOUSE 20.63 40.68 12 
P27659 RL3_MOUSE 20.22 27.05 12 
Q91Y97 ALDOB_MOUSE 20 40.11 10 
O88451 RDH7_MOUSE 19.54 37.34 12 
P06151 LDHA_MOUSE 19.5 37.35 10 
P11499 HS90B_MOUSE 21.37 19.06 11 
P62843 RS15_MOUSE 19.09 55.86 12 
P62264 RS14_MOUSE 18.75 62.25 11 
Q8QZT1 THIL_MOUSE 18.47 34.91 9 
P80316 TCPE_MOUSE 18.36 31.42 9 
Q63886 UD11_MOUSE 20.22 20.00 10 
P80317 TCPZ_MOUSE 18.17 28.06 9 
Q8VCB3 GYS2_MOUSE 18.06 17.76 10 
Q9R0H0 ACOX1_MOUSE 18 21.33 9 
P80314 TCPB_MOUSE 18 26.54 9 
Q9DB20 ATPO_MOUSE 18 53.99 9 
P14131 RS16_MOUSE 17.79 46.58 9 
P62754 RS6_MOUSE 17.72 23.69 9 
Q8VCT4 CES1D_MOUSE 17.68 28.67 12 
P80313 TCPH_MOUSE 17.41 27.57 10 
P32020 NLTP_MOUSE 17.38 26.14 11 
Q9CQ62 DECR_MOUSE 17.22 36.42 9 
Q8CIM7 CP2DQ_MOUSE 17.07 26.20 10 
P54869 HMCS2_MOUSE 16.73 21.65 10 
Q8BMF4 ODP2_MOUSE 16.63 19.63 8 
P97872 FMO5_MOUSE 16.59 24.77 10 
Q9D379 HYEP_MOUSE 16.56 30.77 11 
P47955 RLA1_MOUSE 16.38 74.56 11 
Q6ZWN5 RS9_MOUSE 16.21 27.32 10 
Q63836 SBP2_MOUSE 16.12 23.73 9 
P17563 SBP1_MOUSE 15.4 21.19 8 
Q64459 CP3AB_MOUSE 16.01 21.63 8 
Q61176 ARGI1_MOUSE 16 34.67 8 
P99027 RLA2_MOUSE 16 84.35 8 
O08601 MTP_MOUSE 15.92 13.31 9 
O09173 HGD_MOUSE 15.92 24.94 8 
Q05421 CP2E1_MOUSE 15.79 20.69 9 
P02088 HBB1_MOUSE 15.47 62.59 9 
O88844 IDHC_MOUSE 15.15 22.95 8 
Q9CZM2 RL15_MOUSE 15.09 34.31 8 
P51881 ADT2_MOUSE 14.88 30.20 8 
P27773 PDIA3_MOUSE 14.83 20.20 7 
Q60759 GCDH_MOUSE 14.76 27.40 8 
Q68FD5 CLH1_MOUSE 14.58 8.66 10 
P97461 RS5_MOUSE 14.3 42.65 9 
P29341 PABP1_MOUSE 14.23 13.05 7 
P62889 RL30_MOUSE 14.13 51.30 7 
Q922B2 SYDC_MOUSE 14.09 17.96 7 
P35980 RL18_MOUSE 14.06 29.79 8 
P67984 RL22_MOUSE 14 42.97 7 
P63276 RS17_MOUSE 13.82 41.48 7 
P42932 TCPQ_MOUSE 13.81 16.06 8 
P34914 HYES_MOUSE 13.69 20.58 7 
O35488 S27A2_MOUSE 13.47 17.74 7 
P62301 RS13_MOUSE 13.43 29.80 7 
Q99JY0 ECHB_MOUSE 13.34 28.21 10 
P19157 GSTP1_MOUSE 13.23 53.81 8 
Q61656 DDX5_MOUSE 13.12 11.73 7 
Q64458 CP2CT_MOUSE 13.09 13.88 7 
Q8VCW8 ACSF2_MOUSE 13.02 15.93 7 
P24456 CP2DA_MOUSE 19.35 23.21 10 
P62242 RS8_MOUSE 12.85 29.33 8 
P57776 EF1D_MOUSE 12.65 33.45 7 
P53026 RL10A_MOUSE 12.56 33.18 8 
Q9QXF8 GNMT_MOUSE 12.36 28.67 7 
Q91ZJ5 UGPA_MOUSE 12.1 18.31 6 
P62751 RL23A_MOUSE 12.09 30.13 6 
P50136 ODBA_MOUSE 12.04 23.30 7 
Q9D2G2 ODO2_MOUSE 12 18.94 7 
Q9CPY7 AMPL_MOUSE 12 19.08 6 
Q91VR5 DDX1_MOUSE 11.96 14.05 7 
O88587 COMT_MOUSE 11.92 33.96 6 
P16331 PH4H_MOUSE 11.7 17.88 6 
Q91X83 METK1_MOUSE 11.62 19.95 7 
P16015 CAH3_MOUSE 11.57 29.62 6 
Q9D0I9 SYRC_MOUSE 11.41 11.97 7 
Q9WVL0 MAAI_MOUSE 11.41 50.46 7 
O09167 RL21_MOUSE 11.33 27.50 8 
Q60597 ODO1_MOUSE 11.21 9.38 7 
Q6ZWV3 RL10_MOUSE 11.16 22.43 6 
P86048 RL10L_MOUSE 8.92 16.36 5 
P62245 RS15A_MOUSE 11.12 51.54 8 
P58710 GGLO_MOUSE 10.93 20.00 5 
Q6ZWX6 IF2A_MOUSE 10.9 23.81 6 
P47963 RL13_MOUSE 10.78 20.38 5 
P05202 AATM_MOUSE 10.64 18.14 6 
P24369 PPIB_MOUSE 10.64 27.31 5 
P58252 EF2_MOUSE 10.28 8.04 5 
P17182 ENOA_MOUSE 10.24 19.35 5 
Q8VEK3 HNRPU_MOUSE 10.15 9.62 5 
P62830 RL23_MOUSE 10.14 26.43 5 
P62270 RS18_MOUSE 10.1 36.84 6 
Q80XN0 BDH_MOUSE 10.1 18.95 5 
Q99MN9 PCCB_MOUSE 10.01 14.42 5 
O70251 EF1B_MOUSE 11.49 28.44 6 
Q07417 ACADS_MOUSE 10 22.09 5 
Q922R8 PDIA6_MOUSE 10 17.50 5 
P35979 RL12_MOUSE 10 45.45 6 
Q91V92 ACLY_MOUSE 9.91 7.15 6 
G3X982 AOXC_MOUSE 9.89 5.62 5 
Q9CZX8 RS19_MOUSE 9.82 29.66 6 
P50544 ACADV_MOUSE 9.81 13.11 5 
Q9DB77 QCR2_MOUSE 9.58 18.76 5 
Q9CZ13 QCR1_MOUSE 9.43 15.83 5 
P62196 PRS8_MOUSE 9.28 17.98 5 
P63325 RS10_MOUSE 9.24 23.03 6 
P50580 PA2G4_MOUSE 8.99 17.26 5 
Q91YI0 ARLY_MOUSE 8.83 13.36 5 
Q9QXX4 CMC2_MOUSE 8.8 9.47 4 
Q9CPR4 RL17_MOUSE 8.71 31.52 6 
Q91VR2 ATPG_MOUSE 8.56 20.81 5 
Q8VDM4 PSMD2_MOUSE 8.48 8.92 6 
P62918 RL8_MOUSE 8.45 39.30 8 
Q8VCR2 DHB13_MOUSE 8.39 25.00 5 
P01942 HBA_MOUSE 8.37 38.03 5 
P19253 RL13A_MOUSE 8.36 20.20 5 
Q9D051 ODPB_MOUSE 8.23 16.99 5 
Q9Z0N2 IF2H_MOUSE 8.11 12.92 4 
Q9Z0N1 IF2G_MOUSE 8 12.92 4 
P62900 RL31_MOUSE 8.05 18.40 4 
P62192 PRS4_MOUSE 8.04 15.91 4 
P61358 RL27_MOUSE 8.03 36.03 4 
P62849 RS24_MOUSE 8.03 29.32 5 
Q64442 DHSO_MOUSE 8.03 15.97 4 
Q9DBG1 CP27A_MOUSE 8.01 11.44 4 
Q4LDG0 S27A5_MOUSE 8.01 9.43 4 
Q9DBF1 AL7A1_MOUSE 8 10.58 4 
P51660 DHB4_MOUSE 8 7.07 4 
P43274 H14_MOUSE 8 21.92 4 
Q9CQE8 CN166_MOUSE 8 25.82 4 
P56395 CYB5_MOUSE 8 41.04 4 
O88685 PRS6A_MOUSE 8 13.57 4 
P09405 NUCL_MOUSE 8 7.78 4 
P62852 RS25_MOUSE 7.9 24.00 5 
Q8VC30 DHAK_MOUSE 7.8 12.28 4 
Q9EQ20 MMSA_MOUSE 7.8 9.16 4 
P62911 RL32_MOUSE 7.74 28.15 4 
P14211 CALR_MOUSE 7.62 17.55 5 
Q8BWQ1 UD2A3_MOUSE 7.58 18.35 7 
P68368 TBA4A_MOUSE 34.79 40.85 18 
Q91ZA3 PCCA_MOUSE 7.48 9.94 5 
Q9JJI8 RL38_MOUSE 7.33 47.14 4 
Q8CGP2 H2B1P_MOUSE 6.87 26.19 4 
Q8CGP1 H2B1K_MOUSE 6.87 26.19 4 
Q6ZWY9 H2B1C_MOUSE 6.87 26.19 4 
Q64525 H2B2B_MOUSE 6.87 26.19 4 
Q64478 H2B1H_MOUSE 6.87 26.19 4 
Q64475 H2B1B_MOUSE 6.87 26.19 4 
P10854 H2B1M_MOUSE 6.87 26.19 4 
P10853 H2B1F_MOUSE 6.87 26.19 4 
Q9D2U9 H2B3A_MOUSE 5.35 19.05 3 
Q8CGP0 H2B3B_MOUSE 5.35 19.05 3 
Q64524 H2B2E_MOUSE 5.35 19.05 3 
Q8VDJ3 VIGLN_MOUSE 6.76 5.68 4 
Q99PG0 AAAD_MOUSE 6.76 15.33 4 
Q99LF4 RTCB_MOUSE 6.72 10.89 4 
Q8VEM8 MPCP_MOUSE 6.72 10.92 4 
O88569 ROA2_MOUSE 6.7 13.88 4 
P62855 RS26_MOUSE 6.66 33.91 4 
Q7TMK9 HNRPQ_MOUSE 6.63 9.47 4 
Q6NZJ6 IF4G1_MOUSE 6.59 3.94 4 
Q9DCN2 NB5R3_MOUSE 6.53 14.62 3 
Q9CXW4 RL11_MOUSE 6.45 23.03 4 
P35700 PRDX1_MOUSE 6.29 20.10 4 
Q9DCX2 ATP5H_MOUSE 6.28 30.43 3 
Q9CR57 RL14_MOUSE 6.21 11.52 3 
Q61838 A2M_MOUSE 6.17 3.75 4 
Q60865 CAPR1_MOUSE 6.15 6.51 4 
P50172 DHI1_MOUSE 6.12 15.07 4 
P99024 TBB5_MOUSE 43.81 61.04 28 
Q9EQK5 MVP_MOUSE 6.09 9.41 5 
Q99LC5 ETFA_MOUSE 6.06 12.61 3 
Q9CZS1 AL1B1_MOUSE 11.36 14.64 7 
Q9WV68 DECR2_MOUSE 6.05 16.44 3 
P60867 RS20_MOUSE 6.03 19.33 4 
P49722 PSA2_MOUSE 6.02 23.08 3 
Q9Z1Q9 SYVC_MOUSE 6.01 3.17 3 
P63101 1433Z_MOUSE 6.01 16.73 3 
Q62095 DDX3Y_MOUSE 8 7.14 4 
Q62167 DDX3X_MOUSE 8 7.10 4 
P16381 DDX3L_MOUSE 8 7.12 4 
P35505 FAAA_MOUSE 6 7.64 3 
P35486 ODPA_MOUSE 6 8.21 3 
P62821 RAB1A_MOUSE 6 18.54 3 
P55258 RAB8A_MOUSE 4 10.63 2 
P61028 RAB8B_MOUSE 4 10.63 2 
Q8K386 RAB15_MOUSE 4 10.38 2 
Q6PHN9 RAB35_MOUSE 4 10.95 2 
P61979 HNRPK_MOUSE 6 10.58 3 
P00186 CP1A2_MOUSE 6 8.38 3 
A2AS89 SPEB_MOUSE 6 14.25 3 
Q9R1P1 PSB3_MOUSE 6 23.90 3 
Q8VCH0 THIKB_MOUSE 6 15.09 3 
Q921H8 THIKA_MOUSE 4 9.20 2 
Q8C0C7 SYFA_MOUSE 6 8.66 3 
Q06185 ATP5I_MOUSE 6 50.70 3 
P67778 PHB_MOUSE 5.95 14.71 4 
P62267 RS23_MOUSE 5.85 22.38 7 
Q9Z2U1 PSA5_MOUSE 5.77 18.67 3 
Q8BH95 ECHM_MOUSE 5.72 15.86 3 
Q9DD20 MET7B_MOUSE 5.72 15.98 3 
Q9DBM2 ECHP_MOUSE 5.33 7.52 4 
Q99L45 IF2B_MOUSE 5.28 7.55 3 
Q8BMJ2 SYLC_MOUSE 5.21 2.89 3 
P41105 RL28_MOUSE 5.58 20.44 3 
P62717 RL18A_MOUSE 5.05 19.32 3 
O55022 PGRC1_MOUSE 4.98 15.38 3 
Q8BP67 RL24_MOUSE 4.77 19.11 4 
P10649 GSTM1_MOUSE 4.73 11.93 3 
P19639 GSTM4_MOUSE 4 7.80 2 
Q80W21 GSTM7_MOUSE 4 7.80 2 
P15626 GSTM2_MOUSE 4 7.80 2 
O35660 GSTM6_MOUSE 4 7.80 2 
Q9Z2I9 SUCB1_MOUSE 4.71 10.37 3 
Q8QZR3 EST2A_MOUSE 4.69 8.60 4 
P62281 RS11_MOUSE 4.69 17.72 2 
Q9QZE5 COPG1_MOUSE 4.63 4.69 3 
P56135 ATPK_MOUSE 4.46 26.14 3 
Q99PL5 RRBP1_MOUSE 4.39 1.93 2 
P61255 RL26_MOUSE 4.36 26.90 4 
P12710 FABPL_MOUSE 4.3 32.28 3 
Q00623 APOA1_MOUSE 4.27 12.50 3 
Q9Z2X1 HNRPF_MOUSE 4.26 8.19 2 
Q8R1M2 H2AJ_MOUSE 4.25 28.68 2 
Q8CGP7 H2A1K_MOUSE 4.25 28.46 2 
Q8CGP6 H2A1H_MOUSE 4.25 28.91 2 
Q8CGP5 H2A1F_MOUSE 4.25 28.46 2 
Q8BFU2 H2A3_MOUSE 4.25 28.46 2 
Q6GSS7 H2A2A_MOUSE 4.25 28.46 2 
Q64523 H2A2C_MOUSE 4.25 28.68 2 
Q64522 H2A2B_MOUSE 4.25 28.46 2 
P27661 H2AX_MOUSE 4.25 25.87 2 
P22752 H2A1_MOUSE 4.25 28.46 2 
P54071 IDHP_MOUSE 5.48 10.62 4 
Q3ULD5 MCCB_MOUSE 4.12 6.04 2 
P56593 CP2AC_MOUSE 4.11 8.13 3 
P47740 AL3A2_MOUSE 4.99 9.50 4 
P14115 RL27A_MOUSE 4.04 14.19 3 
Q9CQQ7 AT5F1_MOUSE 4.02 8.59 3 
Q8BG05 ROA3_MOUSE 4.02 5.54 2 
P83882 RL36A_MOUSE 4.02 20.75 3 
Q99MR8 MCCA_MOUSE 4.01 3.91 2 
Q9R062 GLYG_MOUSE 4.01 7.21 2 
Q7TMM9 TBB2A_MOUSE 41.04 54.61 27 
Q9CWF2 TBB2B_MOUSE 39.04 51.91 26 
P43277 H13_MOUSE 8 21.72 4 
Q91X77 CY250_MOUSE 6 8.37 3 
P54775 PRS6B_MOUSE 4 6.70 2 
P38060 HMGCL_MOUSE 4 11.08 2 
Q9D8W5 PSD12_MOUSE 4 5.92 2 
Q8K370 ACD10_MOUSE 4 4.30 3 
Q01405 SC23A_MOUSE 4 3.53 2 
Q9D662 SC23B_MOUSE 2 1.82 1 
P14206 RSSA_MOUSE 4 13.56 3 
P00405 COX2_MOUSE 4 13.22 2 
Q9Z2W0 DNPEP_MOUSE 4 5.71 2 
Q8BK72 RT27_MOUSE 4 5.54 2 
P62334 PRS10_MOUSE 4 7.46 2 
P50285 FMO1_MOUSE 4 5.45 2 
P19783 COX41_MOUSE 4 17.75 2 
P14685 PSMD3_MOUSE 4 5.09 2 
O88986 KBL_MOUSE 4 9.38 2 
Q9EQ06 DHB11_MOUSE 4 12.75 2 
Q8BG32 PSD11_MOUSE 4 5.92 2 
P84099 RL19_MOUSE 4 13.27 2 
P46471 PRS7_MOUSE 4 6.00 2 
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Research Proposal 
Project Quality and Innovation 
(i) Significance: The incidence of type 2 diabetes has reached epidemic proportions, with 
approximately 1 million Australians currently suffering from this disease and another 2 million 
Australians having pre-diabetes. The poor control of blood-glucose levels associated with type 2 
diabetes poses a serious threat to human health, often leading to complications such as stroke, 
coronary artery and peripheral vascular disease, amputations, renal failure, blindness and even 
death
1
.  In addition to decreases in life quality, this disease places a major financial burden on 
Australia’s health system, costing over $1 billion per year. The overall economy loses an estimated 
additional cost of ~ $9 billion in career costs and productivity losses. The scale of this public health 
issue has resulted in diabetes becoming one of the Australian Government’s National Health 
Priority Areas. 
While a determined global effort has resulted in promising advances in the prevention and treatment 
of type 2 diabetes, the magnitude of this problem is increasing apace and requires urgent attention.  
(ii) Background: Liver glycogen, a highly branched glucose polymer, has a critical role in the 
maintenance of blood glucose homeostasis. After a meal, blood glucose concentrations can be 
rapidly controlled by trapping glucose in glycogen. Liver glycogen has three levels of structure: 1) 
glucose units are attached to form linear chains via -(1→4) linkages; 2) these chains are joined 
together via -(1→6)-linked branch points to form highly branched glycogen “” particles (~20 nm 
in diameter); and 3) these  particles are able to be joined together to form much larger “” 
particles (~100-200 nm).  
Given the characteristically poor blood-glucose control associated with type 2 diabetes, a link 
between the structure/function relationships of liver-glycogen and type 2 diabetes is probable. 
However such an association has been unexplored until recently, due to the technological 
difficulties in obtaining even semi-quantitative structural information on a macromolecule as 
complex as glycogen. My undergraduate research
2
, as part of the Advanced Study Program in 
Science, developed breakthrough technologies capable of obtaining size distributions of native 
glycogen, extracted and analysed with minimal degradation. For the first time we are able to 
explore the role of glycogen structure in diabetes. These size distributions are achieved using size 
exclusion chromatography (SEC), a technique routinely used for synthetic polymers but now, as my 
research revealed, capable of analysing highly complex structures such as glycogen. Utilising this 
technology, my Honours year research demonstrated that db/db mice, a model for type 2 diabetes 
with a point mutation in the leptin receptor, have an impaired ability to form the large glycogen  
particles synthesized in the healthy controls, and instead contained predominantly the smaller  
particles. Given the building evidence (including data presented in one of my recent publications
3
 
that smaller glycogen particles 1) have a higher association with glycogen phosphorylase
4
, a key 
enzyme involved in glycogen degradation and 2) are degraded more rapidly in vitro
3,5
, the inability 
to form larger glycogen  particles is predicted to result in a faster, less controlled degradation into 
glucose.  
While the mechanism for the formation of larger glycogen  particles from  particles is currently 
unknown, my finding that diabetic (db/db) mice lack these macromolecules has sparked a number 
of studies aimed at resolving this question. Acid hydrolysis experiments on pig-liver glycogen, 
performed during my PhD, have revealed that the linkage connecting  particles to form  particles 
is most likely proteinaceous in nature, making the search for such a protein “glue” a promising 
research area
6
. If indeed there is a protein involved in holding these particles together, any regulator 
that decreases the expression of this protein may become a promising inhibitory drug target for 
diabetes management. 
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In order to understand why db/db mice are unable to form many  particles, it is essential to first 
understand the mechanism by which they form in non-diabetic hepatocytes. Another study during 
my PhD involved observing the size distribution of liver-glycogen particles from wild-type mice at 
various time points across a dirunal cycle
3
. This revealed two key insights: 1) glycogen initially 
forms as separate  particles, only to be subsequently joined together to form larger  particles after 
the glycogen content has reached its maximum concentration; and 2) during glycogen degradation 
the larger particles were much more resistant to glycogenolysis, persisting significantly longer than 
the smaller  particles. Not only does this data support the theory that glycogen structural features 
such as particle size influence the rate of glycogenolysis, but it strongly suggests that there is a 
mechanism in which separate  particles are able to conglomerate to form an  particle. 
The question still remains, however, as to why db/db mice appear to be lacking this mechanism. 
One potential answer is centred on the observation that while non-diabetic mice go through a 
diurnal cycle of synthesising glycogen during the dark hours (due to their nocturnal nature) and 
having this glycogen slowly degraded during the daylight hours, db/db mice are continually eating 
and maintaining a high liver-glycogen content
7
. It is therefore possible that these mice are unable to 
switch from the glycogen synthesis phase, in which glycogen is being formed as separate  
particles, into the next phase where they come together to form the more resistant  particles. 
iii) Objectives: The initial primary aim of this research proposal is to determine the mechanism 
causing db/db mice to have an impaired ability to form  particles. By utilising the methods 
developed during my research to analyse the structure of glycogen, and coupling these with an in-
depth analysis of the varying expression levels of a number of key proteins involved in glycogen 
metabolism, we will build a much richer understanding of not only glycogen metabolism in general, 
which will include the often neglected (due to hitherto incapable technology) glycogen structure, 
but more importantly the role glycogen metabolism has in type 2 diabetes. The second primary aim 
of this research is to provide a better understanding of human glycogen metabolism by comparing 
human diabetic, prediabetic and non-diabetic samples, moving my research even closer to its 
ultimate goal of developing better treatments for sufferers’ of type 2 diabetes. 
(iv) Approach and Methodology: The effect of leptin administration on the glycogen metabolism 
of ob/ob mice: Given the possibility that the impaired -particle formation observed in db/db mice 
is a direct result of their immediate eating behaviour, being able to separate this aspect of db/db 
mice behaviour from the effects of their obesity and insulin resistance, is of great importance. To do 
this would involve utilising a mouse model with a similar phenotype to db/db mice, but with the 
ability to control their feeding behaviour, without the stress induced by simply using a calorie 
restricted diet. Fortunately there is such a model, with ob/ob mice exhibiting a very similar 
phenotype to that of db/db mice. The similarities in phenotypes arise as both models are unable to 
properly use the leptin satiety pathway, making them continuously hungry. The difference between 
these diabetic models is how this pathway is disrupted. While db/db mice are able to produce the 
peptide leptin in excessive amounts, a point mutation in the leptin receptor makes these mice leptin 
resistant. Ob/ob mice on the other hand, while synthesising a perfectly functioning leptin receptor, 
have a point mutation on the gene encoding the leptin peptide, destroying its functionality. 
It has been shown (in the research group of the overseas host proposed here) that the administration 
of leptin to ob/ob mice leads to a decrease in their food intake and body weight
8
. This research will 
investigate whether by allowing ob/ob mice to become obese and insulin resistant (feeding them ab 
libitum without administration of leptin), ob/ob mice also have an impaired mechanism for  
particle formation. While expected to also exhibit this phenotype, if ob/ob mice do not have a 
similar impairment to db/db mice, this would indicate that the reason why db/db mice are unable to 
form large particles lies within the limited differences between the physiology of db/db and ob/ob 
mice. However, if indeed ob/ob mice are also unable to form  particles, the administration of 
leptin can be used to alter the immediate eating behaviour of the mice. By analysing the glycogen 
size distribution of ob/ob mice (compared to controls) before and after leptin administration, where 
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ob/ob mice are still obese and insulin resistant but have decreased their amount of eating, it could be 
tested whether the effect observed for diabetic mice is indeed due to continuous eating. If the 
glycogen  particle formation is still impaired after the administration of leptin to ob/ob mice, it 
will provide strong evidence that the phenomenon initially observed in db/db mice is not simply due 
to continuous eating. If this is the case the leptin treatment would be extended until the ob/ob mice 
have lost a significant amount of body weight, with the size distributions being tested again. 
Whether or not this extended treatment results in the ob/ob mice being able to form  particles will 
provide very useful insights into the nature of this impairment. 
An important aspect of this investigation will be to analyse glycogen content and structure at 
various time points during a diurnal cycle, allowing a much greater depth of understanding of this 
diurnal process than simply choosing one time point. The expression levels of key enzymes such as 
glycogenin, glycogen synthase, glycogen phosphorylase and phosphoylase kinase will be tested 
using real-time PCR and their total abundance determined using Western blotting. Wild-type (WT) 
mice with the same genetic background as the ob/ob mice will be used as controls. For both ob/ob 
mice and WT mice, half will be administered leptin and half a saline solution, acting as another 
control (as was performed in Prof. Zierath’s recent study8). My previous experience indicates that 
there should be 6 time points evenly distributed across the dirunal cycle. There will be 4 different 
groups per time point: ob/ob-leptin, ob/ob-saline, WT-leptin and WT-saline. To allow for strong 
statistical comparisons there will be 6 mice per group. Therefore this project will require 72 WT 
and 72 ob/ob mice. After this analysis is completed at the Karolinska Institute (within the first 2 
years of the project), key glycogen samples that show any interesting differences from each group 
will be saved for a full proteomics analysis using mass spectroscopy, similar to the methods used 
previously for mice and rats
9
. This is to be completed at UQ in years 3 and 4 of this project.  
The analysis of diabetic and non-diabetic human liver-glycogen: While the use of mouse models is 
an extremely useful way of studying the metabolism of glycogen in terms of structure, the 
translation of this research into human liver-tissues will automatically enhance the physiological 
relevance of any further discoveries. Here I propose to obtain the first size distributions of non-
diabetic, prediabetic and type 2 diabetic human-liver, with the expression levels of key enzymes 
again being compared using rt-PCR and Western blots. This initial analysis will be performed in the 
first 2 years of the project. Research performed in years 3 and 4 of the project will expand on the 
initial investigation by doing an in-depth proteomics analysis in order to compare the proteome of 
extracted liver from these tissue types.  
My experience in this analytical approach and the experience of my intended supervisors indicate 
that the research proposed to be undertaken can be achieved in the 4 years of this fellowship. 
(v) Innovation: This project will for the first time use the newly developed structural 
characterisation techniques to analyse the glycogen structure of diabetic mice that have been 
administered leptin and therefore have an eating behaviour similar to non-diabetic mice. Combining 
this with the analysis of the expression levels of key enyzmes involved in glycogen metabolism will 
greatly improve our understanding of glycogen metabolism in both healthy and diabetic liver. This 
project will also result in the first structural analysis of human liver glycogen as well as a detailed 
analysis of protein expression levels, again focusing on the difference between healthy and diabetic 
tissues. For the first time this project will provide a detailed mass-spectroscopy proteomics analysis 
of extracted glycogen from human liver. A schematic overview of the project is given in Figure 1. 
Research Environment and Feasibility 
The research environments overseas and in Australia both allow ready access to the two main 
requisites for this project: 1) being able to obtain appropriate samples, in this case ob/ob mice and 
human liver tissue; and 2) having access to equipment important for the glycogen structural 
characterisation and the determination of protein expression levels. This project builds on from my 
previous research by linking for the first time the glycogen structural analytical approach I 
pioneered, with the ground breaking research on other biochemical and clinical aspects of glycogen 
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metabolism, being undertaken at two of the world’s leading research teams in this area. This 
promises to be a fertile ground to help enhance our understanding of glycogen behaviour especially 
in relation to diabetes, and to determine the potential for new approaches to treatment of this disease 
based on the moderation of glycogen behaviour. 
 
 
 
Figure 1. Schematic overview of project. 
 
Years 1 and 2 will be performed in the Karolinska Institute in Stockholm, a prestigious and world 
leading facility for biomedical research. This work will be performed under the supervision of Prof. 
Juleen Zierath (H-index of 47), Chair of the Nobel Committee for Physiology or Medicine, who has 
developed a world-leading team of diabetes researchers. Having recently published a study that has 
analysed the effects of leptin administration on the mitochondrial function of ob/ob mice
8
, as well 
as routinely analysing the protein expression levels of targeted enzymes
10
, Prof. Zierath’s research 
team is ideal for this research project. The training I will obtain at the Karolinska Institute will 
equip me with capacities necessary for a future career in biomedical research. Close collaboration 
between Prof. Zierath and surgeon Erik Näslind, who specializes in obesity and is enthusiastic to 
collaborate on this project, allows for the perfect research environment capable of expanding the 
research into human tissues. The structural characterisation of this liver glycogen will be performed 
using state-of the-art size separation equipment located in Dr. Fransisco Vilaplana’s research group 
at nearby KTH Royal Institute of Technology in Stockholm.  I have already established close 
collaborative research links with Dr. Vilaplana, as evidenced by him being a co-author on three of 
my recent publications that involve the structural characterisation of glycogen. The combination of 
expertise available in Stockholm, between the Karolinska Institute and KTH Royal Institute of 
Technology provides an ideal research environment for the first stage of the research project 
outlined here. 
Year 3 and 4 of this fellowship will be based at the Mater Research Institute in Brisbane under the 
supervision of Prof. Josephine Forbes (H-index of 33). The existing close collaboration between 
Prof. Forbes’ diabetes research team and expert clinician Prof. David McIntyre (Head of the Mater 
Clinical School and Director of Endocrinology and Obstetric Medicine at the Mater hospital) will 
allow further analysis on human glycogen. The size exclusion chromatography equipment at the 
University of Queensland has been proven to be excellent at analysing glycogen structure, with all 
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of our publications looking at glycogen structure using these facilities. Prof. Robert Gilbert (my 
current PhD supervisor), a world-leading physical chemist (H-index of 58), will be an enthusiastic 
and active collaborator for the project outlined here. Proteomics of human samples will be 
determined via collaboration with Dr. Ben Schulz using the world-class mass spectrometry facilities 
available in the School of Chemistry and Molecular Bioscience at The University of Queensland, 
and with whom I have already started collaborative proteomic analysis of mouse-liver glycogen. 
Benefit and Expected Outcomes 
Given the rapidly increasing incidence of type 2 diabetes and the tragic effects this disease is having 
on human health, the benefits of enhancing our understanding of this disease and in developing 
improved methods to prevent and treat this poor control of blood glucose are considerable. My 
unexpected discovery that diabetic (db/db) mice have an impaired ability to form large glycogen  
particles and the evidence that this may leave them vulnerable to rapid glycogen degradation has 
made this research a very promising new area for finding new drug targets. This research project 
aims to explain why diabetic mice have an impaired ability to form  particles, moving us closer to 
determining whether it is possible to reverse this effect by medication. By expanding our research to 
human samples this project will move this research closer to the ultimate goal of enhanced diabetes 
treatment. Given the highly innovative yet entirely feasible project outline proposed here, we expect 
there to be high impact journal publications resulting from this work. These outputs will derive 
from the behaviour associated with the administration of ob/ob mice with leptin. One will focus on 
the immediate effects of leptin in which case the ob/ob mice have an altered eating behaviour but 
are still obese and insulin resistant. Another will examine the extended treatment of ob/ob mice with 
leptin, where the mice have a similar body weight to the non-diabetic controls. The potential for 
benefits and novel outcomes arising from the studies using human glycogen samples are substantial. 
We expect the first outcomes to focus on comparisons between the liver-glycogen structure between 
healthy and diabetic humans. Other significant research outcomes will result from doing a detailed 
proteomics analysis on those same samples using mass spectroscopy techniques that have been 
already established for mouse- and rat-liver glycogen
9
. 
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